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Family Planning and HIV Interventions among Women in Low-income Settings 
Abstract 
This dissertation examines the effectiveness of interventions related to family planning and the 
uptake of HIV-related preventive services among women in low-income settings. Women in 
low-income settings and living with HIV face many barriers to care, including limited access to 
services for family planning and HIV-related preventive care. At the same time, national, 
regional, and global efforts are looking for interventions to help control rapid population growth, 
create an HIV-free generation, and provide adequate preventive care for those living with HIV. 
This dissertation cuts across these issues and can help to inform debate and policies to address 
these issues.  
This dissertation comprises three discrete papers. Paper 1 (chapter 1) examines the effectiveness 
of a national scale-up of community-based distribution of family planning services on 
contraceptive use in Malawi’s rural areas during the period 2005-2016. The national-scale up of 
the intervention followed the success of a pilot of a similar intervention implemented in the 
period 1999-2004. As in the pilot, the scaled-up program distributed condoms and oral 
contraceptives and provided family planning education. Further, because education and income 
are important determinants of individual contraceptive use, the paper also examines whether the 
effectiveness of the national scale CBDs varies over these dimensions. The paper uses the 
Malawi Demographic and Health Surveys. The study finds that the intervention increased 
contraceptive use by 6.8 percentage points and the effects were greater among uneducated and 
low-income women. 
Paper 2 (chapter 2) conducts a cost-effectiveness analysis of a trial of cash incentives aimed at 
increasing the uptake of services for the prevention of mother-to-child transmission (PMTCT) of 
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HIV. The trial was conducted in the Democratic of the Congo (DRC) as part of an effort to find 
ways of increasing uptake of PMTCT services in sub-Saharan Africa where uptake of these 
services remains low. The study is conducted from the societal perspective, relies on multiple 
sources within and outside of the DRC for cost data, and reports economic costs in 2016 
International Dollars (I$). At a threshold of 3*GDP per capita for the DRC (I$2409), the study 
finds that the intervention is cost-effective.  
Paper 3 (chapter 3) examines the guideline concordance of the time to follow-up anal cancer 
screening in women living with HIV at high risk for anal cancer. In the US, the incidence of anal 
cancer in women living with HIV has increased significantly in the past 2-3 decades. However, 
early detection of anal cancer, through regular screening, can lead to effective secondary 
prevention of the disease. While guidelines for anal cancer screening exist, very little is known 
about the guideline concordance of the time to follow-up anal cancer screening in women at high 
risk of acquiring anal cancer. Hence this study. The study uses Medicaid Analytic eXtract files 
which compile claims of individuals enrolled in Medicaid—a public health insurance program 
largely for eligible low-income adults and the largest single payer for HIV/AIDS in the US. The 
study finds that time to follow-up screening is not guideline-concordant for most women living 
with HIV, particularly those with one of the two risk factors for anal cancer: a history of 
abnormal cervical test results or a history of genital warts.  
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Chapter 1: The effects of community-based distribution of family planning services on 
contraceptive use in Malawi 
Abstract 
  Background: To address rapid population growth, Malawi implemented and scaled-up a pilot 
project of community-based distribution (CBD) of family planning services. However, the 
effects of the scaled-up (national) CBDs on contraceptive use remain unclear. To address this 
knowledge gap, we evaluated the effectiveness of the national CBDs of family planning on 
contraceptive use. We also investigated whether education and income, two important 
determinants of individual-level contraceptive use behaviors, moderate these effects.  
  Methods: We used the 2000/2004 and 2010/2016 Malawi Demographic and Health Surveys 
(N=57,978) and difference-in-differences analyses to estimate the effects of the 2005 national 
scale-up of CBDs on modern contraceptive use. We used rural and urban communities as the 
intervention and comparison groups since the national CBDs were implemented only in rural 
communities. Contraceptive use is defined as current use of any modern contraceptive method—
e.g., pills—and was modeled using multilevel logistic regression.  
  Results: Prior to the national CBD scale-up (2000/2004), the probability of using 
contraceptives was 21.5% in rural communities and 26.3% in urban communities. In the post-
scale-up period (2010/2016), the probability of using contraceptives increased in both rural and 
urban communities but was greater in rural communities (44.9% vs. 42.9%). The effect 
attributable to CBDs was 6.8 percentage points (95% CI=3.3, 9.7). The effects of the CBD scale-
up were greater among uneducated and low-income women.  
  Conclusions: These findings suggest that national CBDs increase overall contraceptive use, 
particularly in rural communities. Poor and uneducated women benefit more from family 
planning interventions that reduce communication and financial barriers. Further research on the 
effects of national CBDs on fertility, as well as the value and affordability of the national CBDs, 
is needed. 
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1. Introduction 
Since gaining independence from the British in 1964, Malawi has experienced rapid population 
growth [1], [2], which has strained the country’s resources in important sectors of education and 
health and has undermined the country’s efforts to reduce poverty [3]. Malawi’s population grew 
by about 500%, from 3.7 million in 1964 to over 17 million in 2015 [1], [2]. To find ways to 
slow the population growth, the Malawi government with financial support from the World Bank 
rolled out a pilot of the Learning and Innovation Population and Family Planning (Pop/FP) 
Project [4]–[6]. The pilot’s objective was to test the feasibility of implementing a comprehensive 
community approach aimed at increasing the demand for and improving access to family 
planning services among hard-to-reach populations [6], [7]. The project trained community-
based distribution1 (CBD) agents to carry modern contraceptive methods (pills and condoms) 
and conduct family planning education in local languages of their designated communities of 
service [5], [6]. Some CBD agents of family planning referred clients to health facilities for 
services the agents could not provide [4].  
The pilot project was implemented from 1999 to 2003 in 3 districts, one in each region. The 
districts were Chiradzulu in the South, Dowa in the Center and Chitipa in the North [5], [6], 
figure 1. The districts were selected based on the presence of a committed District Health 
Management Team (DHMT), low contraceptive prevalence rate (CPR), high population density, 
and low literacy rates [7]. Each pilot district had one control selected based on proximity and 
comparable socio-demographic characteristics (e.g., education) [5], [7]. The controls were 
                                                 
1 The idea of a community approach to delivering family planning services was not entirely new in Malawi. It was 
first introduced in the late 1980s [4]. In 1991, the Christian Health Association of Malawian—an umbrella body of 
faith organizations providing healthcare services in Malawi—started a similar initiative [4]. The difference, 
however, is that prior efforts were not well coordinated, did not have a large presence in the communities, and had 
little or no involvement of public sector institutions [4]. 
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Mulanje for Chiradzulu, Ntchisi for Dowa and Karonga for Chitipa [5], [7]. An end-of-pilot 
evaluation in 2003 suggested that the pilot was effective in increasing contraceptive use [5], [6]. 
Given the pilot project’s effectiveness, it was scaled-up to the national level in late 2004. 
However, no study has evaluated the effect of the national CBD scale-up. Therefore, the current 
study investigates the effect of the full national scale-up of the CBDs of family planning 
(henceforth, CBDs) on contraceptive use during the period 2005-2016. Furthermore, because 
education and income are important determinants of individual contraceptive use behavior [8]–
[11] and the intervention was designed to reduce or eliminate information and financial barriers 
to accessing contraceptives [5], [6], we also examine whether the effect of the CBDs varies by 
the education or income of the target population. The first hypothesis is that CBDs increased the 
number of women using modern contraceptives. The second hypothesis is that the effects of 
CBDs on contraceptive use are moderated (influenced) by both the education and income of the 
women receiving the services and these effects greater among highly educated and high-income 
women. The scale of the CBDs was done simultaneously across the country [personal 
communication, Malawi’s Ministry of Health, January 2016]. 
Understanding the effect of the full scale-up of Malawi CBDs is important for several reasons. 
First,  many projects implemented in low- and middle-income countries (LMICs) show promise 
of success when implemented as pilots [12]–[16], [17, p. 360], [18], [19], but when scaled to the 
national level, the evidence on the performance of such projects is lacking. This makes it 
difficult for policymakers to respond to emerging challenges and set new goals for the countries 
to achieve. Moreover, the few studies that have evaluated large-scale or scaled-up CBDs in 
Africa were not rigorous enough to provide reliable evidence that can be extrapolated to Malawi 
for evidence-based decision making. The studies either lacked control groups [20], [21] or did 
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not use pre- and post-intervention study designs [22]. This study addresses the methodological 
shortcomings of the previous studies by implementing a difference-in-differences technique to 
mimic an experimental study design to identify the effect of the CBDs on contraceptive use.  
The second reason for evaluating the effects of the national CBDs in Malawi is that the selection 
criteria of the pilot districts (e.g., the presence of a committed DHMT and low district CPR) 
predisposed the pilot of the CBDs to demonstrate a level of effectiveness higher than would have 
been the case had the districts been randomly selected [6], [7]. Therefore, as these criteria 
suggest that the pilot districts were systematically different from the non-pilot districts and that 
the effect of CBDs in the pilot project might have been overstated, it is important to investigate 
the effect of the CBDs in the non-pilot districts after the scale-up.  
Third and importantly, the national scale-up was implemented as a variant of the pilot project as 
not all conditions in the pilot project were maintained in the national scale-up which raises 
questions about the effectiveness of the scaled-up CBDs. A comparison of the pilot and national 
CBDs is provided in table 1. Notably, a monthly $6 cash payment to each CBD agent during the 
pilot was discontinued. Moreover, during the pilot the CBDs were primarily supervised by 
project employees who were given adequate resources, including motorcycles; in the national 
scale-up, primary CBD supervisors are government employees (Health Surveillance Assistants 
[HSA]—a cadre of community health workers) who use push bicycles to conduct the supervision 
[6]. Without the cash incentives and questions about supervision adequacy in the national scale-
up, it is unclear whether the CBDs continued to be as effective as they were in the pilot. 
In sum, an investigation into the effects of Malawi CBDs is needed as evidence on the 
effectiveness of the CBDs at the national level is lacking, but this evidence is important to 
Malawi. The evidence can be used by the Malawi government in the reorganization of the 
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country's priorities as the country works to achieve its target of eliminating poverty, providing 
quality education, and ensuring healthy lives for Malawians [3].  
The rest of the study is organized as follows. Section 2 presents a background to the community-
based distribution of family planning. Sections 3 and 4 present the theoretical/conceptual 
framework and methods. Results are presented in section 5. A discussion of the study's findings, 
strengths and limitations, and implications for policy is presented in section 6. Section 7 
concludes. 
2. Background to community-based distribution of family planning services  
Community-based distribution (CBD) refers to strategies that rely on community structures, 
including community leaders and trained non-professional members of the community, to 
provide health services in the communities [23], [24]. CBDs of family planning promote the use 
of simple and safe non-clinical family planning methods such as oral contraceptives and 
condoms [24]. CBDs were introduced to reduce the unmet need for family planning in many 
parts of the world, particularly in rural areas of LMIC where the healthcare workforce is limited, 
stock-outs of modern contraceptives are frequent, and travel distances to health facilities are long 
[25]–[29]. CBDs were started in Latin America in the 1960s, then in Asia in the 1970s and more 
recently after 1980 in Africa [24], [30]. 
The promotion of CBDs in LMICs is based on theory and evidence which suggest that the CBDs 
have many advantages over services received in clinical settings. First, by bringing services to 
the communities, CBDs are more convenient for many people to access family planning services 
[23], [24], [27]. Second, family planning services received from CBDs cost less because many 
CBD agents work as volunteers or accept a small payment for their services and do not require 
extensive training [27], [31]. Third, it is easier for people in the communities to accept family 
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planning messages from the CBD agents since in many cases, the CBD agents are respectable 
and trusted members of their communities, especially when they are selected by the communities 
themselves [24]. Moreover, because CBD agents usually have many commonalities (e.g., 
language and cultural beliefs) with the rest of the community, it is easier for them to overcome 
social customs and traditions hindering the uptake of contraceptives [24], [27], [29], [32], [33]. 
Fourth, there is repeated messaging: because the CBD agents often reside in communities in 
which they provide the family planning services, there are more opportune occasions (e.g., social 
gatherings) where they can talk about family planning [4], [27]. The CBD agents may also 
informally talk about family planning which can be more appealing than the demand-based and 
static clinical set-up [27].  
2.1. The effectiveness of community-based distribution of family planning 
Despite CBDs being considered an important innovation in the delivery of family planning 
services, evidence of their effectiveness is mixed and mainly comes from pilot projects. Data 
show that CBDs have increased contraceptive use in many parts of Africa [14]–[16], [21], [34], 
[35], and that the positive effects of the CBDs persist when the portfolio of methods carried by 
CBDs is expanded beyond the non-clinical methods to include depot medroxyprogesterone 
acetate (DMPA)—an injectable contraception [12], [17], [36]. Furthermore, CBDs are still 
effective even when the CBDs integrate family planning services with other services [36], or 
when social institutions are the medium for channeling family planning information [24], or in 
makeshift settings in times of crisis [37]. However, evidence suggests that CBDs have not 
increased contraceptive use in some parts of Africa [20], [38], [39].  
The effectiveness of CBDs depends on many factors. CBDs are more effective in communities 
with low CPR [24], [29], in more rural and isolated communities [14], [27], and in earlier periods 
9 
 
of CBD implementation [14]. Characteristics of the CBD agents also affect the effectiveness of 
the CBDs, although this evidence is mixed. Reports show that CBD agents are less effective if 
the agents are not well educated [39], [40]. However, other evidence shows that the agents’ age, 
education, and marital status have no association with CBDs’ productivity [41], although the sex 
of the CBD agent is important in influencing the choice of the contraceptive method [29].  
Despite the evidence that contextual factors and characteristics of the CBD agents influence the 
effectiveness of CBDs, it is unclear whether the education and income of the target population 
also affect the effectiveness of CBDs. It is important to understand the role of education and 
income of the people receiving services from the CBDs because education and income are 
important determinants of individual contraceptive use behavior [8]–[11], and the CBD agents 
disseminate family planning information in ways that are easier to understand and overcome 
financial barriers associated with accessing contraceptives [13], [24]. Therefore, apart from 
investigating the effects of Malawi CBDs on contraceptive use, we also investigate whether the 
education and income of the target population affect the effectiveness of the CBDs. 
3. Theoretical and conceptual framework 
To understand the effect of CBDs on contraceptive use, we draw upon the economic framework 
for fertility analysis and the human capital model of demand for health. The economic 
framework for fertility analysis expands on consumer choice approaches [42] by incorporating 
supply factors and the cost of regulating fertility to understand household fertility behavior [43]. 
The theory notes that a household’s need to regulate fertility arises when its biological supply of 
children exceeds its demand for the children [43]. However, there are costs to fertility regulation. 
The costs could be objective (e.g., transportation and contraceptive costs) or subjective (e.g., 
coping with using contraceptives against one’s beliefs) [44]. While having many children may 
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provide utility to some households [45] or alleviate the subjective feeling of poverty in some 
societies of LMICs [46], the relatively high costs of obtaining modern contraceptives prevent 
many households in LMICs from regulating their fertility [47]–[49]; this is where CBDs become 
relevant and important in Malawi. By bringing contraceptives to the communities, the CBDs 
bring down the objective costs of fertility regulation to almost zero. CBD clients are not required 
to pay for services received from the CBDs because public health services in Malawi are free at 
the point of delivery [50].  
We also draw upon the human capital model of demand for health by Grossman which identifies 
two pathways through which education impacts health behaviors like contraceptive use. First, 
through productive efficiency: educated people are better decision makers and thus have higher 
marginal products in the health production process [51]. Second, through allocative efficiency: 
educated people tend to have more knowledge about health which helps them to change their set 
of choices as well as behaviors to produce more health [51], [52]. The information shared by 
CBDs adds to the knowledge educated people already had, making it easier for them to dispense 
with traditional customs and beliefs that may impede contraceptive use [8]. In sum, although 
both educated and uneducated people might have improved access to contraceptives through 
CBDs, educated people are likely to process family planning information better, discuss and 
follow recommendations for contraceptive use [8], [53], [54]. 
Based on the two economic theories, we developed a conceptual framework of the effect of 
CBDs on contraceptive use while incorporating contextual or community factors which may also 
influence contraceptive use as documented in the literature [8], [9], [55]–[58], figure 2. The 
conceptual framework is specific to rural communities as CBDs work in rural communities only. 
The framework shows that contraceptive use is influenced by CBDs, the intervention, as well as 
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individual-level characteristics (maternal and paternal) of the target population and community-
level factors. As the study has hypothesized that the direct effect of CBDs on contraceptive use is 
moderated by education and income, education and income were extracted from the other 
individual-level characteristics so that their moderating effects on the effect of CBDs on 
contraceptive use could be depicted as hypothesized. Further, the framework shows that 
individual-level characteristics of the target population affect contraceptive use directly or 
indirectly via community characteristics. 
4. Materials and methods 
4.1. Overview 
The study used data from four waves (2000, 2004, 2010, and 2016) of the Malawi Demographic 
and Health Surveys (MDHS) and the difference-in-differences (DD) method to estimate the 
effect of the CBDs on contraceptive use in a weighted sample of 52,768 women aged 15–49 
years. As CBDs were implemented only in rural communities, the rural communities were 
designated as the intervention group and urban communities as controls; primary sampling units 
were used as a proxy for communities. As CBDs were introduced in 2005, data collected before 
2005 (MDHS2000 and MDHS2004) represented the pre-intervention period while MDHS2010 
and MDHS2015 represented the post-intervention period. Contraceptive use was defined as 
current use of any modern contraceptive method—for example, pills. Contraceptive use was 
modeled as a binary variable (“no method” and “modern method”) in a multi-level logistic 
regression with women nested in communities and communities nested in districts. 
4.2. Data sources 
Four waves of the Malawi Demographic and Health Surveys (MDHS2000, MDHS2004, 
MDHS2010 and MDHS2016) were used in this study. The surveys were conducted by the 
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National Statistical Office (NSO) in partnership with the United States Agency for International 
Development (USAID) and the country’s other development partners [57], [59]–[61]. In years 
2000, 2004, 2010, and 2016, the surveys covered 14,213, 15,091, 27,000 and 26,361 households, 
respectively [57], [59]–[61]. From the selected households, eligible women aged 15-49 years and 
men aged 15-54 years in a sub-sample of about one-third of the households were interviewed. 
The surveys provided comprehensive up-to-date information on education, wealth, and 
contraceptive use, among other indicators [57], [59]–[61]. The surveys use two-stage stratified 
cluster sampling to produce representative samples of urban and rural populations at the district, 
regional and national levels. Urban areas are defined as any of the country's major cities or areas 
encompassing district administrative headquarters or any official town planning areas; all the 
other areas are rural [62]. 
4.3. Hierarchical structure of the data 
Since the surveys use multi-stage sampling designs to generate nationally representative samples, 
data from the surveys have a hierarchical or clustered structure [63]–[65]. Elements sampled in 
the first-stage, districts, constitute the highest level while those sampled in the final-stage, 
women, are the lowest units [63]. Thus, women are nested in communities and the communities 
in districts. The nesting means that women from the same community or district are similar and 
do not act as independent observations in their use of contraceptives. The similarity might be due 
to unobserved factors, like having similar cultural and traditional beliefs, which can facilitate or 
hinder contraceptive use [66], [67]. Therefore, statistical modeling of these data should account 
for this dependence to avoid producing biased estimates [63], [68]. As discussed below, 
contraceptive use was modeled using a multilevel model to account for the hierarchical structure 
of the data.  
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4.4. Sample  
The final sample comprised 57,524 women, representing about 79% of women in the four 
MDHS files, figure 3. The data for this study came from the “women recode” files. Figure 3 
shows how the sample was derived and the number of women from each wave of the MDHS. 
Infecund women, defined as women wanting to have another child but not being able to get 
pregnant [69], were excluded. Pregnant women were also excluded because the dependent 
variable was constructed from a question which focused on current contraceptive use. All 
women, regardless of marital status, were included in the study as they can all demand 
contraceptives. However, the association between CBDs and contraceptive use was also 
examined in a subsample of married women to make the findings more comparable to those from 
the pilot of the CBDs which reported contraceptive use among married women only [5].  
4.5. Variable definition 
4.5.1. Dependent Variable 
The dependent variable is current use of modern contraceptive methods, and it is binary (1=using 
a modern method and 0= not using a modern method). The women were asked this question:  
Are you currently [at the time of the interview] doing something or using any method to 
delay or avoid getting pregnant [70]? 
Women answering “YES” to this question were further asked to mention the methods they were 
using [70]. The contraceptive methods were classified as either modern or traditional. Modern 
methods include injections, pills, intrauterine device, diaphragm, condoms, sterilization, 
implants, foam or jelly, and lactational amenorrhea; traditional methods include abstinence and 
withdrawal [69]. Abortion was not considered as contraception because contraception was 
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defined as any effort to reduce the risk of conception. The three categories of contraceptive use 
(“no method”, “traditional method”, and “modern method”) were collapsed into two categories 
“no method” and “modern method” as <2% of the women used “traditional methods”. A test for 
combining categories of the dependent variable proposed by Long and Freese [71] showed that 
“traditional methods” and “no method” could be collapsed into one category as the two 
categories were indistinguishable. 
4.5.2. Explanatory variables 
Consistent with the conceptual framework in figure 2, explanatory variables were classified into 
two broad groups: individual-level variables and community-level variables. Among the 
individual-level variables, the woman’s partner’s education and occupation were included as 
these may also affect contraceptive use regardless of the woman’s characteristics [72], [73]. 
Community variables were also included because these may exert influence on women’s 
behaviors related to contraceptive use [74], [75]. For example, community literacy was included 
because women without any education may get assistance or encouragement to use 
contraceptives from other women with education in the same community. All explanatory 
variables, including definitions and how they were constructed, are presented in Appendix A1.  
4.6. Identification strategy: difference-in-differences 
We used the difference-in-differences (DD) method to identify the effect of CBDs on 
contraceptive use. The method rests on the parallel paths assumption, which states that the 
intervention and comparison groups would have followed the same time trends were there no 
intervention [76]–[78]. An effective policy intervention, therefore, causes the intervention group 
to deviate from its time trend [76], [78], [79]. The assumption, however, requires that the policy 
change should be exogenous or that any of the groups should not systematically select to adopt 
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the policy change. The study identified rural and urban communities as the intervention and 
comparison groups, respectively, although the government did not explicitly say that it was 
introducing CBDs in rural communities. However, by the scope of their work and as 
corroborated by a family planning expert [personal communication, Directorate of Reproductive 
Health and Family Planning in Malawi, January 2017], CBDs operate in rural communities only. 
CBDs target populations residing in hard-to-reach communities and urban communities are not 
hard-to-reach; many urban communities have wealthier households, better roads, and a higher 
supply of both health facilities and healthcare workforce, all of which permit easy access to 
healthcare services [80], [81] and diminish the need for CBDs in the urban communities.  
Furthermore, the period before 2005 was identified as the pre-CBD period while the period after 
2005 was the post-CBD period, figure 4. The introduction of CBDs occurred from December 
2004 to February 2005 while interviews for MDHS2004 started in October 2004 and were 
completed in February 2005 [59]. Although there was an overlap of two months (December and 
January) between the introduction of CBDs and the data collection process, the overlap was not 
expected to affect the identification strategy. This is because data collection for the MDHS2004 
had just started when CBDs were being introduced, and it was likely that CBD effects had a time 
lag. Therefore, the assumption was that the data collected in December 2004 and January 2005 
did not capture CBD effects on contraceptive use. So, MDHS2000 and MDHS2004 were 
designated as the baseline surveys and MDHS2010 and MDHS2016 as the post-intervention 
surveys. However, in sensitivity analysis (Appendix A2), the effect of the overlap was checked 
by redefining the pre-CBD period to the year 2000 and removing the year 2004 from the 
analyses.  
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Finally, the three districts (Chitipa, Ntchisi, and Chiradzulu) in which the pilot of the CBDs was 
conducted (1999 to 2003) were excluded from the analysis. A change in the trend of 
contraceptive use after 2004 in rural communities of these districts was not expected because 
CBDs operated almost continuously from 1999 through 2016. In sensitivity analysis (Appendix 
A2), the validity of the identification strategy was tested by examining contraceptive use in areas 
where CBDs were expected not to have significant effects, namely, in the three pilot districts and 
in urban communities. 
4.7. Statistical analysis 
Data were analyzed using univariable and multivariable statistical approaches. In univariable 
analyses, categorical variables were described using proportions and continuous variables using 
averages. In multivariable analyses, contraceptive use was modeled using multilevel logistic 
regressions to account for the hierarchical structure of the data, as done previously [74], [75], 
[82]. Multilevel modeling (MLM) was also warranted because CBDs were introduced at a higher 
level—the community. Since MDHS' do not have a defined geographic area for communities, 
primary sampling units (PSU) were used as a proxy for communities. On average, each PSU 
comprised 30 households [57], [59]–[61]. The appropriateness of MLM was tested using the 
likelihood ratio (LR) test in a comparison of the single-level to the MLM. The degree of 
clustering in contraceptive use among women at the community and district levels was assessed 
using the intra-class correlation (ICC)—a measure of the relative similarity among observations 
from a sampling process and is estimated by analysis of variance and variance components [83], 
[84].  
All analyses were conducted incorporating weights to correct for the unequal probabilities of 
selection to permit nationally representative estimates of the population. The weights provided in 
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the MDHS public use files were scaled using a weight-scaling method which makes the cluster 
size equal to the effective sample size to make the weights more appropriate for adjusting 
estimations at higher levels of the model [63], [85]. The weight scaling method assumes that 
level-1 weights are non-informative and uncorrelated with covariates multiplying the random 
effect thereby yielding unbiased estimates [63].  
All results are presented as log-odds and marginal effects. We did not use odds ratios because 
they are difficult to interpret when logistic regression includes interaction terms [86], [87]. 
Therefore, we relied the study relied heavily on the marginal effects to understand the effect of 
CBDs on contraceptive use and whether the effect depended on education or income. Statistical 
significance of the results was determined using p-values and confidence intervals. All analyses 
were performed in Stata 14.2 [88, p. 14].  
4.7.1. Model specifications 
4.7.1.1. Effect of CBDs on contraceptive use 
To examine the effect of CBDs on contraceptive use, the study’s primary objective, we first 
estimated a single-level logistic regression and then a multilevel logistic regression in the 
country's 25 districts in which the pilot of CBDs was not conducted. The multilevel logistic 
regression was a 3-level random intercept model and was estimated using Stata's “melogit” 
command [89]. Stata’s melogit performs optimization using the “original metric of variance 
components” and was preferred to other candidate commands like the meqrlogit because model 
convergence time is much shorter using the melogit command than the meqr command [89], 
[90]. The single-level logistic regression for any woman is specified as follows: 
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𝑙𝑜𝑔 ( 
𝜋𝑖
[1−𝜋𝑖]
) = 𝛽0 +  𝛽1(𝑅𝑢𝑟𝑎𝑙) + 𝛽2(𝐶𝐵𝐷𝐴) + 𝛽3(𝑅𝑢𝑟𝑎𝑙 ∗ 𝐶𝐵𝐷𝐴) + 𝜆𝑿𝑖 + 𝛼𝑷𝑗 +
γ𝑘 + 𝛤 + ℇ𝑖                       (1) 
Extending the single-level logistic regression in equation 1, the 3-level random intercept model 
for the ith woman, in the jth community and kth district is specified as follows: 
𝑙𝑜𝑔 ( 
𝜋𝑖𝑗𝑘
[1−𝜋𝑖𝑗𝑘]
) = 𝛽0 +  𝛽1(𝑅𝑢𝑟𝑎𝑙𝑗𝑘) + 𝛽2(𝐶𝐵𝐷𝐴) + 𝛽3(𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ∗ 𝐶𝐵𝐷𝐴) + 𝜆𝑿𝑖𝑗𝑘 +
𝛼𝑷𝑗𝑘 + 𝛤 + 𝑈𝑘 + 𝑈𝑗𝑘 + ℇ𝑖𝑗𝑘            (2) 
Where;  
πijk is the proportion of women using contraceptives and (1-πijk) is the proportion of 
women not using any contraceptives. 
Rural=1 if the community is in a rural area; Rural=0 for communities in urban areas. 
CBD=1 if year =2010 or 2016; CBD=0 if year = 2000 or 2004. 
Xijk is a vector of individual-level variables e.g., age (see table A1) and λ is a vector of 
parameters corresponding to the individual-level characteristics.  
Pjk is a vector of community-level variables e.g., community child mortality (see table 
A1) and 𝞪 is a vector of parameters corresponding to the community-level variables. 
Γ captures fixed effects for the years 2000, 2004, 2010 and 2016.  
Uk, Ujk, and ℇijk are adjusted district random effects, community random effects, and 
individual-level residuals, respectively, and they are all assumed to be independent and 
normally distributed with zero means [76]. The district and community effects represent 
the unobserved district and community characteristics which influence contraceptive use. 
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It these unobserved factors which cause correlation in contraceptive use among women 
from the same community or district [75, 76].    
Thus, for a binary outcome variable Yijk, in equation 2, πijk = Pr(Yijk=1) is the probability that the 
ith woman in the jth community in the kth district uses contraceptives and log (πijk/[1-πijk]) is the 
natural log of using contraceptives versus not using contraceptives.  
We assessed the fitness of the model in equation 2 by comparing observed vs. predicted values 
of contraceptive use and deviance residuals. 
4.7.1.2. Assessing moderation  
To assess whether education or income moderate (influence) the relationship between CBDs and 
contraceptive use, we extended the model in equation 2 as follows: 
Education as a moderator 
𝑙𝑜𝑔 ( 
𝜋𝑖𝑗𝑘
[1−𝜋𝑖𝑗𝑘]
) = 𝛽0 +  𝛽1(𝑅𝑢𝑟𝑎𝑙𝑗𝑘) + 𝛽2(𝐶𝐵𝐷𝐴) + 𝛽3(𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑗𝑘) + 𝛽4(𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ∗
𝐶𝐵𝐷𝐴) +
 
 𝛽
5
(𝑅𝑢𝑟𝑎𝑙 ∗ 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑗𝑘) +  𝛽6(𝐶𝐵𝐷𝐴 ∗ 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑗𝑘) + 𝛽7(𝑅𝑢𝑟𝑎𝑙 ∗ 𝐶𝐵𝐷𝐴 ∗
𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑗𝑘) + 𝜆𝑿𝑖𝑗𝑘 + 𝛼𝑷𝑗𝑘 +  𝛤 + 𝑈𝑘 + 𝑈𝑗𝑘 + ℇ𝑖𝑗𝑘            (3)  
Income as a moderator 
𝑙𝑜𝑔 ( 
𝜋𝑖𝑗𝑘
[1−𝜋𝑖𝑗𝑘]
) = 𝛿0 +  𝛿1(𝑅𝑢𝑟𝑎𝑙𝑗𝑘) + 𝛿2(𝐶𝐵𝐷𝐴) + 𝛿3(𝐼𝑛𝑐𝑜𝑚𝑒𝑖𝑗𝑘) + 𝛿4(𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ∗ 𝐶𝐵𝐷𝐴) +
 
 𝛿5(𝑅𝑢𝑟𝑎𝑙 ∗ 𝐼𝑛𝑐𝑜𝑚𝑒𝑖𝑗𝑘) +  𝛿6(𝐶𝐵𝐷𝐴 ∗ 𝐼𝑛𝑐𝑜𝑚𝑒𝑖𝑗𝑘) + 𝛿7(𝑅𝑢𝑟𝑎𝑙 ∗ 𝐶𝐵𝐷𝐴 ∗ 𝐼𝑛𝑐𝑜𝑚𝑒𝑖𝑗𝑘) +
𝜆𝑿𝑖𝑗𝑘 + 𝛼𝑷𝑗𝑘 + 𝛤 + 𝑈𝑘 + 𝑈𝑗𝑘 + ℇ𝑖𝑗𝑘            (4) 
We defined the parameters, variables, and variances in equations 3 and 4 as in equation 2 above.   
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5. Results 
5.1. Trends in contraceptive use 
We examined trends in contraceptive use among rural and urban women before and after 
implementation of CBDs, figure 5. Over the two periods, the proportion of women using 
contraceptives increased in both rural communities (where CBDs were implemented nationally) 
and urban communities. However, the increase was greater among rural women by about 8 
percentage points. 
5.2. Sample characteristics 
We examined the characteristics of a weighted sample of 52,978 (unweighted sample=57,524) 
women aged 15-49 years, table 2. About 80% of the women were from rural communities. 
While the percent of women with primary or secondary education increased in both 
communities, in each period rural women were more likely not to have any education. The 
percent of low-income women declined in rural communities and stayed the same in urban 
communities, although in both periods rural women were still less likely to have higher incomes 
than urban women. In either period, both rural and urban women were more likely to be married 
but rural women were higher in the percent that was married. The percent of women exposed to 
family planning information declined in both rural and urban communities, but rural women 
were less likely to be exposed. Both rural and urban women were most likely not to want to have 
any more children in both periods, and the percent of women that wanted to delay fertility 
increased in both communities. Finally, rural communities were more likely to report problems 
of access to healthcare, higher community child mortality, be poor, illiterate, and want to have 
more children; these indicators, however, improved after introduction of CBDs. 
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5.3. Average community and district contraceptive use 
We assessed contraceptive use among women from 2,567 communities in 25 districts and found 
that the odds of using contraceptives in an “average” community and district—given by the 
overall intercept when district and community effects are equal to zero—was about 0.55 (95% 
confidence interval (C.I.) =0.51, 0.60) corresponding to a probability of 0.36 (95% C.I.=0.34, 
0.38). We also found between-district and between-community variations of 0.04 (95% C.I. = 
0.02, 0.09) and 0.28 (95% C.I. = 0.23, 0.35), respectively. These estimates were obtained from 
an empty multilevel model, and we present caterpillar plots with 95% confidence intervals of 
average community and district contraceptive use in figures 6 and 7.  
In figure 6 and 7, the line at zero represents average log-odds of using contraceptives. We found 
that in many communities the 95% confidence intervals of contraceptive use overlapped with the 
zero line, with about 15% of the communities significantly deviating from the overall average. 
Furthermore, nearly 40% of the districts had contraceptive use that differed significantly from 
the district average and one district—Mangochi—had below average outlying contraceptive use. 
In sum, we found significant heterogeneity in contraceptive use at the community and district 
levels, providing preliminary evidence supporting using an MLM so that each district and 
community could have its own intercept. 
5.4. Appropriateness of multilevel models  
When the single level and multilevel logistic regressions of contraceptive use were compared, we 
found that the multilevel logistic regression was more appropriate [LR Chi (2) =1852, 
p<0.0001]. Next, a comparison of two- and three-level logistic regressions showed that the three-
level model should be preferred [LR Chi (1) =121, p<0.0001]. The evidence confirmed that 
women do not act as independent observations in contraceptive use; they are clustered at the 
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community and district levels. The clustering was about 4 times stronger among women in the 
same community than among women from different communities of the same district. 
5.5. Effect of CBDs on contraceptive use 
We present the effect of CBDs on contraceptive use estimated from the MLM in table 3. For 
comparison, we also include estimates from the single-level model. In all, the results from the 
two models are consistent with each other, although estimates from the MLM are slightly higher 
in many cases. Furthermore, the multilevel model had consistently larger standard errors and 
wider confidence intervals than the single-level model. This suggests that were we to use the 
single-level model, the probability of type 1 error (rejecting a true null hypothesis) would have 
been slightly higher than the nominal level as the statistical significance of our results would 
have been overstated [91], [92]. Our findings suggest that the effect of CBDs on contraceptive 
use was not homogenous in rural and urban communities as the coefficient of the interaction of 
CBDs and rural is statistically significant. The results also show that community factors explain 
the use of modern contraceptive methods in Malawi. The effect of the CBDs on contraceptive 
use is presented as marginal effects in table 4. 
We found that CBDs increased contraceptive use by 6.8 percentage points among all women, 
table 5. The probabilities were predicted using the fixed part of the random coefficient model 
which is equivalent to setting the community and district random effects to zero. Thus, the 
average probabilities are for women in the median community [76]. Before CBDs were 
introduced, the probability of using contraceptives was 21.5% in rural communities and 26.3% in 
urban communities. After CBDs were introduced, however, the probability of using 
contraceptives in rural communities increased substantially and was higher than in urban 
communities (44.9% vs. 42.9%). Subtracting the urban-rural difference before CBDs from the 
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urban-rural difference after CBDs shows that CBDs increased contraceptive use by about 6.8 
[95% C.I.=3.3, 9.7] percentage points, all other factors held constant. In a sub-sample of married 
women, CBDs increased the probability of using contraceptives by about 8.2 [95% 
C.I.=4.1,12.3] percentage points. 
5.6. Assessing whether education and income are moderators of CBD effects 
When we examined whether the association between contraceptive use and CBDs depended on 
education and income, we found that the association depended on both these factors, table 5. The 
effect of the CBDs varied by education and was significantly higher among women without any 
education followed by those with primary education in comparison with women with at least a 
secondary education.  Similarly, the effect of CBDs was also moderated by income and was 
significantly greater among women with low and medium incomes compared to women with 
high income.  
Figures 8 and 9 present the predicted probabilities of contraceptive use at various levels of 
education and income before and after the CBDs were introduced. The CBDs increased the 
probability of using contraceptives in each group of women and the percentage point changes 
were as follows: women without education (+22.8); women with primary education (+17.23); 
women with at least a secondary education (+9.69); low-income women (+19.85); medium-
income women (+17.00); and high-income women (+10.05). Thus, women without any 
education benefitted the most from the CBDs with a 13-point net increase in the probability of 
contraceptive use over and above women with at least a secondary education. Compared to urban 
women, the change in contraceptive use was greater among rural women at every level of 
education. In terms of income, differences in contraceptive use were not statistically different 
between women in rural and urban communities.   
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5.7. Sensitivity analysis of the identification strategy 
Because the data used for this study were not collected for evaluating the effect of CBDs, we 
performed three robustness checks to validate the identification strategy. To identify the effect of 
CBDs, we made three assumptions. First, we assumed that after the national rollout, the effect of 
CBDs was only in the 25 districts in which the pilot of the CBDs was not implemented. So, we 
tested this assumption by examining the effect of CBDs in the three districts in which the pilot of 
the CBDs was implemented, expecting the CBDs not to have significant effects in these districts. 
As expected, the coefficient of the interaction between CBDs and rural was not significant at 5% 
(log-odds=0.738, 95% C.I.= -0.418,1.894). A more detailed analysis of these results is presented 
in appendix A2.  
Second, we assumed that the introduction of CBDs was exogenous and only in rural 
communities. Therefore, we expected CBDs not to have significant effects on contraceptive use 
in urban communities. We tested this assumption by examining the effect of CBDs in urban 
communities and whether education and/or income moderate the effect of CBDs on 
contraceptive use in urban communities. We found that CBDs and its interaction with education 
or income did not have a statistically significant effect on contraceptive use in urban 
communities at 5%, Appendix A2. However, these variables had significant effects in rural 
communities as reported earlier. This result reinforces the findings from the first sensitivity 
analysis and we conclude that our strategy identifies the effect of CBDs. A more detailed 
analysis of these results is presented in Appendix A2. 
Third, we assumed that MDHS data collected in the years 2000 and 2004 served as the baseline 
for contraceptive use in the 25 districts in which the pilot of CBDs was not implemented. In 
these districts, CBDs were introduced after 2004, so MDHS2000 and MDHS2004 should not 
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capture CBD effects. We tested this assumption by examining the effect of changing the baseline 
years. We found that CBDs increased contraceptive use by 7.58 and 5.25 percentage points when 
the baseline years are 2000 and 2004, respectively, compared with 6.8 percentage points when 
both (2000+2004) are used as the baseline, Appendix A2. Thus using 2004 as the base year 
underestimated the effect of CBDs which suggests that the overlap between MDHS2004 and the 
introduction CBDs might be attenuating the effect of CBDs. In all, the sensitivity analyses 
showed that our identification strategy is valid, and in any case, we are underestimating the 
effect of the CBDs.   
5.8. Model fitness 
We tested model goodness-of-fit tests using two approaches both of which suggested that the 
model is a good fit for the data. First, we compared observed vs. predicted values of 
contraceptive use to understand how well the theoretical (binomial) distribution of the data fits 
the empirical distribution. We classified all women with a <0.5 probability of using 
contraceptives as not using contraceptives, while those with a ≥0.5 probability as using 
contraceptives. Second, we examined deviance residuals and identified outlying values. A 
residual was outlying if it lied outside two standard deviations of a mean residual value of zero.  
We found that our model correctly predicted about 75% of women as either using or not using 
contraceptives. However, the model had higher accuracy of predictions among nonusers of 
contraceptives compared to users (>80% vs. > 60%), possibly because there were more nonusers 
of contraceptives than there were users. Deviance residuals in figure 9 also confirm that the 
model correctly predicted the status of contraceptive use for many women although less than 2% 
of predictions were outlying.  
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6. Discussion 
Our primary objective was to estimate the effect of CBDs on contraceptive use in Malawi during 
the period 2005-2016. As hypothesized, we found that CBDs increased the probability of using 
modern contraceptives by 6.8 percentage points among rural women. Our finding is consistent 
with Kalanda’s who reported that the pilot of CBDs in Malawi increased the probability of 
contraceptive use by 7 percentage points [5]. Because Kalanda reported contraceptive use among 
married women only and we report contraceptive use for all groups of women regardless of 
marital status, we also conducted a secondary analysis of the effect of CBDs in a sub-sample of 
married women only to make our findings more comparable. In the secondary analysis, we found 
that CBDs increased the probability of married women using contraceptives by about 8.2 
percentage points, higher than reported in the pilot.  
There are two possible explanations for the bigger effect of CBDs among married women in the 
national scale-up than in the pilot. First, the pilot was only for three years which may not have 
been adequate to see the full effects of the CBDs; to influence people to have positive attitudes 
towards contraceptives and for them to begin to use contraceptives consistently requires more 
time [93], [94]. Second, the scaled-up program has been evolving to include more contraceptive 
methods than there were in the pilot and increasing the number of contraceptive methods carried 
by CBDs is associated with increased contraceptive use [95]. USAID reported that from 2010 the 
Malawi Ministry of Health began to allow Health Surveillance Assistants—primary supervisors 
of CBDs—to administer DMPA [96]. Although few Health Surveillance Assistants administer 
the DMPA [96], it is probable that without this development fewer women would have reported 
using modern methods. This explanation is consistent with reports from pilot studies that 
including DMPA within the existing CBD programs increases contraceptive use, attracts new 
27 
 
users, and equally satisfies women as DMPA obtained in health clinic [12], [17, p. 360], [18], 
[36], [96], [97]. 
Our findings are also consistent with reports from previous studies examining the effect of 
community interventions in other parts of Africa. For example, contraceptive use increased in 
Mali following the introduction of village-level family planning promoters [15], in Ghana where 
health workers with basic training in curative health services were deployed with community 
volunteers to provide family planning services [14], in the Gambia where family planning was 
promoted through traditional social and religious institutions [24], and in South Sudan where a 
CBD program was implemented among displaced people [37].  
Other studies have reported different results, however. In Ethiopia, Tawye et al. reported that 
community-based interventions, increased contraceptive use in some regions but not in others 
[20], perhaps because the study did not have a control group to serve as a counterfactual and/or 
may not have properly identified effects of the community intervention [20]. In Kenya, the 
African Medical and Research Foundation (AMREF) documented that traditional birth 
attendants and male herbalists working as CBDs did not increase contraceptive use [39], 
although AMREF attributed the null findings to the illiteracy of the CBDs. In the DRC, Bertrand 
et al. reported that CPR was relatively unchanged despite the introduction of CBDs [38]. 
Although the study was a pretest-posttest design, Bertrand et al. did not have a control group to 
fully and properly identify the effect of the intervention, unlike the current study which used a 
pre- and post-test design with a control group. 
The current study also adds to the literature in its assessment of whether the effect of CBDs is 
moderated by education and income. As hypothesized, we found that the effect of CBDs is 
moderated by both education and income; we also found that the effect of CBDs varied more 
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strongly with education than with income. A surprising finding, however, was the finding that 
the effect of CBDs was strongest among women with no education and declined as the education 
level increased. There are two potential explanations for this finding. First, because CBDs 
provide family planning information in the simplest form possible, they may be seen to work to 
meet the needs of uneducated women. Second, CBDs carry a very limited number of 
contraceptives—in many cases pills and condoms only—which may be less appealing to highly 
educated women. As a result, highly educated women may be reluctant to seek services from 
CBDs. Since highly educated women are also more likely to have higher incomes, it means they 
can afford to pay for alternative methods of contraception or seek contraceptives elsewhere 
which is consistent with the finding that the effect of CBDs was strongest among low-income 
women. Low-income women are more likely to be receptive to commodities offered by CBDs 
because they have limited contraceptive choices and contraceptive sources. 
6.1. Strengths and limitations 
Findings from this study must be understood in the context of the following strengths and 
limitations. The key strength of our study is the use of nationally representative data to examine 
the effects of the CBDs on contraceptive use. Also, the incorporation of within- and between-
community variation and unobserved community random effects makes our findings 
generalizable beyond the women from communities in the sample [98]. Additionally, by pooling 
independent cross-sections in different time periods, we can make inferences about changes in 
contraceptive use at the population level. Furthermore, our study produces more valid estimates 
of the effect of CBDs because the data were not reported by the CBDs themselves; data obtained 
directly from CBDs can be suspect or incomplete which can introduce bias [16], [95]. Moreover, 
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we performed a series of sensitivity analyses which validated our identification strategy and 
suggested that our findings are robust.  
The study also has many limitations. First, because the MDHS’ do not have defined geographic 
areas called communities, we used PSUs as a proxy for communities which might not be precise. 
Despite this limitation, it is still reasonable to think that women from the same PSU are more 
likely to have shared interests and attitudes and therefore constitute a community [9], [74], [75]. 
Second, while communities were dichotomized as rural or urban, communities occur on the 
urban-rural continuum. It is possible for some communities to have been misclassified and 
because the data come with PSU already classified as rural or urban, we were unable to perform 
a sensitivity analysis of our findings to changes in the urban-rural taxonomy.  
Third, many variables used in the study, including contraceptive use, education, and income, are 
based on women’s self-reports which may not accurately measure what we say they are 
measuring [99]–[101]. Our findings are thus biased to the extent of differential bias in self-
reporting between rural and urban women and/or before and after CBD implementation and if 
the bias exists, its direction is unclear. Notwithstanding this limitation, we still used the self-
reported measures because they are readily available and reflect the respondents’ own view. 
Moreover, current contraceptive use has been validated before and women’s self-reports were 
found to be more valid than men’s [102]. A fourth limitation is that the data were not collected 
for purposes of evaluating the effect of CBDs on contraceptive use. Among women reporting 
contraceptive use, we do not know how many got the methods from CBDs or from other sources 
e.g., health centers. That said, the current analysis suggests that with a proper identification 
strategy it is possible to leverage national data (e.g., MDHS) collected for other purposes to 
answer programmatic questions. 
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Finally, due to data limitations, we were unable to check if CBD effects spilled over from the 
pilot districts to the neighboring districts during the CBD pilot project. Any spillovers are more 
likely to have occurred through the diffusion of family planning information than through 
contraceptive methods crossing district boundaries because the CBD agents had defined villages 
in which they worked; in Malawi, village boundaries do not transcend district boundaries. If 
spillover effects occurred, however, it means our estimates are biased towards the null as 
contraceptive use in the districts sharing borders with the pilot districts was higher than should 
have been at the time of the national scale-up of the CBDs.  
6.2. Policy implications 
From this research, several policy implications are evident. First, CBDs should be continued and 
strengthened if the country is to sustain the gains made in contraceptive use. Among other things, 
the government, the country’s development partners, and stakeholders should ensure that supply 
of contraceptives to the communities is uninterrupted, CBDs receive refresher training regularly, 
supervision of the CBDs is active and frequent, provision of CBD agents’ working kits (e.g., 
bicycles and gumboots) to facilitate follow-up of clientele. The availability of these facilities will 
help ensure that women relying on CBDs continue to get quality services and prevent 
intermittent use of contraceptives among the rural women.  
Second, this work suggests that there may be a need to increase the portfolio of contraceptive 
methods carried by the CBDs. As noted, methods carried out by CBDs are not meeting the needs 
of women with more education and high income. With proper accountability and support, we 
suggest that all CBDs and their supervisors should be carrying DMPA and natural methods (e.g., 
cycle beads) in addition to the condoms and pills. Third, given the success of CBDs in rural 
communities, our results suggest that urban communities can benefit from the introduction of 
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CBDs or an equivalent of the CBDs in the urban communities. For example, health posts 
manned by Health Surveillance Assistants could be introduced in urban communities which have 
limited access to health centers or have high population densities. As the government of Malawi 
continues with efforts to increase contraceptive use, it is important that both urban and rural 
communities are targeted and that the efforts should not create or perpetuate rural/urban 
disparities in contraceptive use as noted in this study.  
6.3. Future research 
While we have reported that CBDs in Malawi increased contraceptive use, we make two 
recommendations for future research. First, the value of the CBDs should be established. Doing 
this would require analyzing both the costs and effects of the CBDs after the national scale-up; 
we have only examined their effectiveness. Examining costs and hence the value of the CBDs is 
important because prior evidence suggests that CBDs can add as much as 30% per capita to the 
primary healthcare budgets [103]. Second, this study has only reported the effect of CBDs on 
contraceptive use—a proximate determinant of fertility. The goal of introducing CBDs was to 
reduce fertility or at least increase birthing intervals in Malawi. Therefore, future studies should 
focus on evaluating the effects of CBDs on these outcomes. 
7. Conclusion 
Following the success of a pilot of CBDs from 1999 to 2003, the Malawi government scaled the 
CBDs to all rural communities of Malawi in 2005. We have found that CBDs increased 
contraceptive use during the period 2005 to 2016, and the intervention can help the country to 
achieve its long-term agenda of reducing population growth. Before the implementation of the 
CBDs, contraceptive use in rural communities was lower than in urban communities. After the 
implementation of the CBDs, however, contraceptive use increased significantly in the rural 
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communities to the extent that urban communities are now lagging. The effect of CBDs was 
strongest among uneducated and poor women suggesting that delivering messages and 
interventions using the communities’ local languages and structures is important if any 
intervention is to reach the target population, particularly rural communities. While the CBDs 
should be continued and strengthened, it is important to establish whether the CBDs have also 
reduced fertility or are cost-effective. 
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Table 1. Comparison of the pilot and national CBDs in Malawi 
Component Pilot National 
Training Yes Yes 
CBD incentives   
Certificates of recognition Yes Yes 
Umbrellas, boots, raincoats, backpacks, and push bicycles Yes Yes 
US$6 per month Yes No 
Uniforms and badges Yes No 
Dedicated resources for supervision*   
Motor vehicle (program-specific) Yes No 
Motorcycles Yes No 
Push bicycles No Yes 
District Health Management Teams   
Commitment Yes Unknown 
Information, education, and communication   
Health talks, dramas, leaflets, flyers, and posters Yes Yes 
T-shirts, radio jiggles, cassette players, and, comic books Yes No 
Family planning commodities   
Pills Yes Yes 
Condoms Yes Yes 
*In the pilot, project employees supervised CBDs. In national CBDs, Health Surveillance 
Assistants (community health workers) employed by the government conduct the supervision.  
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Table 2: Descriptive statistics (Weighted sample size: n=52,978)  
  Rural (n=42,707) Urban (n=10,272) 
Variable 
Pre-CBD 
(n=14,320) 
Post-CBD 
(n=28,386) 
Pre-CBD 
(n=3,200) 
Post-CBD 
(n=7,073) 
Personal-level factors         
Current contraceptive use*         
None 0.743 0.572 0.669 0.574 
Modern 0.257 0.428 0.331 0.426 
Education***         
None 0.276 0.149 0.083 0.046 
Primary 0.636 0.682 0.505 0.411 
Secondary 0.087 0.162 0.392 0.437 
Higher 0.001 0.007 0.020 0.106 
Income (wealth)***         
Low 0.410 0.406 0.045 0.036 
Medium 0.355 0.374 0.079 0.109 
High 0.235 0.219 0.876 0.856 
Occupation***         
Not employed 0.428 0.385 0.602 0.532 
Self-employed 0.449 0.506 0.093 0.102 
Professional 0.123 0.110 0.305 0.366 
Age (years)***         
15-19 0.217 0.229 0.248 0.225 
20-29 0.423 0.374 0.481 0.423 
30-39 0.233 0.268 0.189 0.254 
40-49 0.127 0.129 0.081 0.098 
Marital status***         
Never married 0.169 0.210 0.299 0.319 
Currently married 0.706 0.659 0.598 0.572 
divorced 0.092 0.104 0.062 0.078 
Widowed 0.033 0.027 0.040 0.031 
Fertility desire***         
wants child in < 1 year 0.091 0.056 0.085 0.056 
wants child in >1 year but 
<3years 0.153 0.120 0.115 0.116 
wants child after 3 years 0.315 0.410 0.346 0.434 
no more children 0.440 0.415 0.454 0.393 
Partner's education***         
None 0.313 0.373 0.343 0.399 
Primary 0.549 0.439 0.297 0.199 
Secondary 0.133 0.173 0.323 0.310 
Higher 0.005 0.015 0.037 0.092 
Exposure to family planning information*       
Not exposed 0.516 0.338 0.352 0.168 
Some exposure 0.484 0.662 0.648 0.832 
Autonomy**         
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Little or no autonomy 0.476 0.378 0.479 0.358 
Semi or complete autonomy 0.524 0.622 0.521 0.642 
Religion***         
Catholic or Anglican 0.272 0.222 0.259 0.226 
Other Christians 0.593 0.642 0.626 0.673 
Muslims 0.135 0.137 0.115 0.102 
Community-level factors        
Healthcare access problems**        
Yes 0.653 0.373 0.787 0.595 
No 0.347 0.627 0.213 0.405 
Community literacy***         
Not literate 0.519 0.263 0.048 0.039 
Literate 0.481 0.737 0.952 0.961 
Community income***         
Low 0.419 0.432 0.008 0.006 
Medium 0.382 0.389 0.025 0.034 
High 0.198 0.179 0.967 0.960 
Community religion**         
Catholic or Anglican 0.171 0.092 0.069 0.032 
Other Christians 0.700 0.777 0.895 0.929 
Muslims 0.129 0.131 0.036 0.039 
Community child mortality (mean) 209.167 136.050 135.498 106.898 
* p < 0.05, ** p < 0.01, *** p < 0.001   
All variables are categorical, except community child mortality, and proportions are presented in the table. For the 
categorical variables, we tested whether the proportion of women under each variable was the same in the periods 
before and after CBDs were introduced across both rural and urban communities. For the continuous variable, 
community child mortality, we tested whether the means were different in the two CBD periods across rural and 
urban communities. The tests were performed using the Wald test. 
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Table 3: Effect of CBDAs on contraceptive use in Malawi (2005-2016)   
  Single-level model Multi-level model 
  Coefficient 95% C.I. Coefficient 95% C.I. 
Dependent variable: Contraceptive use     
Main explanatory variables     
CBDAs 0.919*** [0.767,1.071] 0.954*** [0.706,1.202] 
Rural -0.411*** [-0.540,-0.281] -0.314*** [-0.481,-0.147] 
Ref: Urban, before CBDAs     
 Rural, after CBDAs 0.421*** [0.272,0.571] 0.424*** [0.236,0.612] 
Individual-level factors     
Age (ref: 15-19 years)     
 20-29yr 0.568*** [0.470,0.666] 0.588*** [0.486,0.689] 
 30-39yr 0.555*** [0.446,0.663] 0.582*** [0.455,0.710] 
 40-49yr 0.357*** [0.234,0.479] 0.393*** [0.242,0.544] 
Occupation (ref: unemployed)     
 Self-employed/agriculture 0.093** [0.036,0.149] 0.087* [0.018,0.155] 
 Professional/formal 0.240*** [0.159,0.320] 0.251*** [0.190,0.312] 
Marital status (ref: never married)     
 Married 2.257*** [2.116,2.398] 2.353*** [2.086,2.619] 
 Divorced 1.356*** [1.210,1.502] 1.389*** [1.192,1.587] 
 Widowed 0.929*** [0.736,1.123] 0.978*** [0.757,1.200] 
Exposure to family planning information 
(ref: no exposure)     
 Some exposure 0.210*** [0.156,0.264] 0.216*** [0.163,0.269] 
Fertility desire (ref: wants child <1y)     
 >1y but <3y 1.777*** [1.615,1.940] 1.854*** [1.726,1.981] 
 Child after 3y 2.080*** [1.926,2.233] 2.170*** [2.023,2.317] 
 No more children 2.381*** [2.228,2.534] 2.454*** [2.319,2.590] 
Autonomy (ref: no autonomy)     
 At least some autonomy 0.113*** [0.053,0.173] 0.111* [0.025,0.198] 
Partner education (ref: no education)     
 Primary 0.127*** [0.051,0.202] 0.120** [0.040,0.201] 
 Secondary 0.189*** [0.099,0.280] 0.166*** [0.068,0.265] 
 Higher 0.244* [0.055,0.432] 0.234* [0.010,0.458] 
Religion (ref: Catholic/Anglican)     
 Other Christians -0.107*** [-0.171,-0.044] -0.093*** [-0.147,-0.039] 
 Muslims -0.312*** [-0.428,-0.196] -0.279*** [-0.411,-0.147] 
Community-level factors     
Access problem (ref: no problem)     
 Some problem -0.061* [-0.119,-0.002] -0.082* [-0.138,-0.026] 
Literacy (ref: illiterate)     
 Literate 0.055 [-0.009,0.120] 0.102** [0.037,0.166] 
Income (ref: low)     
 Medium income 0.104*** [0.044,0.165] 0.126*** [0.069,0.182] 
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 High income 0.135** [0.054,0.217] 0.219*** [0.124,0.315] 
Religion (ref: Catholic/Anglican)     
 Other Christians 0.0601 [-0.022,0.142] 0.069 [-0.015,0.153] 
 Muslims -0.299*** [-0.429,-0.169] -0.185 [-0.382,0.012] 
Community child mortality -0.0001 [-0.0005,0.0003] -0.0006* [-0.001,-0.0001] 
Year fixed effects (ref: 2000)     
2004 -0.015 [-0.110,0.079] 0.014 [-0.081,0.109] 
2010 -0.776*** [-0.846,-0.707] -0.775*** [-0.875,-0.675] 
Constant 0.004*** [0.003,0.006] 0.003*** [0.002,0.004] 
AIC 57312  56619  
BIC 57587  56833  
Number of districts 25  25  
Observations 52978   52978   
* p < 0.05, ** p < 0.01, *** p < 0.001         
†Effect of CBDAs was estimated in the 25 districts in which the CDBA pilot was not implemented.   
The table summarizes and compares the effect of CBDs (community-based distribution) on contraceptive use modeled 
using a single-level logistic regression and a multilevel (3-level random intercept) logistic regression. While both 
models show that the CBDs increased contraceptive use, estimates from the multilevel model are generally larger and 
have wider confidence intervals. In both models, contraceptive use was significantly associated with both individual- 
and community-level explanatory variables, but the association was stronger with individual-level variables. 
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Table 4: Average predicted probabilities of contraceptive use before and after CBDs, by urban status  
  Rural Urban     
  Probability 95% C.I. Probability 95% C.I. 
First difference 
(D) [95% C.I.] 
Second difference 
(DD) [95% C.I.] 
Before CBDs 0.215 [0.199, 0.231] 0.263 [0.237, 0.288] -0.048   
After CBDs 0.450 [0.430, 0.469] 0.429 [0.400, 0.459] 0.020  
First difference (D) 0.235   0.1668     0.068 [0.031, 0.098]  
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Table 5: Assessment of education and income (wealth) as moderators of CBD effects on 
contraceptive use in rural areas 
  Model 1A (Education) Model 1B (Income) 
  Coefficient  95% C.I. Coefficient  95% C.I. 
Ref: Before CBDs     
    CBDs 1.500*** [1.310,1.691] 1.521*** [1.346,1.696] 
Ref: No education     
    Primary 0.128** [0.0338,0.223]   
    Secondary 0.113 [-0.0262,0.251]   
Ref: No education, before CBDs     
    Primary, after CBDs -0.172* [-0.310,-0.0348]   
    Secondary, after CBDs -0.505*** [-0.657,-0.353]   
Ref: Low income     
    Medium income   0.226*** [0.116,0.336] 
    High income   0.388*** [0.241,0.536] 
Ref: Low income, before CBDs     
    Medium income, after CBDs   -0.229*** [-0.323,-0.135] 
    High income, after CBDs   -0.575*** [-0.731,-0.419] 
Observations 42865   42865  
Number of districts 25   25   
The table summarizes results of examining whether education and income influence the effect of CBDs on 
contraceptive use. For ease of interpretability and understanding, models for education and income were run 
separately. In both models, the coefficient of the interaction terms (CBD*education and CBD*income) is statistically 
significant at 5% which suggests that both education and income individually influence the association between 
CBDs and contraceptive use.  
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Figure 1: District participation in a community-based distribution (CBD) pilot of family 
planning services in Malawi, 1999-2003 
This figure is a map of Malawi showing intervention and control districts in a pilot project 
testing whether a comprehensive community approach to family planning could increase 
contraceptive use in Malawi, 1999-2003.  
Source of shapefiles: Global Administrative Areas (http://www.gadm.org) 
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*CBD stands for community-based distribution of family planning service.               
†Refers to women's characteristics except when the word partner is used.           
Figure 2. A conceptual framework for understanding the effect of CBDs on contraceptive use in rural areas of 
Malawi 
The figure shows a conceptual framework of the effect of CBDs on contraceptive use in Malawi's rural areas. It also shows that 
the effect of CBDs on contraceptive use is moderated by both education and income. The figure also shows that individual-level 
characteristics may affect contraceptive use directly or indirectly via community characteristics. 
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Figure 3: A flowchart for deriving a sample for examining the effect of community-based distribution (CBDs) on contraceptive use in 
Malawi 
The flowchart shows the exclusions applied to derive a sample of women to examine the effect of community-based distribution agents (CBDs) of 
family planning on contraceptive use in Malawi. The data were drawn from four waves (2000, 2004, 2010 and 2016) of the Malawi Demographic 
and Health Surveys (MDHS). The data came from women recode files of the MDHS and contained responses from all women (ages 15-49 years) 
interviewed in the surveys. 
 
  
MDHS2000 MDHS2004 MDHS2010 MDHS2016
Excluded
  infecund   infecund  infecund    infecund
  pregnant   pregnant pregnant    pregnant
1,358 1,404 2,389
1,557 1,449 2,162
Excluded ExcludedExcluded
2,824
1,833
All women 
n=13,220
Fecund women
n=11,862
All women 
n=11,698
Fecund women
n=10,294
Sample
n=8,845
Sample
n=10,305
Total sample
n=57,524
All women 
n=23,020
Fecund women
n=20,631
Sample
n=18,469
All women 
n=24,562
Fecund women
n=21,738
Sample
n=19,905
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Figure 4. Timeline for implementation of community-based distribution (CBD) of family planning services and data collection in the 
Malawi Demographic and Health Surveys (MDHS) 
This figure shows the timeline for the scale-up of national CBDs and MDHS data collection. The blue color (   ) shows the timeline for pilot or 
national CBD implementation, orange color (   ) shows the pre-CBD period while green color (   ) shows the timeline for the MDHS. Thus, the 
study identified MDHS 2000/2004 as the pre-CBD period while MDHS 2010/2016 as the post-CBD period. Data collection for MDHS 2004 was 
from October 2004 to January 2005. CBD scale-up was from December 2004 to February 2005, overlapping in December 2004 and January 2005.  
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Figure 5: Urban-rural trends in contraceptive use before and after national CBDs in Malawi 
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Figure 6: Average community contraceptive use 
This figure shows contraceptive use in each community relative to the average contraceptive use in all the communities. The line at 
zero represents the average log-odds of using contraceptives. We found that in many communities the 95% confidence intervals of 
contraceptive use overlapped with the zero line, although a significant number deviated from the overall average. 
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Figure 7: Average district contraceptive use 
This figure shows contraceptive use in each district relative to the average contraceptive use in all the districts. The line at zero 
represents the average log-odds of using contraceptives in all the districts. We found that four districts had below average 
contraceptive use while 6 had above average contraceptive use. 
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Figure 8: Predicted probability of contraceptive use by women’s education. 
This figure shows that contraceptive use increased among both rural and urban women, but the increases were greater among rural 
women with rural uneducated women benefitting the most from the scale-up of the CBDs.  
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Figure 8: Predicted probability of contraceptive use by women’s income. 
This figure shows that contraceptive use increased among both rural and urban women, but the increases were greater among women 
with low incomes. The figure also shows that the increases in contraceptive use were similar for both rural and urban women at every 
level of income.  
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Figure 9: A goodness-of-fit test using deviance residuals 
This figure shows that very few observations have outlying (above the red line) predictions, suggesting that the model is a good fit for 
the data.  
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Appendices 
Appendix A1: Variable definition and construction  
Table A1: Definition and construction of variables for examining the effect of community-based distribution agents on contraceptive use in Malawi  
 Variable Type  Definition  Explanation/ justification 
Key variables 
Current contraceptive 
use 
Binary Dependent variable: 1=using a modern 
method, 0=not using a modern method. 
Women were asked if they were using any contraceptives at the time of the 
interview. We classified women using traditional methods (<2% of the total) 
as not using any contraceptive method. 
Community-based 
distribution (CBD) of 
family planning services 
Binary CBD=1 if year is 2010 or 2016 (post-CBD 
period) and CBD=0 if year is 2000 or 2004 
(pre-CBD period).  
This is the key explanatory variable and it is the variable whose effect on 
contraceptive use we are assessing. Our hypothesis is that CBDs increased 
contraceptive use. 
Rural/urban status Binary Rural=1, urban=0. This is the second key explanatory variable. CBDs were introduced in rural 
communities only, so we designated the rural communities as the intervention 
and urban communities as the comparison group.  
Individual-level variables 
Maternal education Categorical 2=secondary or higher, 1=primary, 0=no 
education. 
Highly educated women are more likely to use contraceptives. We grouped 
women with higher than secondary education with those with secondary 
education; <2% of the women had an education higher than secondary level. 
Partner's education Categorical 2=secondary or higher, 1=primary, 0=no 
education. 
Women with highly educated partners are more likely to use contraceptives. 
We grouped partners with higher than secondary education with those with 
secondary education; fewer than 2% of the women's partners had an 
education higher than secondary level. 
Income* Categorical 3=high, 2=medium and 3=low. High-income women are more likely to use contraceptives.  
Age Categorical 4="40-49yr", 3="30-39yr", 2="20-29yr", 
1="15-19yr".  
Contraceptive use among women increases with age but begins to decline 
after age 39. This age classification is consistent with other studies on 
contraceptive use in Africa [8], [104], [105]. 
Occupation (woman or 
her partner) 
Categorical 2=professional employment, 1=self-employed 
or agriculture, 0=Unemployed. 
This variable is highly correlated with education and income. Women in the 
professional sector or with partners in the professional are most likely to face 
a higher opportunity cost of raising children. 
Marital status Categorical 3=widowed, 2=divorced, 1=married, 0=never 
married. Married women are most likely to use contraceptives.  
Exposure to family 
planning methods† 
Binary 1=Little or no exposure 0=moderate or 
substantial exposure. 
Exposure to reproductive health messages via media in the month preceding 
the surveys. Women exposed to family planning information are more likely 
to use contraceptives. 
Autonomy‡ Binary 
  
0=Little or no autonomy, 1=semi or complete 
autonomy. 
Autonomy is the woman's ability to consciously make decisions about her 
health and life without fear of reprisals. Autonomous women are more likely 
to use contraceptives.  
Religion Categorical 1=Catholic or Anglican, 2= other Christians, 
3=Muslims, 4=no religion. 
The religion to which a woman belongs. Some religions encourage 
contraceptive use while others do not.  
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Fertility desire Categorical  4=wants no more children, 3=wants child after 
3 years, 2= wants a child in >1 year but 
<3years, 1=wants child in < 1 year. 
Women desiring to have children in less than one year are less likely to use 
contraceptives.  
Community-level and residency variables 
Community literacy Categorical 2=literate, 1=partly literate, 0=not literate. Constructed from the maternal education variable by assigning the education 
category with the highest number of women to the whole community. We 
created this variable because women without any education may still get 
assistance from others with an education in the same community. 
Community income Categorical 3=high, 2=medium, 1=low. We averaged wealth scores were averaged at the community level and created 
percentiles for each of the survey years. 
Community religion Categorical 1=Catholic or Anglican, 2= other Christians, 
3=Muslims. 
Assigned to the whole community based on which religion had the largest 
membership in that community.  
Community access 
problems to care 
Categorical 1=some problem, 0=no problem. Women were asked to report if they had any problems accessing health care 
services in the 12 months preceding the study. Women with problems of 
access to care are less likely to use contraceptives. 
Distance to health 
facility§ 
Continuous n/a Distance to a health facility. Women who travel longer distances to health 
clinics are less likely to use contraceptives.  
Community child 
mortality¶ 
Continuous n/a Child deaths per 1,000 live births. Women in communities with high child 
mortality are less likely to use contraceptives. 
District  Categorical District dummy variables. These are the country's 28 administrative districts. 
*The Malawi Demographic and Health Surveys (MDHS) do not collect data on income; we used wealth as a proxy for the income. MDHS provides wealth scores reflecting 
ownership of durable goods and housing characteristics. We created the wealth categories separately for each year to reflect income distributions in the years of the surveys. 
†Exposure to family planning variable was created from the following media: radio, TV, and newspaper. Exposure to each medium was given a score of 1 and then 
summed. In 2016, exposure to family planning messages via phone messages was added but for consistency with previous surveys, it was not included. Those with a zero 
score were regarded as not exposed. 
‡The variable was constructed based on the extent to which the woman had a final say on the following: 1) Making large household purchases; 2) Making household 
purchases for daily needs; 3) Visiting family or relatives; 4) The woman's own health care; and 5) Meals prepared each day. For each of the five domains, there were 5 
options on who made the decision: the woman alone; together with her partner; together with someone else; partner alone; someone else or decision was not made. The 
responses were scored on a scale of 1-5 (to be consistent with the response options) and then summed to get the total score for each woman. From the total scores, 2 groups 
were created with a cut-off point at the 50th percentile.  
§Straight line distance (kilometers) from the community to the nearest health facility, calculated in ArcGIS 10.3.1. To calculate the distance, the MDHS files were joined to 
the Malawi 2012 Service Provision Assessment file (SPA)—also a public use file. The MDHS files provided coordinates for the communities while coordinates for health 
facilities came from the Malawi 2012 SPA. Since the Service Provision Assessment data only provided geographic coordinates for health facilities, we do not expect the 
temporal difference between the two surveys to influence the distances between the communities and health facilities. 
¶Calculated at the community level and each household in the community is assumed to face this child mortality rate regardless of whether the household itself experienced 
child mortality. Community child mortality is used instead of household child mortality because the latter would be endogenous in a model of contraceptive use. 
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Appendix A2: Robustness of the identification strategy 
Because the data used for this study were not collected for evaluating the effect of CBDs, we 
performed three robustness checks to validate our identification strategy. To identify the effect of 
CBDs, we made three assumptions. First, we assumed that after the national rollout, the effect of 
CBDs was only in the 25 districts in which the pilot of the CBDs was not implemented. So, we 
tested this assumption by examining the effect of CBDs in the three districts in which the pilot of 
the CBDs was implemented, expecting the CBDs not to have significant effects in these districts. 
Second, we assumed that the introduction of CBDs was exogenous and only in rural 
communities. We, therefore, expected CBDs not to have significant effects on contraceptive use 
in urban communities. We tested this assumption by examining the effect of CBDs in urban 
communities and whether education and/or income were moderators of the effect of CBDs on 
contraceptive use in the urban communities. Third, we assumed that MDHS data collected in the 
years 2000 and 2004 served as the baseline for contraceptive use in the 25 districts in which the 
pilot of CBDs was not implemented. In these districts, CBDs were introduced after 2004, so 
MDHS2000 and MDHS2004 should not capture CBD effects. We tested this assumption by 
examining the effect of changing the baseline years. In all, the sensitivity analysis showed that 
our identification strategy is valid, see detailed results below. 
CBD effects in CBD-pilot districts 
 
In the first sensitivity analysis, we applied the model in equation 2 to the three districts (Chitipa, 
Ntchisi, and Chiradzulu) in which the CBDs were piloted. In these districts, the nationwide 
adoption of CBDs was a continuation of the pilot. For emphasis, the model is repeated below:  
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𝑙𝑜𝑔 ( 
𝜋𝑖𝑗𝑘
[1−𝜋𝑖𝑗𝑘]
) = 𝛽0 +  𝛽1(𝑅𝑢𝑟𝑎𝑙𝑗𝑘) + 𝛽2(𝐶𝐵𝐷𝐴) + 𝛽3(𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ∗ 𝐶𝐵𝐷𝐴) + 𝜆𝑿𝑖𝑗𝑘 +
𝛼𝑷𝑗𝑘 + 𝛤 + 𝑈𝑘 + 𝑈𝑗𝑘 + ℇ𝑖𝑗𝑘            (5) 
For valid identification, β3 was expected to be not statistically significant at 5% in equation 5. 
Results of this analysis are presented in table A2. In the three pilot districts, the effect of CBDs 
was not statistically significant at 5%. This suggests that our strategy properly identified the 
effects of CBDs on contraceptive use. However, some caution is warranted: the non-significant 
result of the interaction term could also be a result of the sample size being smaller in the pilot 
districts rather than the scale-up of the CBDs not having a statistically significant effect in the 
pilot districts. The estimate for the pilot districts was estimated with less precision, given the 
wider confidence interval, than the one for the non-pilot districts. 
Table A2: Effect of CBDs on contraceptive use in CBD pilot and CBD non-pilot districts  
  Non-pilot districts Pilot districts 
  Coefficient 95% C.I. Coefficient 95% C.I. 
Contraceptive use     
Main explanatory variables     
CBDAs 0.954*** [0.706,1.202] 0.738 [-0.418,1.894] 
Rural -0.314*** [-0.481,-0.147] -0.367 [-1.469,0.735] 
Ref: Urban, before CBDAs     
 Rural, after CBDAs 0.424*** [0.236,0.612] 0.871 [-0.248,1.990] 
Individual-level factors     
Age (ref: 15-19 years)     
 20-29yr 0.588*** [0.486,0.689] 0.287 [-0.011,0.586] 
 30-39yr 0.582*** [0.455,0.710] 0.146 [-0.178,0.470] 
 40-49yr 0.393*** [0.242,0.544] -0.097 [-0.460,0.266] 
Occupation (ref: unemployed)     
 Self-employed/agriculture 0.087* [0.018,0.155] 0.063 [-0.093,0.218] 
 Professional/formal 0.251*** [0.190,0.312] 0.119 [-0.113,0.352] 
Marital status (ref: never married)     
 Married 2.353*** [2.086,2.619] 3.010*** [2.576,3.445] 
 Divorced 1.389*** [1.192,1.587] 2.016*** [1.589,2.442] 
 Widowed 0.978*** [0.757,1.200] 2.012*** [1.462,2.561] 
Exposure to FP information (ref: no exposure)    
 Some exposure 0.216*** [0.163,0.269] 0.221** [0.0714,0.370] 
Fertility desire (ref: wants child <1 yr)    
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 >1yr but <3yr 1.854*** [1.726,1.981] 1.964*** [1.539,2.390] 
 Child after 3 yrs 2.170*** [2.023,2.317] 2.225*** [1.825,2.625] 
 No more children 2.454*** [2.319,2.590] 2.218*** [1.821,2.615] 
Autonomy (ref: No autonomy)     
 At least some autonomy 0.111* [0.025,0.198] 0.061 [-0.119,0.241] 
Partner education (ref: no education)     
 Primary 0.120** [0.040,0.201] 0.0521 [-0.197,0.301] 
 Secondary 0.166*** [0.068,0.265] -0.055 [-0.324,0.214] 
 Higher 0.234* [0.010,0.458] -0.213 [-0.742,0.317] 
Religion (ref: Catholic/Anglican)     
 Other Christians -0.0934*** [-0.147,-0.039] -0.05 [-0.216,0.115] 
 Muslims -0.279*** [-0.411,-0.147] 0.111 [-0.347,0.568] 
Community-level factors     
Access problem (ref: no problem)     
 Some problem -0.082* [-0.138,-0.026] -0.164* [-0.318,-0.009] 
Literacy (ref: illiterate)     
 Literate 0.102** [0.037,0.166] 0.00454 [-0.232,0.241] 
Income (ref: low)     
 Medium income 0.126*** [0.069,0.182] 0.390*** [0.222,0.558] 
 High income 0.219*** [0.124,0.315] 0.457*** [0.223,0.691] 
Religion (ref: Catholic/Anglican)     
 SDA and Other Christians 0.069 [-0.015,0.153] 0.135 [-0.060,0.329] 
 Muslims -0.185 [-0.382,0.012] 0.039 [-0.515,0.593] 
Community child mortality -0.0006* [-0.001,-0.0001] 0 [-0.001,0.001] 
Year fixed effects (ref: 2000)     
2004 0.014 [-0.081,0.109] -0.099 [-0.486,0.288] 
2010 -0.775*** [-0.875,-0.675] -0.965*** [-1.143,-0.786] 
Constant 0.003*** [0.002,0.004] -5.947*** [-7.277,-4.618] 
Number of districts 25  3  
Observations 52978   4546   
* p < 0.05, ** p < 0.01, *** p < 0.001. †The results in non-pilot districts are the same as the multilevel results already presented 
in table 3, but they are duplicated here to facilitate comparison. 
 
 
Education and income as moderators of CBD effects in urban communities 
 
In the second sensitivity analysis, we examined the effect of CBDs in urban communities and 
whether this effect is moderated by education or income. This analysis was performed using the 
model in equation 2 but only in urban communities of the 25 non-pilot districts. Because CBDs 
were implemented in rural communities only, the effect of CBDs and the interaction of CBDs 
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and education, as well as that of CBDs and income in urban communities should not be 
statistically significant at 5%.  In Panel 1 of table A3, we present the log odds of using 
contraceptives in urban communities while in Panel 2 we reproduce the log odds for rural 
communities (already presented in table 6). We found that CBDs and its interaction with 
education or income did not have a statistically significant effect on contraceptive use in urban 
communities; confidence intervals of these variables overlapped with a log-odds of 0 and the p-
values were greater than 0.05. As reported earlier, however, these variables had significant 
effects in rural communities. This result reinforces our earlier findings from the first sensitivity 
analysis and we conclude that our strategy identifies the effect of CBDs. 
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Table A3: Sensitivity analysis of the moderating effects of education and income on the association between 
CBDs and contraceptive use 
 Panel 1: Urban Panel 2: Rural 
 
M2A 
(Education) 
M2B (Income) 
M1A 
(Education) 
M1B (Income) 
 Coefficient  Coefficient  Coefficient  Coefficient  
  [95% C.I.] [95% C.I.] [95% C.I.] [95% C.I.] 
Ref: Before CBDs     
    CBDs 1.18 0.945 1.500*** 1.521*** 
 [-1.527,3.886] [-2.499,4.389] [1.310,1.691] [1.346,1.696] 
Ref: No education     
    Primary 1.493  0.128**  
 [-0.654,3.639]  [0.0338,0.223]  
    Secondary 1.382  0.113  
 [-0.746,3.509]  [-0.0262,0.251]  
Ref: No education, before CBDs     
    Primary, after CBDs -1.077  -0.172*  
 [-4.126,1.971]  [-0.310, -0.0348]  
    Secondary, after CBDs -0.669  -0.505***  
 [-3.705,2.367]  [-0.657, -0.353]  
Ref: Low income     
    Medium income  -0.341  0.226*** 
  [-3.937,3.255]  [0.116,0.336] 
    High income  -0.346  0.388*** 
  [-3.579,2.887]  [0.241,0.536] 
Ref: Low income, before CBDs     
    Medium income, after CBDs  -0.656  -0.229*** 
  [-4.252,2.940]  [-0.323, -0.135] 
    High income, after CBDs  -0.56  -0.575*** 
  [-3.905,2.784]  [-0.731, -0.419] 
Observations 10113 10089 42865 42865 
The table summarizes sensitivity analysis results of examining whether education and income influence (moderate) the 
effect of CBDs on contraceptive use in urban areas. For ease of interpretability and understanding, models for education and 
income were run separately. In the urban panel, the coefficient of the interaction terms (CBD*education and CBD*income) 
is not statistically significant at 5% which suggests that both education and income do not individually influence the 
association between CBDs and contraceptive use. 
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Varying the definition of the pre-CBD period: 2000 or 2004 
 
We earlier explained and showed in figure 4 that there was an overlap of about 2 months 
between the introduction of CBDs and data collection in MDHS2004. Although we expected 
CBDs not to have affected contraceptive use by the time the data were being collected, we still 
checked the effect of the overlap by defining the baseline as the year 2004 or 2000. If 
MDHS2004 captured the effects of the CBDs, our estimate would be biased towards the null. We 
first examined whether contraceptive use was different between years 2000 and 2004. We found 
that the log-odds of using contraceptives were lower in 2004 than in 2000, but the difference was 
immaterial. Thus either year (2000 or 2004) could be used to define the pre-CBD period.   
We present results of defining the baselines as the year 2000 or 2004 in the table A4, while 
results in Panel A combine years 2000 and 2004 (like those presented earlier in table 3). We 
found that, for many coefficients, the direction and strength of association with contraceptive use 
were the same across the three models. We also found that CBDs increased contraceptive use by 
7.58 and 5.25 percentage points when the baseline years are 2000 and 2004, respectively, 
compared with 6.8 percentage points when both are used as the baseline. Thus using 2004 as the 
base year underestimated the effect of CBDs which suggests that the overlap between 
MDHS2004 and the introduction CBDs might be attenuating the effect of CBDs. While this 
evidence points to using 2000 as the baseline, we preferred to use a model that combined 2000 
and 2004 as the baseline. This is because estimates from the model in Panel A are measured with 
the most precision and this model allowed us to account for year fixed effects; the other models 
cannot do this because of collinearity problems among year, CBDs, and the intercept. 
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Table A4: Effect of CBDs on contraceptive use in response to changing the baseline     
 A (main results) † B C 
 Baseline: 2000+2004 Baseline: 2000 Baseline: 2004 
  Coefficient 95% C.I. Coefficient 95% C.I. Coefficient 95% C.I. 
Dep var contraceptive use       
Main explanatory variables       
CBDA 0.954*** [0.706,1.202] 0.870*** [0.638,1.102] 1.011*** [0.721,1.300] 
Rural -0.314*** [-0.481,-0.147] -0.403*** [-0.587,-0.219] -0.284* [-0.536,-0.032] 
Ref: Urban, before CBDAs       
 Rural, after CBDAs 0.424*** [0.236,0.612] 0.483*** [0.278,0.688] 0.339** [0.114,0.564] 
Individual-level factors       
Age (ref: 15-19 years)       
 20-29yr 0.588*** [0.486,0.689] 0.622*** [0.514,0.729] 0.558*** [0.449,0.667] 
 30-39yr 0.582*** [0.455,0.710] 0.585*** [0.447,0.722] 0.550*** [0.421,0.680] 
 40-49yr 0.393*** [0.242,0.544] 0.329*** [0.171,0.488] 0.338*** [0.162,0.513] 
Occupation (ref: unemployed)       
 Self-employed/agriculture 0.087* [0.018,0.155] 0.098** [0.024,0.172] 0.071 [-0.021,0.162] 
 Professional/formal 0.251*** [0.190,0.312] 0.261*** [0.184,0.338] 0.222*** [0.151,0.293] 
Marital status (ref: never 
married)       
 Married 2.353*** [2.086,2.619] 2.328*** [2.065,2.591] 2.480*** [2.159,2.800] 
 Divorced 1.389*** [1.192,1.587] 1.405*** [1.218,1.593] 1.482*** [1.277,1.686] 
 Widowed 0.978*** [0.757,1.200] 1.045*** [0.780,1.309] 1.131*** [0.866,1.396] 
Exposure to FP information (ref: no exposure)      
 some exposure 0.216*** [0.163,0.269] 0.203*** [0.145,0.261] 0.172*** [0.107,0.236] 
Fertility desire (ref: wants child 
<1y)       
 >1y but <3y 1.854*** [1.726,1.981] 1.900*** [1.741,2.058] 1.871*** [1.691,2.051] 
 Child after 3y 2.170*** [2.023,2.317] 2.198*** [2.042,2.354] 2.161*** [1.957,2.366] 
 No more children 2.454*** [2.319,2.590] 2.506*** [2.349,2.664] 2.429*** [2.222,2.635] 
Autonomy (ref: No autonomy)       
 Some or total autonomy 0.111* [0.025,0.198] 0.134** [0.039,0.228] 0.105 [-0.026,0.236] 
Partner education (ref: no 
education)       
 Primary 0.120** [0.040,0.201] 0.116** [0.040,0.192] 0.113* [0.027,0.199] 
 Secondary 0.166*** [0.068,0.265] 0.118* [0.0214,0.215] 0.107* [0.008,0.206] 
 Higher 0.234* [0.010,0.458] 0.183 [-0.039,0.405] 0.172 [-0.086,0.430] 
Religion (ref: Catholic/Anglican)       
 Other Christians -0.093*** [-0.147,-0.039] -0.0784* [-0.145,-0.011] -0.085** [-0.145,-0.024] 
 Muslims -0.279*** [-0.411,-0.147] -0.265*** [-0.422,-0.108] -0.305*** [-0.447,-0.163] 
Community-level factors       
Access problem (ref: no 
problem)       
 Some problem -0.082* [-0.138,-0.026] -0.059 [-0.119,0.001] -0.052 [-0.107,0.003] 
Literacy (ref: illiterate)       
 Literate 0.102** [0.037,0.166] 0.128** [0.043,0.212] 0.081* [0.018,0.144] 
Income (ref: low)       
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 Medium income 0.126*** [0.069,0.182] 0.120*** [0.052,0.187] 0.137*** [0.082,0.192] 
 High income 0.219*** [0.124,0.315] 0.189*** [0.090,0.289] 0.232*** [0.126,0.338] 
Religion (ref: Catholic/Anglican)       
 SDA and Other Christians 0.069 [-0.015,0.153] 0.056 [-0.053,0.165] 0.025 [-0.098,0.148] 
 Muslims -0.185 [-0.382,0.012] -0.219 [-0.443,0.005] -0.305* [-0.546,-0.064] 
Community child mortality -0.001* [-0.001,-0.000] -0.001** [-0.001,-0.000] -0.001 [-0.001,0.000] 
Year fixed effects       
2004 0.014 [-0.081,0.109]     
2010 -0.775*** [-0.875,-0.675] -0.762*** [-0.867,-0.658] -0.766*** [-0.872,-0.659] 
Constant 0.003*** [0.002,0.004]     
Observations 52978   44503   43162   
* p < 0.05, ** p < 0.01, *** p < 0.001. †These results are the are the same as the multilevel results already presented in 
table 3, but they are duplicated here to facilitate comparison.   
 
  
60 
Stata do file 
///ANALYSIS 
use analysis_cbda.dta, clear 
set more off 
log using contra_use, text replace 
 
*setting the font for graphs to times roman new 
 graph set window fontface "Times New Roman" 
  
*trends in contraceptive use 
*graph bar (mean) none (mean) modern, over(year) percentages blabel(bar, 
size(small) format(%9.2g)) by(, title(Urban-rural trends in contraceptive use 
in Malawi)) by(rural, total)  
graph bar (mean) none (mean) modern, over(cbda, label(labsize(3.0))) stack 
/// 
by(urban, note(" ") graphregion( color(white)) plotregion(fcolor(white) 
ifcolor(white))) /// 
subtitle(,  fcolor(white) lcolor(white)) /// 
bar(1, lpattern(solid) color(bluishgray)) bar(2, lpattern(dot) 
color(eltblue)) bar(3, lpattern(solid)) blabel(bar, size(3.0) 
position(center) format(%9.2g)) /// 
by(, title("Figure 3: Urban-rural trends in contraceptive use before and 
after national CBDs in Malawi", size(3.0) color(black))) /// 
ytitle("Proportion", size(3)) scheme(s2color) ///  
legend(label(1 "Not using modern contraceptives ") label(2 "Using modern 
contraceptives") order(2 "Using modern contraceptives" 1 "Not using modern 
contraceptives" )) 
graph save Graph "U:\Home\Health Behavior and 
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\urban-
ruraltrends_1.gph", replace 
**Conducting a test of the IIA assumption 
mlogit contra_use cbda##rural , base(0) 
estimates store m_1 
mlogit contra_use urban##education if (contra_use != 1), base(0) /*excludes 
traditional methods*/ 
estimates store m_2 
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hausman  m_1 m_2, alleqs constant /*alleqs means to test using all 
equations*/ 
*the test statistic from the above is negative so the more appropriate test 
is suest 
suest m_1 m_2 
test [m_1_modern=m_2_modern],  common const /*we fail to reject the null, the 
IIA assumption is met*/ 
 
*test for combining categories 
mlogit contra_use comm_fertpref comm_wealth comm_literacy 
 
*random effects model 
set more off 
use analysis_cbda, clear 
 
*combining nonusers and traditional users 
gen contra_use_orig= contra_use 
recode contra_use 2=0 
 
*setting weights 
 
svyset community, weight(comm_wt) || _n, weight(sampweight) 
 
/*checking the effect of weights*/ 
tab region 
tab region  [iweight=sampweight] 
tab region  [iweight=comm_wt] 
 
*empty or null model with 3 levels 
melogit contra_use if notpilot==1 [pw=sampweight] ||district: ||community:, 
pw(comm_wt) or covariance(unstructured) 
estimates store null_3levels 
estat icc 
gen _prob=exp(_b[_cons])/(1+ exp(_b[_cons])) 
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di _prob 
drop _prob 
 
*empty or null model with 2 levels 
melogit contra_use if notpilot==1 [pw=sampweight] ||community:, pw(comm_wt) 
or covariance(unstructured) 
estimates store null_2levels 
 
*single level logit 
logit contra_use if notpilot==1 [pw=sampweight],  or  
estimates store null_singlelevel 
 
*comparing the two-level to the single-level  
lrtest null_3levels null_singlelevel, force 
 
*comparing the three level to the single level  
lrtest null_3levels null_singlelevel, force 
 
*comparing the 2-level and 3-level models 
lrtest null_3levels null_2levels, force /*shows that the 3-level model should 
be preferred*/ 
 
 
**drawing caterpiller plots from the variance components model 
melogit contra_use if notpilot==1 [pw=sampweight] ||district: ||community:, 
pw(comm_wt) or covariance(unstructured) 
estimates replay null_3levels, or 
 
*reffects and reses calculate the shrunken residuals/best linear unbiased 
prediction of random intercepts and standard errors 
predict u0dist u0comm, reffects reses(u0sedist u0secomm) 
 
*district caterpillars 
egen pickonedist=tag(district) 
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sort u0dist 
gen u0rankdist=sum(pickonedist) 
*to draw the caterpillar graph with 95% confidence band of intercept 
residuals 
serrbar u0dist u0sedist u0rankdist if pickonedist==1, scale(1.96) mvopts( 
msymbol(square) mlabel(district) mlabcolor(black) /// 
 mlabsize(*0.95) mlabposition(6) mlabgap(huge) mcolor(red) 
mlabangle(vertical)) ytitle(District random effects) xtitle(District rank) 
yline(0) /// 
 title("Figure 4b: Average district contraceptive use" , size(medium 
large)) 
 graph save Graph "J:\Home\Health Behavior and 
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\District_residuals.gph", 
replace 
 *counting the number of districts outside average district 
contraceptive use 
 count if ((u0dist + 1.96*u0sedist)<0 | (u0dist - 1.96*u0sedist)>0) & 
pickonedist==1 
 
*community caterpillars 
egen pickonecomm=tag(community) 
sort u0comm 
gen u0rankcomm=sum(pickonecomm) 
*to draw the caterpillar graph with 95% confidence band of intercept 
residuals 
serrbar u0comm u0secomm u0rankcomm if pickonecomm==1, scale(1.96) mvopts( 
msymbol(smx) mcolor(red)) /// 
 ytitle(Community random effects) xtitle(Community rank) yline(0) /// 
 title("Figure 4a: Average community contraceptive use" , size(medium 
large)) 
 graph save Graph "J:\Home\Health Behavior and 
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\comm_residuals.gph", 
replace 
 *counting the number of communities outside average average 
contraceptive use 
 count if ((u0comm + 1.96*u0secomm)<0 | (u0comm - 1.96*u0secomm)>0) & 
pickonecomm==1 /*93*/ 
//effect of CBDS 
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*full model standard logistic regression 
global controls "i.age_cat i.occup i.marstatus i.exp_fp_inf 
i.fertility_desire i.autonomy i.ptnr_education i.religion i.access_prob 
i.comm_literacy i.comm_wealth i.comm_religion comm_childmort i.year" 
 
logit contra_use  cbda##rural $controls  if notpilot==1 [pw=sampweight], or 
estimates store full_std 
 
*full model with random effects 
melogit contra_use  cbda##rural  $controls  if notpilot==1 [pw=sampweight] 
||district: ||community:, pw(comm_wt) or covariance(unstructured) 
estimates store full_re 
 
//cluster specific margins or probabilities 
margins, at(cbda=(0 1) rural=(0 1)) predict(mu fixed) noestimcheck post 
margins r.cbda##r.rural, predict(mu fixed) contrast noestimcheck post 
 
*average margins in a sub-sample of married women only 
global controls "i.age_cat i.occup i.exp_fp_inf i.fertility_desire i.autonomy 
i.ptnr_education i.religion i.access_prob i.comm_literacy i.comm_wealth 
i.comm_religion comm_childmort i.year" 
 
melogit contra_use  cbda##rural $controls  if notpilot==1 & marstatus==1 
[pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured)  
estimates store full_marriedonly 
 
//cluster specific margins or probabilities 
margins, at(cbda=(0 1) rural=(0 1)) predict(mu fixed) noestimcheck post 
margins r.cbda##r.rural, predict(mu fixed) contrast noestimcheck post 
 
 
//average margins, including random effects 
drop u0dist u0comm u0sedist u0secomm pickonedist u0rankdist pickonecomm 
u0rankcomm 
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estimates restore full 
*reffects calculate the shrunken residuals/best linear unbiased prediction of 
random intercepts 
predict prmeandist prmeancomm, remeans reses(prsedist prsecomm) 
 
*table 4, CBDA effects in single and multi-level models 
 
esttab full_std full_re using CBDA_effect.rtf, nogaps wide eform b se  aic 
bic replace  nonum label  /// 
  refcat(cbda "Main explanatory variables" 1.cbda#1.rural "Ref: 
Urban, before CBDAs"  /// 
  2.age_cat "Age (ref: 15-19 years)" 2.occup "Occupation (ref: 
unemployed)" 1.marstatus "Marital status (ref: never married)" /// 
  1.exp_fp_inf "Exposure to FP inf (ref: no exposure)" 
2.fertility_desire "Fertilify desire (ref: wants child <1 yr)" /// 
  1.autonomy "Autonomy (ref: No autonomy)" 1.ptnr_education 
"Partner education (ref: no education)" /// 
  2.religion "Religion (ref: Catholic/Anglican)" 1.access_prob 
"Access problem (ref: no problem)" /// 
  1.comm_literacy "Literacy (ref: illiterate)" 2.comm_wealth 
"Income (ref: low)"  /// 
  2.comm_religion "Religion (ref: Catholic/Anglican)" 2004.year 
"Year fixed effects (ref: 2000)" 0.education "Individual-level factors" /// 
  0.access_prob "Community-level factors" , nolabel) ///  
  mtitle("Single-level Logistic Regression" "Multi-level Logistic 
Regression")  ///  
  title( "Table 4: Effect of CBDAs on contraceptive use") /// 
  collabels("Odds Ratio" "Standard errors" "95% Confidence 
Interval" "Odds Ratio" "95% Confidence Interval") /// 
  coeflabels (eq1 ""cbda "CBDAs" 1.cbda "CBDAs" 1.rural "Rural" 
1.cbda#1.rural " Rural, after CBDAs" /// 
  1.access_prob " Some problem" 2004.year " 2004" 2010.year " 2010" 
comm_childmort "Community child mortality") /// 
  drop (0.rural 0.cbda  0.cbda#0.rural 1.cbda#0.rural 
0.cbda#1.rural 2000.year  /// 
  2015.year 1.age_cat 1.occup 0.marstatus 0.exp_fp_inf 0.autonomy  
/// 
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  1.fertility_desire 1.religion 0.ptnr_education 1.comm_wealth 
1.comm_religion 0.comm_literacy) obslast  
 
//The effect of education 
 
*Mediation 
*unadjusted 
melogit contra_use cbda i.education if notpilot==1 [pw=sampweight] 
||district: ||community:, pw(comm_wt) or covariance(unstructured) 
estimates store unadj_edu 
coefplot,  xline(0)  
 
*adjusted but without education 
melogit contra_use cbda rural i.wealth $controls if notpilot==1 
[pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured) 
estimates store cbda_adj_noedu 
 
*adjusted with education 
melogit contra_use cbda i.education rural i.wealth $controls if notpilot==1 
[pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured) 
estimates store cbda_adj_edu 
coefplot,  xline(0) keep(*education) 
 
 
esttab cbda_only unadj_edu cbda_adj_noedu cbda_adj_edu using 
edu_mediation.rtf, eform b ci noeqlines eqlabels(none)  keep(cbda 
*.education) /// 
  coeflabels (eq1 ""cbda "CBDA" ) /// 
  drop(0.education) /// 
  refcat(1.education "Ref: No education") /// 
  title( "Table 6: Assessment of education as a mediator of CBDA 
effects on contraceptive use") /// 
  mtitle("Model 1A" "Model 1B" "Model 2A" "Model 2B") label replace 
nonum 
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//the effect of wealth 
*unadjusted 
melogit contra_use cbda i.wealth if notpilot==1 [pw=sampweight] ||district: 
||community:, pw(comm_wt) or covariance(unstructured) 
estimates store unadj_wealth 
 
*adjusted but without wealth 
melogit contra_use cbda rural i.education $controls if notpilot==1 
[pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured) 
estimates store cbda_adj_nowealth 
 
*adjusted with wealth 
melogit contra_use cbda i.education rural i.wealth $controls if notpilot==1 
[pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured) 
estimates store cbda_adj_wealth 
 
esttab cbda_only unadj_wealth cbda_adj_nowealth cbda_adj_wealth using 
wealth_mediation.rtf, eform b ci noeqlines eqlabels(none) /// 
        keep(cbda *.wealth) nogaps /// 
  coeflabels (eq1 ""cbda "CBDA" ) /// 
  drop(1.wealth) /// 
  refcat(2.wealth "Income (Ref: Low income)") /// 
  title( "Table 6B: Assessment of income (wealth) as a mediator of 
CBDA effects on contraceptive use") /// 
  mtitle("Model 1A" "Model 1B" "Model 2A" "Model 2B") label replace 
nonum 
 
*Moderation 
global controls "i.age_cat i.occup i.exp_fp_inf i.fertility_desire i.autonomy 
i.ptnr_education i.religion i.access_prob i.comm_literacy i.comm_wealth 
i.comm_religion comm_childmort i.year" 
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recode education 3=2 
 
melogit contra_use  cbda##ib0.education $controls if notpilot==1 & rural==1 
[pw=sampweight] ||district: ||community:, pw(comm_wt)  
covariance(unstructured) 
estimates store moderation_education_r 
 
melogit contra_use  cbda##ib1.wealth $controls if notpilot==1 & rural==1 
[pw=sampweight] ||district: ||community:, pw(comm_wt)  
covariance(unstructured) 
estimates store moderation_wealth_r 
 
coefplot (moderation_education_r, label("Education") keep(*:1.cbda 
1.cbda#0.education 1.cbda#1.education )) (moderation_wealth_r, 
label("Income") keep(*:1.cbda#1.wealth 1.cbda#2.wealth)), bylabel(Rural) /// 
  ||, eform cismooth levels(95 90) msymbol(S) xline(1) xscale(r(1 
2)) xlabel(1(0.5)4) ylab(, labsize(3)) /// 
  xtitle("Odds ratios", size(2.5)) ytitle("CBDA effect by 
education/income", size(3.5)) grid(none) /// 
        title("Figure 6: Education and income as moderators of CBDA effects", 
span size(4) color(black)) 
  graph save Graph 
"U:\Dissertation\Paper_1\Analyis\Graphs\moderation_main2.gph", replace 
 
*making a table of the moderating effects of education and wealth 
esttab moderation_education_r moderation_wealth_r using 
edu_wealth_moderation1.rtf, b ci wide noeqlines eqlabels(none) /// 
  title( "Table 6: Assessment of education and income (wealth) as 
moderators of CBDA effects on contraceptive use in rural areas") /// 
  keep(*1.cbda *.wealth *.education) nogaps /// 
  refcat(1.cbda "Ref: Before CBDAs" 0.education "Ref: No education" 
1.cbda#1.education "Ref: No education, before CBDAs" 1.wealth /// 
  "Ref: Low income" 1.cbda#1.wealth "Ref:Low income, before CBDAs") 
/// 
  coeflabels (eq1 "" cbda "CBDAs" 1.cbda "CBDAs" 1.cbda#1.education 
"Primary, after CBDAs" 1.cbda#2.education "Secondary, after CBDAs" /// 
  1.cbda#2.wealth "Medium income, after CBDAs" 1.cbda#3.wealth " 
High income, after CBDAs") /// 
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  mtitle("Model 1A" "Model 1B") label replace nonum aic bic 
    
*this makes bar graphs   
*coefplot moderation_education moderation_wealth, eform keep(1.cbda#*) 
vertical recast(bar) barwidth(0.25) fcolor(*.5) ciopts(recast(rcap)) citop 
citype(logit) xtitle(Repair Record 1978) ytitle(Proportion) 
 
**another moderation graph, strength of the association between education and 
wealth 
 
melogit contra_use  cbda##education##wealth $controls if notpilot==1 & 
rural==1 [pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured) 
estimates store moderation_2 
 
gen education1=education 
recode education1 3=2  
label copy education education1 
label values education1 education1 
 
*predicting probabilities 
predict predprob, fixedonly 
 
*getting average probabilities by education and income 
table education1 wealth cbda, c(mean predprob) 
 
*setting the font 
graph set window fontface "Times New Roman" 
 
graph bar (mean) predprob if rural==1,  over(education1 ) over(wealth, 
label(labsize(small))) over(cbda)   asyvars /// 
 ytitle(Predicted probability) /// 
 b1title("") /// 
 legend(rows(1) /// 
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 subtitle(Education level)) /// 
 bargap(0) /// 
 bar(1, lpattern(solid) color(dkorange)) bar(2, lpattern(solid) 
color(brown)) bar(3, lpattern(solid) color(green) fintensity(70) ) /// 
 title("Figure 8: Predicted probability of contraceptive use by income 
and education among rural women", size(3) color(black))  
 graph save Graph "U:\Home\Health Behavior and 
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\moderationbyeducation2.g
ph", replace 
 
//*Model diagnostics 
 
use analysis_cbda, clear  
global controls "age agesq i.occup i.marstatus i.exp_fp_inf 
i.fertility_desire i.autonomy i.ptnr_education i.religion i.access_prob 
i.comm_literacy i.comm_wealth i.comm_religion comm_childmort i.year" 
melogit contra_use  cbda##rural i.education i.wealth $controls  if 
notpilot==1 [pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured)  
estimates store for_residuals 
 
*goodness of fit test using predicted probabilities 
predict probability, fixedonly 
gen predicted_contra=0 
replace predicted_contra=1 if probability>0.5 
tab   contra_use predicted_contra if notpilot==1, row 
count if contra_use==1 & predicted_contra==1 & notpilot==1 | contra_use==0 & 
predicted_contra==0 & notpilot==1 
drop probability predicted_contra 
 
*goodness of fit test using residuals 
gen n = _n 
predict residuals, deviance 
label var n "Observation number" 
twoway (scatter residuals n if contra_use) (scatter residuals n if 
!contra_use) if notpilot==1, /// 
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 yline(-2 2) legend(off) text(3.8 10000 "Using contraceptives") text(0.2 
10000 "Not using contraceptives")  /// 
 title("Figure 8: Goodness-of-fit test using deviance residuals", 
size(4) color(black)) /// 
 ytitle("Deviance residuals") 
 graph save Graph "J:\Home\Health Behavior and 
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\deviance_residuals.gph", 
replace 
///***sensitivity analysis 
global controls "i.age_cat i.occup i.marstatus i.exp_fp_inf 
i.fertility_desire i.autonomy i.ptnr_education i.religion i.access_prob 
i.comm_literacy i.comm_wealth i.comm_religion comm_childmort i.year" 
melogit contra_use  cbda##rural $controls  if notpilot==1 [pw=sampweight] 
||district: ||community:, pw(comm_wt) or covariance(unstructured)  
estimates store sensitivity_pilot 
 
melogit contra_use  cbda##rural $controls  if notpilot==0 [pw=sampweight] 
||district: ||community:, pw(comm_wt) or covariance(unstructured)  
estimates store sensitivity_notpilot 
 
*joint test of the interaction term and the main effects 
test _b[1.cbda]=_b[1.rural]=_b[1.cbda#1.rural] 
 
esttab  sensitivity_pilot sensitivity_notpilot using Sensitivity_1.rtf, 
nogaps wide b ci  replace  nonum label  /// 
  refcat(cbda "Main explanatory variables" 1.cbda#1.rural "Ref: 
Urban, before CBDAs"  /// 
  2.age_cat "Age (ref: 15-19 years)" 2.occup "Occupation (ref: 
unemployed)" 1.marstatus "Marital status (ref: never married)" /// 
  1.exp_fp_inf "Exposure to FP inf (ref: no exposure)" 
2.fertility_desire "Fertilify desire (ref: wants child <1 yr)" /// 
  1.autonomy "Autonomy (ref: No autonomy)" 1.ptnr_education 
"Partner education (ref: no education)" /// 
  2.religion "Religion (ref: Catholic/Anglican)" 1.access_prob 
"Access problem (ref: no problem)" /// 
  1.comm_literacy "Literacy (ref: illiterate)" 2.comm_wealth 
"Income (ref: low)"  /// 
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  2.comm_religion "Religion (ref: Catholic/Anglican)" 2004.year 
"Year fixed effects (ref: 2000)" /// 
  0.access_prob "Community-level factors" , nolabel) ///  
  mtitle("Pilot districts" "Non-pilot districts")  ///  
  title( "Table 4: Effect of CBDAs on contraceptive use") /// 
  collabels("Odds Ratio" "95% Confidence Interval" "Odds Ratio" 
"95% Confidence Interval") /// 
  coeflabels (eq1 ""cbda "CBDAs" 1.cbda "CBDAs" 1.rural "Rural" 
1.cbda#1.rural " Rural, after CBDAs" /// 
  1.access_prob " Some problem" 2004.year " 2004" 2010.year " 2010" 
comm_childmort "Community child mortality") /// 
  drop (0.rural 0.cbda  0.cbda#0.rural 1.cbda#0.rural 
0.cbda#1.rural 2000.year  /// 
  2015.year 1.age_cat 1.occup 0.marstatus 0.exp_fp_inf 0.autonomy  
/// 
  1.fertility_desire 1.religion 0.ptnr_education 1.comm_wealth 
1.comm_religion 0.comm_literacy) obslast  
 
**Moderation: effects of education and wealth 
melogit contra_use  cbda##ib3.education##ib3.wealth $controls if notpilot==1 
& rural==1 [pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured) 
estimates store moderation_education_u 
 
melogit contra_use  cbda##ib3.wealth $controls i.education if notpilot==1 & 
rural==0 [pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured) 
estimates store moderation_wealth_u 
 
coefplot (moderation_education_u, label("Education") keep(*: 1.cbda 
1.cbda#0.education 1.cbda#1.education) ) (moderation_wealth_u, 
label("Income") keep(*: 1.cbda#1.wealth 1.cbda#2.wealth) ), bylabel(Panel A: 
urban)  /// 
  || (moderation_education_r, label("Education") keep(*:1.cbda 
1.cbda#0.education 1.cbda#1.education)  ) (moderation_wealth_r, 
label("Income") keep(*: 1.cbda#1.wealth 1.cbda#2.wealth)), bylabel(Panel B: 
rural) /// 
  ||,  eform xline(1) cismooth levels(99.999) byopts(xrescale) 
msymbol(S) label ylab(, labsize(3)) /// 
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  xtitle("Odds ratios", size(3)) ytitle("CBDA effect by 
education/income", size(3)) grid(none) /// 
  graphregion(color(white)) /// 
  title("Figure B1: CBDA effects and the role of education and 
income as moderators of the effects", span size(3.3) color(black)) 
  graph save Graph 
"U:\Dissertation\Paper_1\Analyis\Graphs\moderation_senstiv2.gph", replace 
 
**Examining the effect of using 2000, 2004 as baselines 
use analysis_cbda.dta, clear 
 
global controls "i.age_cat i.occup i.marstatus i.exp_fp_inf 
i.fertility_desire i.autonomy i.ptnr_education i.religion i.access_prob 
i.comm_literacy i.comm_wealth i.comm_religion comm_childmort i.year" 
 
quietly melogit contra_use  cbda##rural $controls  if notpilot==1 & 
year!=2004 [pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured)  
estimates store _2000 
 
quietly melogit contra_use  cbda##rural $controls  if notpilot==1 & 
year!=2000 [pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured)  
estimates store _2004  
 
quietly melogit contra_use  cbda##rural $controls  if notpilot==1  
[pw=sampweight] ||district: ||community:, pw(comm_wt) or 
covariance(unstructured)  
estimates store full  
 
esttab _2000 _2004 full using year_sensitivity.rtf , nogaps eform b ci wide  
replace  nonum label /// 
  refcat(cbda "Main explanatory variables" 1.cbda#1.rural "Ref: 
Urban, before CBDAs"  /// 
  2.age_cat "Age (ref: 15-19 years)" 2.occup "Occupation (ref: 
unemployed)" 1.marstatus "Marital status (ref: never married)" /// 
  1.exp_fp_inf "Exposure to FP information (ref: no exposure)" 
2.fertility_desire "Fertility desire (ref: no more child)" /// 
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  1.autonomy "Autonomy (ref: No autonomy)" 1.ptnr_education 
"Partner education (ref: no education)" /// 
  2.religion "Religion (ref: Catholic/Anglican)" 1.access_prob 
"Access problem (ref: no problem)" /// 
  1.comm_literacy "Literacy (ref: illiterate)" /// 
  2.comm_religion "Religion (ref: Catholic/Anglican)" 2004.year 
"Year fixed effects" 0.education "Individual-level factors" /// 
  0.access_prob "Community-level factors" , nolabel) ///  
  mtitle("Baseline: 2000" "Baseline: 2004" "Baseline: 2000+2004")  
///  
  title( "Table S2: Effect of CBDAs on contraceptive use in 
response to changing baseline") /// 
  coeflabels (eq1 ""cbda "CBDA" 1.cbda "CBDA" 1.rural "Rural" 
1.cbda#1.rural " Rural, after CBDAs" /// 
  1.access_prob " Some problem" 2004.year " 2004" 2010.year " 2010" 
comm_childmort "Community child mortality") /// 
  drop (0.rural 0.cbda  0.cbda#0.rural 1.cbda#0.rural 
0.cbda#1.rural 2000.year  /// 
  2015.year 1.age_cat 1.occup 0.marstatus 0.exp_fp_inf 0.autonomy  
/// 
  1.fertility_desire 1.religion 0.ptnr_education 1.comm_wealth 
1.comm_religion 0.comm_literacy) obslast 
estwrite * using results, replace 
estread results 
log close 
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Chapter 2: Conditional cash transfers to increase the uptake of services for the prevention 
of mother-to-child transmission of HIV: a trial-based cost-effectiveness analysis 
Abstract 
  Background: Innovative strategies have been implemented to address the prevention of 
mother-to-child transmission (PMTCT) of HIV in sub-Saharan Africa (SSA). A recent 
randomized controlled trial found that conditional cash transfers (CCTs) to pregnant women with 
HIV increases the uptake of PMTCT services. The current study evaluates the cost-effectiveness 
of the CCTs.  
  Methods: A cost-effectiveness analysis, from the societal perspective, was conducted for a 
randomized controlled trial of CCTs in 89 clinics in the Democratic Republic of the Congo 
(DRC), 2013-2015. The trial had two arms. The intervention group (n=216) received the 
standard of care plus US$5 at the first visit and increased by US$1 at every scheduled visit. The 
control group (n=217) only received the standard of care. Health outcomes were measured using 
PMTCT uptake and PMTCT retention. We expressed incremental effectiveness using the 
number needed to treat (NNT). We evaluated economic costs by trial arm and relied on the trial, 
negotiated drug price lists, and the literature for cost estimates. We reported the costs in 2016 
International Dollars (I$). The threshold for cost-effectiveness was based on 3x GDP per capita 
for the DRC in 2016 (I$2409). We used both deterministic sensitivity analyses and cost-
effectiveness acceptability curves to examine the uncertainty associated with the ICERs. 
  Results: The CCTs increased PMTCT uptake and retention, but at a higher cost. The NNT was 
7.0 (95% C.I.=6.7-7.6) for PMTCT uptake and 12.1 (95% C.I.=11.6-12.8) for PMTCT retention. 
The mean costs/participant in the intervention and control groups were I$516 and I$431, 
representing an incremental cost of I$85 (95% C.I.=59-111). The ICER was I$595 (95% C.I. 
=567-624) for PMTCT uptake and I$1026 (95% C.I.=960-1101) for PMTCT retention. In 
uncertainty analyses, the CCTs were still cost-effective even in the worst case. 
  Conclusion: CCTs are a cost-effective way to increasing uptake of PMTCT services in the 
DRC and similar settings. However, additional research is needed to understand the effectiveness 
and cost-effectiveness of the CCTs in larger populations and over a longer analytic time horizon 
before further scale-up of CCTs.  
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1. Introduction  
Despite global progress in reducing the number of new HIV infections, mother-to-child 
transmission (MTCT) of HIV remains a challenge. The United Nations Joint Program on 
HIV/AIDS (UNAIDS) estimated that over 440 children (ages 0-14 years) were infected with 
HIV every day in 2016, mostly through vertical transmission [106]. Most of these infections 
(88%) occurred in sub-Saharan Africa (SSA) where nearly 70% (26 million) of all people with 
HIV lived in 2016 and uptake of services for the prevention of mother-to-child transmission of 
HIV (PMTCT) is low (<70 percent overall and as low as 32 percent in countries like Nigeria) 
[106], [107]. Evidence suggests that PMTCT services, which include the provision of highly 
efficacious preventive antiretroviral drugs to both the mother and the infant, can reduce the risk 
of MTCT to <5%. However, in the absence of PMTCT services, the risk of MTCT is about 40% 
[108]–[110].  
The low uptake of PMTCT services despite the advantages and wide availability of the services 
in SSA poses challenges to global ambitions of eliminating the AIDS epidemic by 2030 [111]. 
This raises a need to find innovative and cost-effective approaches to help overcome barriers 
preventing the uptake of and demand for these services. One such approach is the use of 
conditional cash transfers (CCTs), an approach previously used to modify individual and 
household behaviors in health and other sectors like education [112]–[114]. To test whether 
CCTs can be used to increase the uptake of PMTCT services, a randomized controlled trial 
(RCT) of the CCTs was implemented in the Democratic of the Congo (DRC) [115]. The 
expectation was that the CCTs would help to overcome demand-side barriers, particularly 
transport costs—one of the major factors preventing the uptake of PMTCT services in SSA 
[116]–[119]. 
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Results from the DRC trial suggested that CCTs can increase the number of women taking up 
PMTCT services [115], but it is unclear whether the CCTs are cost-effective. Therefore, the goal 
of the present study is to conduct a trial-based cost-effectiveness analysis of the CCTs to 
establish whether the CCTs represent a good value for the money. We emphasize that the main 
contribution of this study is in the cost and cost-effectiveness analysis and not in establishing the 
effectiveness of the intervention. 
2. Overview of the trial   
In 2013-2015, an RCT was launched in the DRC to test the effectiveness of paying pregnant 
women with HIV cash to help overcome demand-side barriers to healthcare [115]. These barriers 
include lack of transport money and the opportunity of time spent seeking PMTCT services 
[117], [118]. The trial, funded by the National Institutes of Health, was conducted in Kinshasa in 
89 facilities already offering PMTCT services as part of maternal and child health clinics. All 
women newly diagnosed with HIV, <32 weeks of gestation, and registered for ANC at any of the 
89 facilities were considered for participation.  
The trial enrolled 433 women, with 216 randomized to the intervention group and 217 to the 
control group. The intervention group received standard PMTCT care plus the cash incentives 
while the control group only received the standard PMTCT care. At the initial visit, each 
participant in the intervention group received US$5 which increased by US$1 at the next visit 
but was reset to $5 if the participant missed a scheduled visit or refused a proposed service [115]. 
Option B+ was the standard of care at the time of the trial [115]. Under this protocol, pregnant 
women with HIV—irrespective of gestation age or HIV disease stage—are initiated on 
antiretroviral drugs and continue to take the drugs for life [120], [121]. Table 1 lists the 
protocol’s recommendations. 
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2.1. Trial outcomes 
The trial had two primary health outcomes: uptake of PMTCT services and retention in PMTCT 
care. Uptake was defined as timely attendance (within 5 days) of all scheduled clinic visits from 
randomization through 6 weeks’ postpartum and acceptance of all proposed services listed in 
table 1. Retention was defined as being in HIV care at 6 weeks’ postpartum regardless of the 
reason for missing any prior scheduled visits [115]. 
3. Methods 
3.1. Overview 
We conducted a trial-based cost-effectiveness of CCTs aimed at increasing uptake of PMTCT 
services and retention in PMTCT care in the DRC. We conducted the study from both the 
societal and healthcare perspectives and largely followed recommendations by the World Health 
Organization (WHO) for cost-effectiveness analysis in resource-limited settings [122]–[124]. 
Data on resource utilization came from the trial but cost data came from multiple sources. We 
report economic costs in constant 2016 international dollars (I$). Costs in local currency were 
first adjusted for inflation using DRC’s gross domestic product (GDP) deflator and then 
converted to 2016 I$. In line with the trial, we measured the effectiveness of the CCTs using two 
health outcomes: uptake of PMTCT services and retention in PMTCT care. We expressed 
incremental effectiveness in terms of the number needed to treat (NNT)—the number of 
participants needed to receive the cash incentives for one more participant to take up the services 
or be retained in care. We did not discount the costs or effects to net present value as participant 
follow-up was <1 year. The threshold for cost-effectiveness was based on 3x GDP per capita for 
the DRC in 2016 (I$2409). We used both deterministic sensitivity analyses and cost-
effectiveness acceptability curves to examine the uncertainty in the ICERs. This study was 
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approved as exempt by the Internal Review Board of Virginia Commonwealth University (IRB#: 
HM20009283).  
3.2. Study perspective 
We conducted the study from a societal perspective as recommended by the WHO [122]. The 
perspective included formal healthcare sector costs (e.g., drugs) and informal healthcare sector 
costs (e.g., patient transport costs) [122]. We summarize the costs included in this study in table 
2.  
3.3. Identifying cost sources 
As the trial was not designed for an economic evaluation and therefore, did not collect detailed 
cost data, we relied on multiple sources for the cost data. The sources included peer-reviewed 
studies and the grey literature from within and outside of the DRC. We searched Google, Google 
Scholar, PubMed, and Medline using the terms in Appendix B1. We also manually searched 
reference lists of identified studies for studies not captured by our search terms.  
We restricted the search to cost sources contextually relevant to the DRC. We defined contextual 
relevance in three ways: the time of the study, geography, and income—measured using GDP 
per capita as classified by the World Bank. In terms of time, the search was restricted to studies 
conducted from the year 2005 onward as antiretroviral drugs and PMTCT strategies were widely 
introduced after 2004 [125], [126]. In terms of geography, the search was restricted to studies in 
SSA. In terms of income, the search was restricted to countries with low GDP per capita, similar 
to the DRC [127]. For prices of antiretroviral drugs, we relied on price lists of international 
negotiated prices publicly available through the Clinton Health Access Initiative (CHAI) [128]. 
Appendix B2 lists the candidate cost sources. 
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3.4. Identifying unit costs in base case analysis 
From the list of candidate cost sources in appendix B2, we selected estimates from high-
quality studies to represent base case unit costs, table 3. We defined high-quality studies as peer-
reviewed studies and project reports which clearly articulated data sources, how costs were 
assigned, followed recommended guidelines for estimating costs in cost and cost-effectiveness 
analyses, and presented costs in disaggregated form—for example, cost per visit. If multiple 
high-quality sources were available, we selected estimates from studies closest to 2016 as they 
are likely to be more applicable to the current context.  
3.5. Valuation of goods and services, inflation adjustment, and discounting 
We valued the cost of the CCTs in international dollars (I$)—a hypothetical currency with the 
same purchasing power as the US$ has in the United States [122], [123]. The I$ reflects the 
correct value of goods because it distinguishes between tradable and non-tradable goods; without 
this distinction, non-tradable goods would be undervalued countries with higher purchasing 
power such as the DRC [122], [124]. Tradable goods (e.g., medications) are those goods that can 
be imported or exported and converted their estimates using nominal (official) exchange rates. 
On the other hand, non-tradable goods are produced locally and cannot be imported or exported 
(e.g., labor) [122], [124] and converted their estimates using purchasing power parity (PPP) 
exchange rates. All exchange rates came from a World Bank database [129].   
As the trial was conducted for >1 year and cost estimates were extrapolated from multiple time 
periods [122], we adjusted the costs for inflation and reported the costs in constant 2016 I$—the 
year with the most recent conversion factors at the time of this study. To adjust for inflation, we 
used the implicit gross domestic product (GDP) deflator accessible through the World Bank 
database [130]. Unlike other candidate inflation-adjustment tools like the consumer price index, 
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the GDP deflator covers price changes in a broader range of economic activity, including the 
health sector [36]. We first applied inflation adjustment and then converted the inflation-adjusted 
estimates to I$. We did not discount costs or effects as participant follow-up was <1 year [131]. 
3.6. Cost assignment 
We assigned costs to participants based on the number of visits or services utilized and used both 
micro-costing and gross-costing to estimate the costs. For example, we assigned the cost of 
transport and drugs based on micro-costing and the cost of utilities and staff wages using gross-
costing. Micro-costing entails conducting a detailed identification and measurement of all 
activity inputs to value costs [132], [133]. Micro-costing can yield more precise estimates [132], 
but it was not possible to use this method to value all costs. Thus, we also used gross-costing—
use of mean costs aggregated at a higher level from other studies to determine the value of an 
activity [132]. Gross-costing is simple, tractable and quick to use [132], although it may produce 
biased estimates because of overgeneralization [132], [134].    
3.6.1. Medications and laboratory costs 
To assign the cost of medications, we multiplied the number of days a participant was on the 
medications by the unit cost of the medications. We calculated the number of days on the 
medications by taking the difference between the date a participant was started on the medication 
and the date the participant was last followed-up. Participants lost to follow-up at six weeks were 
assumed to have taken the medications for 3 weeks (half-way between the first visit date and the 
would-have-been visit at six weeks). We also estimated the cost of infant NVP suspension but 
only for six weeks after delivery because thereafter participants were not followed-up. Unit 
prices of medications, which came from CHAI and represent drug acquisition costs only, were 
increased by 15% to cover shipping costs [135]. 
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Among laboratory tests, we estimated the cost of CD4 cell counting and DNA PCR testing of 
infant dried blood sample (DBS). We also estimated the cost of transporting the DBS to a central 
laboratory in Kinshasa where the testing was done. We did not cost HIV testing and counseling 
as these services were provided to all pregnant mothers attending ANC clinics, regardless of 
study participation and therefore, would not contribute to incremental costs. We did not cost viral 
load tests because these tests were not performed or recorded systematically during the trial.  
3.6.2. Delivery and post-delivery counseling 
We estimated the cost of health facility deliveries as an episode. Separately, we also estimated 
the cost of post-delivery counseling on family planning and safe infant feeding practices. We 
assumed two post-delivery counseling sessions—one session soon after delivery but before the 
participant was discharged from the clinic and the other at six weeks’ postpartum. We calculated 
the cost of the two counseling sessions separately because some participants who delivered in 
health facilities did not return at six weeks’ post-partum.  
3.6.3. Labor and overhead costs 
We assigned labor costs to each visit, except the visit for hospital delivery which we assumed 
was included in the overall cost of the deliveries. We separately estimated labor costs for clinical 
and support staff. We used a nurse salary to approximate the labor cost of clinical staff. We 
assumed that a nurse saw 20 patients in a day [136] and worked for 22 days in a month. 
Therefore, we divided a nurse monthly salary by 440 (20*22) to find the labor cost of each visit. 
Using a similar approach, we derived the labor cost of support staff for each visit.  
At each visit, we also calculated the cost of overheads—resources shared by other programs—
which included utilities and equipment. Many of the studies from which we abstracted overhead 
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costs assigned costs to participants per month [137]–[139], so we assumed that the monthly cost 
was for one visit. We summed the costs per visit then multiplied by the number of visits to find 
the total cost of all visits per participant. 
3.6.4. Patient and peer/family support costs 
We also included costs incurred by participants and their supporters (peers or family) in the form 
of transport costs and the opportunity cost of time spent seeking PMTCT services [133]. 
Evidence suggests that women with HIV receiving PMTCT services are accompanied by their 
peers/family to the health facilities and they value their time and effort [140]. The trial recorded 
self-reported one-way transport costs which we doubled to get the transport cost per visit. We 
assigned the peer/family member the same transport cost as the participant. We also assumed 
that one clinic visit took one working day of the participant’s time and that a participant’s 
support lost an equal amount of time. Further, assumed the participant and their support lost 2 
days for delivering in health clinics. We used a minimum day’s wage for the DRC of 1680 FC in 
2016 as the opportunity cost of time [141].  
3.7. Missing data 
In preliminary analyses, we found that about 40% of the participants had missing transport costs 
which we replaced using multiple imputations to introduce variation in the imputed values and 
derive asymptotically consistent estimates [142]. We assessed the pattern of data missingness 
and found that the missingness was not systematic—a key assumption is multiple imputations 
[143]. We performed the multiple imputations using predictive mean matching which does not 
make any assumptions about the distribution of the data [144], [145]. We included the dependent 
variable and all explanatory variables from equation 1 (below) in the imputation, as 
recommended [146].   
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3.8. Analysis 
All analyses were by intention-to-treat. That is, all participants were kept in the groups to which 
they were randomized, regardless of deviations from the trial’s protocol [147]. For example, one 
participant assigned to the control group and randomly selected to receive the cash incentives 
was still analyzed as part of the control group. We analyzed effects and costs using univariable 
and multivariable approaches and then estimated the incremental effectiveness and incremental 
costs. We then multiplied the incremental effectiveness and incremental costs to derive ICERs. 
3.8.1. A general statistical model for analyzing effectiveness and costs 
To model the effectiveness and costs of the CCTs, we used marginal models estimated via 
generalized estimating equations (GEE) and adjusted for potential clustering at the clinic level. 
Ignoring the potential clustering could have led to a narrower 95% confidence interval [148] and 
thus increasing the probability of type 1 error [91]. We also adjusted for baseline participant 
characteristics as randomization might still fail to equalize trial arms due to sampling error [77]. 
GEEs produce population-averaged coefficients which are desirable because they can inform 
policymakers, on average, the effectiveness or cost of the CCTs were all pregnant HIV-positive 
women to receive the intervention. Other candidate models like the generalized linear mixed 
models produce cluster-specific coefficients and not population-averaged coefficients [66], 
[149]. Another advantage of GEE is that the coefficients from these models are robust to 
misspecification of the variance structure making them appropriate for studies interested in 
estimating coefficients and not the variance itself; GEEs treat the variance as a nuisance thereby 
making correct variance specification less important [66], [149], [150]. While GEEs may 
produce biased estimates when the number of clusters is small (<10) and study arms are not 
balanced [148], [151], we have confidence in the estimates as the trial had a high number of 
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clusters (89 clinics) and the  arms were balanced (216 vs. 217). We implemented the models 
using “xtgee” in Stata 14.2 [152].  
The following was the generalized linear model: 
𝐹−(𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑖𝑗) = 𝛽0 +  𝛽1𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛𝑖𝑗 + 𝑿𝑖𝑗𝐀       (1) 
where: 
Outcomeij was either PMTCT uptake or PMTC retention or cost for the i
th participant at 
the jth clinic; 
Intervention=1 if the participant received CCTs and 0 otherwise; β1 was the coefficient of 
interest.  
Xij is a vector of participant characteristics and A a corresponding vector of coefficients.  
We specified an exchangeable within-group correlation structure for both effectiveness and 
costs, but the links and distributions were different. An exchangeable structure means that the 
correlation between any pair of participants receiving PMTCT services at the same clinic was 
equal but non-zero [66], [149]. 
3.8.2. Effectiveness 
To model the effectiveness of the CCTs, we specified a Poisson distribution and a logarithmic 
link in equation 1. We specified a Poisson distribution because a log-binomial model could not 
converge within the GEE environment in Stata 14.2. While the Poisson and log-binomial 
regressions produce identical estimates, standard errors from the Poisson are larger [153], [154] 
which increases the probability of failing to reject the null (type 2 error) [91]. To make the 
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standard errors smaller and comparable to those from a log-binomial model, we estimated the 
Poisson model with robust error variances [154].  
To duplicate published results from the trial [115], we reported the effectiveness using relative 
risks. Thus, for PMTCT uptake in equation 1, participants who received the CCTs had β1 times 
the risk of taking up PMTCT services compared with participants who did not receive the CCTs. 
Similarly, for PMTCT retention, participants who received the CCTs had β1 times the risk of 
being retained in PMTCT care compared with participants who did not receive the CCTs. 
3.8.3. Incremental effectiveness 
Next, we estimated the incremental effectiveness of the CCTs expressed using NNT, like several 
other studies in the HIV literature[155], [156]. NNT is an epidemiological measure that 
quantifies the number of participants needed to receive a treatment to avoid a poor outcome 
[157], for example, not taking up PMTCT services. NNT is a natural number and therefore easier 
to interpret clinically than other candidate measures of incremental effectiveness like risk 
differences [157]. Thus, a higher NNT means that the treatment is less effective in avoiding the 
unwanted outcome. We were unable to use traditional measures of incremental effectiveness like 
the disability-adjusted life years (DALY) averted because participant follow-up time was too 
short, and the study was not powered to detect the effect of the CCTs on survival.  
Calculation of NNT, like for relative risks, was based directly on the underlying risk of PMTCT 
uptake or PMTCT retention in each trial arm. We emphasize that we could not directly estimate 
the NNT using the relative risks from the Poisson regression. Therefore, after estimating the 
Poisson regression in equation 1, we derived the NNT in the following steps: 
1. Predicted the absolute risk for each participant. 
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2. Calculated the mean absolute risk in each arm. 
3. Calculated the mean absolute risk difference between the intervention and control arms.  
4. Calculated the NNT, which is the reciprocal of the mean absolute risk difference [158].  
We interpreted the NNT as the number of participants needed to receive the cash incentives for 
one more participant to take up PMTCT services, compared to standard of care. We made a 
similar interpretation for PMTCT retention. 
3.8.4. Economic costs 
To determine total costs in each trial arm, we multiplied resources used by each participant by 
the unit cost of that resource and then added. We described costs using both the median and 
mean but in multivariable regressions modeled mean costs only. While reporting of median costs 
is recommended as cost data are almost always positively skewed [131], we also report mean 
costs because budgeting and policy decisions are made based on expectation [159]. We tested 
differences in means and medians using t-tests and rank sum tests. The t-test, which assumes a 
normal distribution, is still robust when the sample size is greater than 150 or when the number 
of participants in the intervention and control groups is similar [160], as in this study.  
3.8.5. Incremental costs 
To estimate incremental costs, we also used equation 1 with cost as the outcome. We specified 
an exchangeable within-group correlation structure, a gamma distribution, and an identity link. 
These specifications were based on results of testing several correlation structures and cost 
distributions using the quasi-likelihood under the independence model criterion (QIC) [161]. By 
specifying an identity link, β1 was in the original cost values and represented the difference in 
costs between the intervention and the control arms—or the incremental cost of the CCTs.  
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3.8.6. Incremental cost-effectiveness ratio 
To derive ICERs, we multiplied incremental costs and incremental effectiveness (incremental 
costs*NNT)2. Because the ICER is a ratio and therefore does not have standard errors to use in 
calculating the 95% confidence intervals, we used Fieller’s theorem to generate the confidence 
intervals [131], Appendix B4. Unlike other parametric methods which assume a normal 
distribution of the ratio, Fieller’s method considers the skewed distribution of the ICER [131], 
[162].  
3.8.7. Are the CCTs cost-effective? 
To determine whether the CCTs are cost-effective, we compared the ICER of the CCTs to cost-
effectiveness thresholds based on 3x the GDP per capita for the DRC in 2016 (I$2409) [163]. 
Thus, I$2409 represented the maximum willingness-to-pay for an additional participant to take 
up PMTCT services or be retained in care. However, because of concerns that a threshold of 3x 
GDP per capita may be too high [164]–[166], we also considered a lower threshold (1.5x the 
GDP per capita for the DRC in 2016 or I$1205).  
3.8.8. Uncertainty analysis 
We also assessed uncertainty in the cost variables and the estimated ICER[122], [133], [167]. 
Sources of the uncertainty included: abstraction of cost data in different unit costs outside of the 
trial, use of gross costing, and imputation of transport costs [143], [167], [168]. We used 
deterministic sensitivity analyses to examine uncertainty in cost variables and cost-effectiveness 
acceptability curves to examine uncertainty in ICERs.   
                                                 
2 In the traditional approach, ICER=ΔC/ΔE, where ΔC is the incremental cost and ΔE is the incremental 
effectiveness. Estimating effectiveness using absolute risk means that the ΔE is the risk difference (RD). Thus, 
ICER=ΔC/RD= ΔC*1/RD. But 1/RD=NNT. Therefore, ICER=ΔC*NNT. 
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3.8.8.1. One-way sensitivity analysis 
In one-way sensitivity analyses, we identified the main cost drivers by varying the cost of key 
components one at a time across a plausible range of values, holding other cost components at 
their base values [133], [169]. A component was key if it had high unit costs or high utilization 
relative to the other components, and therefore, more likely to substantially affect costs if varied 
[170]. We selected values for lower and upper bound unit costs from the sources of the base case 
unit costs  [170]. We used the limits of the 95% confidence intervals of the base case unit costs 
as the upper and lower bounds in the sensitivity analyses. If the base unit cost did not have a 95% 
confidence interval, we decreased and increased base case estimate by 50% to derive the lower 
and upper bound estimates, as done previously [169], [171], [172]. In each one-way sensitivity 
analysis, we calculated new ICERs and report the results using tornado diagrams [173], [174]. 
Table 3 presents the key components and the unit costs in the sensitivity analysis. 
3.8.8.2. Multi-way sensitivity analyses: best- and worst-case scenarios  
Since multiple variables may be uncertain, we examined the effect of simultaneously varying key 
cost variables in multi-way sensitivity analysis [169]. We created best- and worst-case scenarios. 
We combined the most optimistic unit costs (lower bound unit costs) in table 3 to create the best 
case and the most pessimistic unit costs (upper bound unit costs) to create the worst case. In each 
scenario, we calculated new ICERs and the associated 95% confidence intervals. 
3.8.8.3. Cost-effectiveness acceptability curve 
To examine the uncertainty associated with the ICERs in the base case, we used cost-
effectiveness acceptability curves. These give the probability that an intervention is cost-
effective compared with the alternative, for varying levels of willingness-to-pay [175]. To derive 
the cost-effectiveness acceptability curves, we implemented the following steps: 
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1. Using simple random sampling with replacement, we drew a sample of 216 observations 
from the trial data, similar to the size of the intervention arm [162], [176], [177]. 
2. From the resampled data, we calculated the mean cost and effectiveness [162], [176], 
[177]. 
3. We repeated steps 1 and 2 to obtain the mean cost and effectiveness in the control arm. 
4. Next, we combined the resampled datasets and calculated a new ICER. 
5. We repeated steps 1-4 for 4000 times although 1500 times is recommended [178]. This is 
because the bootstrapped costs and effects were normally distributed after 4000 samples. 
We bootstrapped costs and effects together because of their interdependence. 
6. From the 4000 ICERs, we estimated differences in costs and differences in effects.  
From the differences in costs and effects in step 6, we derived the cost-effectiveness 
acceptability curves. We also plotted the joint distribution of the differences in costs and effects 
on a cost-effectiveness plane. To construct the CEAC, we modified an existing Stata program by 
changing the program’s default confidence limits and maximum values [179].  
4. Results 
4.1. Effectiveness of CCTs 
We found that CCTs significantly increased the uptake of PMTCT services and retention in 
PMTCT care. About 68% (146/216) of women in the intervention group took up PMTCT 
services compared with 53% (116/217) in the control group. About 81% (174/216) of women in 
the intervention group were retained in PMTCT care compared with 72% (157/217) in the 
control group. Compared to participants who did not receive the cash incentives, participants 
who received the cash incentives were 28% and 12% more likely to take up PMTCT services and 
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being retained in PMTCT care, respectively, table 4. Further, women with a secondary education 
and those who walked to clinics were significantly more likely to take up PMTCT services.    
4.1.1. The incremental effectiveness of CCTs (number-needed-to-treat) 
We present incremental effectiveness (NNT) of the CCTs and the values at each step of deriving 
the NNT in table 5. We emphasize that NNT cannot be derived directly from relative risks and 
therefore, results in table 4 could not have been used to derive the NNT. The NNT for PMTCT 
uptake was 7.0 (95% C.I.=6.7-7.6)—that is 7 participants needed to receive the cash incentives 
for one more participant to take up the PMTCT services. For PMTCT retention, the NNT was 
12.1 (95% C.I.=11.6-12.8).  
4.2. The economic cost of the CCTs 
We summarize economic costs in table 6. The mean total cost ± SD per participant in the 
intervention group was I$516 (116), compared with I$431 (132) in the control group (p-value 
<0.001). The median cost was also higher in the intervention group (I$540, IQR (485-590) vs. I$ 
468, IQR (392-512)) (p-value <0.001). As a share of mean total costs, the cost of delivering in a 
health facility was the highest in both arms, although lower in the intervention group (52% vs. 
58%). In the intervention arm, the cost of the CCTs ranked second tied with the cost of 
medications (10%). Overall, participants in the intervention group made 35 visits (934 vs. 899), 
with a mean cost per visit of I$119 (vs. I$104 in the control group). 
4.2.1. The incremental cost of the CCTs 
Table 7 presents the incremental costs of the CCTs. The CCTs had an incremental cost of I$85 
(95% C.I.=59-111). The Incremental costs did not differ significantly by participant 
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characteristics although the costs were higher among those who were married, without any 
education, and walked to the clinics. 
4.3. Incremental cost-effectiveness ratios of CCTs 
In the following subsections, we present incremental cost-effectiveness ratios in the base case 
and in uncertainty analyses.  
4.3.1. Base case analysis 
Table 8 presents the incremental cost-effectiveness ratios of the CCTs in the base-case analysis. 
The incremental cost-effectiveness ratio of the CCTs with respect to PMTCT uptake was I$595 
(95% C.I. =567-624) and I$1026 (95% C.I.=960-1101) with respect to PMTCT retention. Thus, 
the CCTs were very cost-effective in increasing PMTCT uptake (ICER <1x DRC GDP per capita 
or I$803) and cost-effective in increasing PMTCT retention (ICER> I$803 but <3x DRC GDP 
per capita or I$2409). 
 I$595 (95% C.I. =567-624) for PMTCT uptake and I$1026 (95% C.I.=960-1101) 
4.3.2. One-way sensitivity analysis 
Figure 1, a tornado diagram, presents the results of the one-way sensitivity analysis and the 
associated ICERs. The vertical line in the diagram corresponds to the ICER in the base case. The 
variables are ranked so that the most influential variable is at the top. The x-axis measures the 
change in ICER from the base case while the labels of the bars are the lower and upper bound 
unit costs used in the sensitivity analysis. The CCTs followed by delivery in health facilities 
were the main drivers of the incremental cost-effectiveness ratios. For example, paying each 
participant I$20 (or US$11) at every visit while holding other variables constant increases the 
93 
ICER from I$1026 per additional HIV+ mother retained in PMTCT care in the base case to 
I$1,570, but still cost-effective. 
4.3.3. Multi-way sensitivity analysis 
Table 9 presents results of multi-way sensitivity analysis. In the best-case, the ICERs were <1x 
GDP per capita and therefore very cost-effective. In the worst case, the CCTs were still cost-
effective as the 95% confidence intervals of the ICERs were < I$2409 (PMTCT uptake: 
ICER=I$1175, 95% C.I. (1118-1235); PMTCT retention: ICER=I$2027, 95% C.I. (1893-2178).  
4.3.4. Cost-effectiveness acceptability curves and willingness to pay for CCTs 
We present the joint distribution of differences in costs and effects for PMTCT uptake in figure 
2 and for PMTCT retention in figure 3. In both figures, all the data points (incremental cost-
effectiveness ratios) are in the northeast quadrant of the cost-effectiveness plane—thus the CCTs 
increased both effectiveness and costs in all the resampled datasets. Furthermore, the clustering 
of ICERs in the same part of the quadrant shows that the values of the ICERs from the resampled 
datasets were close and did not greatly vary from the ICER estimate from the original trial data.  
Based on the joint distribution of incremental costs and effects, we capture the uncertainty 
surrounding the incremental cost-effectiveness of CCTs at different willingness-to-pay 
thresholds in figure 4. This acceptability curve shows the level of uncertainty surrounding the 
ICER estimate and the probability that the CCTs were cost-effective, compared to the control 
group, for a given level of willingness-to-pay. Points B and F correspond to the ICER point 
estimates3 reported in table 7 and all points on the solid black line in figures 2 and 3. These 
                                                 
3 The ICER point estimates in figures 2, 3, and 4 are slightly different from the ICERs in the main results (table 8). 
This is because in resampling the original trial data 4000 times, each resampled dataset had its own ICER. 
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points have 0.5 probabilities of being cost-effective. The steep slope and the rapid rise of the 
curves (A to C and E to G) suggest small deviations from the original ICER estimate, and 
therefore, a high degree of certainty associated with the ICERs. 
In addition to showing a high degree of certainty surrounding the ICERs, figure 4 also shows that 
the CCTs were cost-effective at many of the thresholds of willingness-to-pay proposed in this 
study. For example, if the willingness-to-pay is I$2409 (3x GDP per capita in 2016), the 
probability that the CCTs were cost-effective is almost 1. At a threshold of I$1205 (1.5x GDP 
per capita in 2016), the probability that the CCTs were cost-effective is almost 1. At a threshold 
of I$803 (1x GDP per capita in 2016), the probability that the CCTs were cost-effective in 
increasing PMTCT uptake is almost 1 (point D), but for PMTCT retention the probability is 
almost zero. At any threshold < I$570, the CCTs have no chance of being cost-effective. 
5. Discussion  
Uptake of PMTCT services in SSA remains low despite scale-up of Option B+ in the region 
[106], posing challenges to global ambitions of eliminating MTCT of HIV. Coupled with 
inadequate domestic funding and lack of growth in international financing towards the 
HIV/AIDS response [181], [182], it is imperative to find innovative and cost-effective strategies 
that can increase the uptake of the PMTCT services. We examined the cost-effectiveness of a 
trial of one such strategy—small but increasing cash incentives aimed to increase PMTCT 
uptake and PMTCT retention in the DRC. The findings suggest that the cash incentives were 
cost-effective from the societal perspective. To our knowledge, this is the first study to evaluate 
                                                 
Therefore, figures 2, 3, and 4 present the mean of the ICERs while table 8 presents ICERs from the original trial 
data. It is not unusual for ICERs from the original trial data and resampled datasets to differ slightly [180]. 
 
95 
the cost-effectiveness of cash incentives aimed to increase the uptake of PMTCT services and 
retention in PMTCT care. 
From the societal perspective, the estimated incremental cost of the cash incentives was I$85, 
with corresponding ICERs of I$585 for PMTCT uptake and I$1081 for PMTCT retention. For a 
willingness-to-pay threshold of 3x DRC GDP per capita in 2016 (I$2409), these estimates 
suggest that the cash incentives were very cost-effective in increasing PMTCT uptake but cost-
effective in increasing PMTCT retention. In a sensitivity analysis, the cash incentives were the 
main cost drivers and the intervention was still cost-effective even in the worst case. 
The study’s finding that the cash incentives were cost-effective is consistent with reports from 
previous studies which examined the cost-effectiveness of other strategies aimed at increasing 
uptake of PMTCT services although some of the studies predate the Option B+ era. We 
emphasize that literature on interventions aimed at increasing uptake of PMTCT services is 
limited. Instead, the literature is replete with cost-effectiveness studies comparing different 
treatment protocols (for example, no intervention vs Option A vs. Option B vs. Option B+) or 
different HIV testing and counseling strategies [183]–[185]. For example, universal HIV testing 
of all pregnant mothers during ANC clinics was cost-effective in multiple countries [186], as 
were HIV rescreening late in pregnancy in South Africa [187] and couple counseling in Kenya 
[188]. Evidence from studies of non-conventional models for the delivery of PMTCT services 
suggests that these models are also cost-effective, although comparability is still limited because 
of health outcomes used. The Futures Institute reported that low and high levels of integration of 
PMTCT services with maternal, neonatal, and child health within antenatal care clinics in 
Malawi, Uganda, and Mozambique were cost-effective [189]. The study reported health 
outcomes using number of HIV infant infections averted over a period of 100 years [189]. 
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Similarly, the JSI Research and Training Institute, which used data from Kenya and reported 
health outcomes using number of infant infections averted and QALYs gained, reported that 
Civil Society Organizations delivered PMTCT services more cost-effectively than did public 
health facilities [190]. Peer mentors like Mother2mothers—initially implemented in South Africa 
and later scaled to other parts of SSA [191], [192]—increased uptake of PMTCT services, 
improved health outcomes, and represent a good value for the money according to another report 
by the JSI Research and Training Institute [193]. However, comparability of findings is limited 
because the study had a longer analytic time horizon and was a cost-benefit analysis—that is, it 
expressed incremental effectiveness in monetary terms [193].  
This study contributes to a broader, although limited, literature on the cost-effectiveness of cash 
incentives to improve individual/household behaviors and well-being. The findings from this 
limited literature are mixed overall but suggest that the cash incentives are cost-effective in 
resource-limited settings [194]–[196] or when the analytic time horizon is longer—for example 
over a lifetime [197]. The lack of evidence that cash incentives are cost-effective is largely for 
two reasons. First, the lack of comprehensive data about costs and effects. Second, not 
considering the effects of the cash incentives more broadly [198], [199]. This is particularly true 
for effects because the impact of the cash incentives is likely to go beyond the specific sector of 
interest [198]–[201]. For example, in Malawi, cash incentives averted one HIV infection among 
school going girls aged 13-22 years at a cost more than 15 times Malawi’s GDP per capita [202], 
and therefore less cost-effective. However, the cash the incentives also increased retention of the 
girls in school [202]. Thus, although less cost-effective when considered more narrowly (via the 
lens of HIV financing only), the cash incentives could be cost-effective and make economic 
sense when co-financing models (for example, including resources from education) are 
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considered [203]. Given that this study did not include all the possible benefits of the cash 
incentives, for example, increases in uptake of family planning services and improvements in 
overall health-seeking behaviors, it is likely that the current study underestimates the cost-
effectiveness of the CCTs. Further, the evidence suggests that cash incentives are less-cost 
effective in high-income countries perhaps because the size of the incentives relative to 
household income is not large enough to be effective [204], [205], [206, p.]. On the other hand, 
cash incentives do appear to be cost-effective in developing countries where the cash incentives 
increased school enrollment and attendance and improved secondary school outcomes [194], 
[195]. Cash incentives were also cost-effective in increasing household food security and child 
development [196] and preventing undernutrition in emergency situations [171]. Therefore, 
although the evidence is mixed, this study adds to the building evidence that cash incentives are 
cost-effective and can be used to promote good social behaviors, particularly in resource-limited 
settings like in many countries in SSA. 
5.1. Limitations  
This study has limitations. First, because the trial did not collect detailed data for each cost 
component, there may be bias in the cost estimates. We relied on external sources, made a series 
of assumptions, and imputed missing data to estimate the costs. However, recognizing that this 
may have introduced bias [207], we conducted sensitivity analyses and the findings suggest that 
the cash incentives were still cost-effective even in the worst of circumstances.  
Second, we were unable to use traditional health outcome measures for incremental effectiveness 
analysis like the number of DALYs [163] or HIV-infections averted. This is because participant 
follow-up, which was up to six weeks post-partum, was not long enough to have definitive 
results about the HIV status of infants in each trial arm. This limits the comparability of the 
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study’s findings with other cost-effectiveness analysis studies. Despite the limitation, these 
findings serve as a foundation for future cost-effectiveness studies that can incorporate final, 
versus intermediate, health outcomes. Moreover, the success of PMTCT services in achieving 
the desired goals begins with the uptake of the PMTCT services [108]–[110] and the findings 
from this study suggest that the cash incentives increase PMTCT uptake and do so cost-
effectively. 
Third, the thresholds based on GDP per capita have been criticized in the literature for not 
reflecting the opportunity cost of local resources used in the interventions [164]–[166], as 
recommended [208]. This suggests that most interventions deemed effective using these 
thresholds, may not be cost effective if the thresholds reflected the opportunity cost of the local 
resources used in the interventions. Furthermore, we emphasize that these thresholds based on 
GDP per capita were developed for cost-effectiveness analyses using final health outcome like 
DALYs averted or QALYs gained  [163], and not intermediate outcomes like NNT. Noting these 
limitations, we considered a more conservative threshold (1.5x DRC GDP per capita) in 
uncertainty analysis and found that the cash incentives were still cost-effective. Moreover, results 
from studies using thresholds based on GDP per capita continue to help inform policy. For 
example, Option B+, an intervention already adopted and expanded by the DRC and many 
countries in SSA was found to be cost-effective based on these thresholds [209]–[211]. 
5.2.  Implications for future research  
While these findings suggest that the cash incentives are cost-effective, additional research is 
needed before any recommendations to scale-up the intervention can be made. First, we need to 
understand the cost-effectiveness of the cash incentives using final health outcomes like DALYs 
averted or life-years saved, as might be done in mathematical modeling studies. Such studies can 
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also examine whether the cash incentives are still cost-effective in larger populations and with 
different HIV profiles.  Second, there is a need to understand whether the cash incentives can be 
combined with other cost-effective strategies also aimed at increasing the uptake of PMTCT 
services. This is important because the cash incentives, even if scaled widely, cannot overcome 
all barriers preventing the uptake of PMTCT services. Overcoming barriers to uptake of PMTCT 
services like stigmatization of people living with HIV and lack of partner support [118], [212] 
would require other interventions, particularly those that are community-based. Several of these 
interventions have shown effectiveness in increasing uptake of PMTCT services in Tanzania 
[213], South Africa [214], [215], Nigeria [216],  Malawi [217], Zimbabwe [218], and Uganda 
[219]. Therefore, if these interventions are also cost-effective, future research should focus on 
whether some of these interventions can be combined with the cash incentives.  
6. Conclusion  
Low uptake of PMTCT services is a challenge in SSA, with implications on global efforts of 
realizing an HIV-free generation. Based on WHO’s thresholds for cost-effectiveness, conditional 
cash transfers are cost-effective in increasing uptake of PMTCT services and retention in 
PMTCT care in the DRC and similar settings. Additional research is needed to understand the 
effectiveness and cost-effectiveness of the cash incentives using final health outcomes and in 
larger populations before further scale-up of the intervention. Given that the cash incentives can 
overcome financial, vs. social barriers like stigmatization, considerations to combine the cash 
incentives with other cost-effective community-based strategies should also be made.  
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Table 1: Definition of standard PMTCT care 
HIV counseling and testing     
HIV posttest counseling     
CD4 cell count       
Cotrimoxazole prophylaxis 
AZT if CD4 cell count ≥350 cells/mm3 or triple ARV therapy if <350 cells/mm3* 
Delivery in a health facility     
Post-partum care, including counseling on infant feeding options 
Nevirapine suspension for the infant 
  Cotrimoxazole prophylaxis for infants 
 
DNA PCR and Serologic testing for infants   
*Participants with CD4 cell counts <350 cells/mm3 were referred to an HIV clinic where they 
received AZT. Source: Yotebieng et. al, 2016.  
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Table 2: Included costs, societal perspective* 
Sector Type of impact 
Formal healthcare sector  
 
Health outcomes (effects)† 
Uptake of PMTCT services 
In PMTCT care six weeks' postpartum 
Medical costs 
Medications 
Laboratory tests  
Transportation of infant dried blood samples‡ 
Health facility deliveries 
Post-delivery counseling 
Labor (wages for clinical and support staff) 
Overhead costs (utilities) 
Capital costs (equipment) 
Informal healthcare sector  
 
Patient time costs 
Peer/family support time costs 
Patient transportation costs 
Peer/family support transportation costs 
*This table is based on recommendations by the second US Panel on Cost-effectiveness in 
Health and Medicine [220] and not the World Health Organization. † The study had two primary 
outcomes: uptake of PMTCT services and retention in PMTCT care. Uptake of PMTCT services 
was defined as timely attendance (within 5 days) of all scheduled clinic visits from 
randomization through 6 weeks’ postpartum and accepting all proposed services listed in box 1. 
‡ Infant dried blood samples from all clinics participating in the study were transported to a 
central laboratory in Kinshasa for DNA PCR testing.   
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Table 3. Unit Costs, in I$2016 
    
 
Cost component Unit of measurement Base case* Lower bound† Upper bound† Reference 
Cash Incentives Per visit 9-20‡ 9.00 20.00 Trial data 
Medications 
    
 
AZT (mother) Per dose (30 days) 7.48 3.74 10.87 [128] 
ART (mother) Per dose (30 days) 7.83 3.92 12.58 [128] 
Cotrimoxazole (mother) Per dose (30 days) 1.08 0.51 3.25 [221] 
Nevirapine (infant) Per dose (6 weeks) 11.63 5.82 17.45 [128] 
Cotrimoxazole (infant) Per dose (6 weeks) 4.14 2.07 6.21  [222] 
Laboratory tests 
    
 
        CD4 count Per test 15.3 7.65 22.95 [138] 
DNA PCR (infant) Per test 45.28 22.64 67.92 [138] 
Transportation of DBS§ Per sample 2.33 1.16 3.49 [223] 
Health facility deliveries ‖   
    
 
        Delivery Per delivery 281.31 28.13 843.92 [224] 
    Post-delivery counselling Per session 0.47 - - [184] 
Labor 
    
 
Wages for clinical staff Per visit 3.32 - - [225] 
Wages for support staff Per visit 1.61 - - [226] 
Capital and overhead costs 
    
 
Equipment Per visit 1.70 - - [227] 
Utilities Per visit 0.90 - - [138] 
Patient and peer/family support costs 
    
 
Time  Per day 3.00 1.50 4.49 [141] 
Transportation (varies by patient) Per visit 0.19-5.75 0.19 5.75 Trial data 
*Base-case values were used to derive total mean costs in each trial arm for the main analysis. †Lower and upper bounds were created from 95% confidence intervals of the 
base case unit costs. If a base unit cost did not have a 95% confidence interval, the base unit cost was decreased by 50% to derive the lower bound and increased by 50% to 
derive the upper bound unit cost. The lower and upper bounds were individually used in one-way deterministic sensitivity analysis and in combination to create best- and 
worst-case scenarios in multi-way sensitivity analysis. ‡This range in USD is 5-11. §DBS (dry blood sample) was transported from the study clinics to a central laboratory in 
Kinshasa. ‖ Health facility deliveries: as the trial did not collect data on facility type, delivery method, and employment status, we made the following assumptions. For the 
base case unit cost, we assumed that all study participants delivered in secondary health centers, the baby was delivered normally and that all participants were unemployed. 
For the lower bound unit cost, we assumed that all study participants delivered in primary health centers, delivery was normal and that they were all were unemployed. For 
the upper bound unit cost, we assumed that all study participants delivered in primary health centers, delivery was through cesarean section and that all study participants 
were employed.  
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Table 4: Effectiveness of conditional cash transfers   
  PMTCT Uptake† PMTCT Retention‡ 
  Relative risk 95% C.I. Relative risk 95% C.I. 
Intervention 1.276** [1.09,1.50] 1.12* [1.01-1.23] 
Age 1.003 [0.99,1.02] 0.99 [0.99,1.00] 
Marital status (ref: not married)     
Married 0.975 [0.83,1.15] 1.00 [0.89,1.13] 
Education (ref: no education)     
Primary 0.916 [0.73,1.15] 1.04 [0.90,1.21] 
Secondary or higher 1.396** [1.14,1.71] 1.10 [0.94,1.29] 
Wealth (ref: first quintile (poorest))§     
Second quintile 0.939 [0.74,1.19] 0.98 [0.83,1.15] 
Third quintile 1.07 [0.86,1.331] 1.02 [0.87,1.19] 
Fourth quintile 0.91 [0.69,1.20] 0.99 [0.84,1.16] 
Fifth quintile (richest) 1.092 [0.85,1.40] 0.99 [0.84,1.17] 
Transport mode (ref: other means)     
Walk 1.209* [1.04,1.40] 1.091 [0.99, 1.20] 
Constant 0.423*** [0.27,0.66] 0.80 [0.61,1.04] 
Observations 433   433   
Abbreviations: PMTCT, prevention of mother-to-child transmission of HIV.  
* p<0.05, ** p<0.01, *** p<0.001. † PMTCT uptake was defined as meeting the following conditions: 
attended all scheduled clinic visits from enrollment date through 6 weeks' postpartum, gave birth in a study 
clinic, accepted all proposed services including providing blood samples for CD4 cell count and dried blood 
spot sample for early infant diagnosis of HIV at six weeks' postpartum. ‡ PMTCT retention was defined as 
being in HIV care at 6 weeks’ postpartum regardless of the reason for missing any prior scheduled visits 
[115]. §Wealth quintiles were created from twelve variables using principal components analysis (PCA). The 
following variables were included in the PCA: maternal education, average number of household members 
per room, number of beds in the household, water source for the household (private or communal) and 
cooking fuel type (electrical stove, or firewood/charcoal). Ownership status of the following durable assets 
was also used in the PCA: radio, television, mobile telephone, refrigerator, and car [115]. 
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Table 5: Number-needed-to-treat (NNT), and steps for deriving the NNT 
  PMTCT uptake PMTCT retention 
Steps   
Predicted mean absolute risk in the treatment group 0.68 0.81 
Predicted mean absolute risk in the control group 0.53 0.72 
Calculated absolute risk reduction*  0.14 0.08 
Number-needed-to-treat (NNT) †  7.01 (6.69-7.57)‡ 12.11 (11.55-12.81)‡ 
The values in the table may not be exact due to rounding *We subtracted the predicted mean absolute 
risks between the intervention and control groups to derive the absolute risk reduction. †We took the 
reciprocal of the absolute risk reduction to derive the NNT. ‡These numbers represent the 95% 
confidence intervals and were generated using Fieller’s method. 
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Table 6. Mean cost per participant, by trial arm (2016 I$) 
  Intervention        Control   
Cost Mean 95% C.I. Mean 95% C.I. p-value* 
Cash Incentives 51.10 [48.56-53.64] 0.31† [0.00-0.93] <0.001 
Medications 
     
AZT (mother) 18.27 [16.19-20.34] 17.40 [15.33-19.47] >0.1 
ART (mother) 13.45 [11.18-15.73] 11.96 [9.81-14.1] >0.1 
Cotrimoxazole (mother) 5.04 [4.79-5.29] 4.86 [4.58-5.13] >0.1 
Nevirapine (infant) 10.12 [9.6-10.65] 9.43 [8.82-10.05] <0.1 
Cotrimoxazole (infant) 3.91 [3.78-4.04] 3.68 [3.51-3.86] <0.05 
Laboratory tests 
     
CD4 35.99 [33.98-38] 31.66 [29.65-33.67] >0.1 
DNA PCR (infant) 30.61 [27.75-33.46] 24.21 [21.17-27.24] <0.01 
Transportation of dry blood sample 1.57 [1.43-1.72] 1.24 [1.09-1.4] <0.01 
Health facility deliveries 265.68 [257-274.36] 250.19 [238.33-262.05] <0.05 
Post-delivery counselling 0.44 [0.43-0.46] 0.42 [0.4-0.44] <0.05 
Labor 
     
Wages for clinical staff 11.21 [10.63-11.8] 10.80 [10.18-11.41] >0.1 
Wages for support staff 4.97 [4.71-5.23] 4.79 [4.52-5.06] >0.1 
Capital and overhead costs 
     
Equipment 5.74 [5.44-6.04] 5.52 [5.21-5.84] >0.1 
Utilities 3.04 [2.88-3.2] 2.93 [2.76-3.1] >0.1 
Patient and peer/family support costs 
     
Patient and family support’s time  35.96 [34.74-37.18] 34.02 [32.73-35.31] <0.05 
Transportation (varies by patient) 18.83 [17.22-20.43] 18.00 [16.28-19.73] >0.1 
Total cost 515.94 [500.37-531.51] 431.43 [413.75-449.11] <0.001 
*The p-values were from tests of medians based on the Wilcoxon rank sum tests. †The mean cost of cash 
incentives in the control group is not zero because one randomly selected participant in the control group received 
an incentive of I$ 82 (or US$ 45). We truncated the confidence interval for the cash incentives in the control group 
at zero; the actual confidence interval was [-0.31-0.93].  
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Table 7. Adjusted costs of conditional cash transfers, I$2016  
  Cost 95% C.I. 
Intervention 84.77*** [58.72,110.82] 
Age -1.68 [-3.64,0.28] 
Marital status (ref: not married)   
Married 22.8 [-9.12,54.64] 
Education (ref: no education)   
Primary -1.97 [-29.94,26.00] 
Secondary or higher -0.13 [-56.11,55.84] 
Wealth (ref: first quintile (poorest))†   
Second quintile -8.90 [-45.27,27.47] 
Third quintile -1.63 [-33.14,29.89] 
Fourth quintile -28.90 [-70.35,12.47] 
Fifth quintile (richest) -28.80 [-70.33,12.70] 
Transport mode (ref: other means)   
Walk 13.00 [-13.45,39.48] 
Constant 469.00*** [408.31,529.71] 
Observations 433   
* p<0.05, ** p<0.01, *** p<0.001. †Wealth quintiles were created from twelve variables using 
principal components analysis (PCA). The following variables were included in the PCA: 
maternal education, average number of household members per room, number of beds in the 
household, water source for the household (private or communal) and cooking fuel type 
(electrical stove, or firewood/charcoal). Ownership status of the following durable assets was 
also used in the PCA: radio, television, mobile telephone, refrigerator, and car. 
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Table 8. Incremental cost-effectiveness ratios of conditional cash transfers 
               PMTCT Uptake   PMTCT Retention 
  Estimate 95% C.I. Estimate 95% C.I. 
Incremental effectiveness (NNT)* 7.01 [6.69-7.57] 12.11 [11.55-12.81] 
Incremental cost (I$) 84.77 [58.72-110.82] 84.77 [58.72-110.82] 
ICER*† 594.54 [567.04-624.26] 1026.23 [959.99-1101.26] 
Abbreviations: PMTCT, prevention of mother-to-child transmission of HIV; NNT, number-needed-to-treat); 
ICER, incremental cost-effectiveness ratio. 
*Confidence intervals generated using Fieller's theorem. †At a cost-effectiveness threshold 3x DRC GDP per 
capita in 2016 (I$2409), the conditional cash transfers were cost-effective. 
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Table 9. Multi-way sensitivity analysis of the cost-effectiveness of CCTs: best and worst cases 
  PMTCT Uptake PMTCT Retention 
 ICER 95% C.I.* ICER 95% C.I.* 
Base case 594.54 [567.04-624.26] 1026.23 [959.99-1101.26] 
Best case† 219.78 [210.01-230.37] 379.36 [355.36-406.62] 
Worst case‡ 1174.51 [1118.11-1235.32] 2027.34 [1893.95-2178.09] 
Abbreviations: PMTCT, prevention of mother-to-child transmission of HIV; ICER, incremental cost-
effectiveness ratio. 
*The 95% confidence intervals generated using Fieller's theorem. †The best case was created by combining 
lower-bound unit costs of the key cost components. ‡ Worst-case scenario created by combining upper-bound 
unit costs of the key components. At a cost-effectiveness threshold 3x DRC GDP per capita in 2016 (I$2409), 
the conditional cash transfers were still cost-effective. 
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Figure 1: One-way sensitivity analysis of changes in unit costs on the ICER 
This figure shows how ICERs respond to changes in unit costs of one variable while holding 
costs of other variables at their baseline values. The thick vertical lines in the graphs correspond 
to the ICERs derived using unit costs in the base case. The labels at the end of each bar are the 
lower and upper bound unit costs used in the sensitivity analysis. The length of the bar on either 
side of the vertical line represents the new ICER associated with each of the unit costs, and its 
value can be read from the x-axis. Cash incentives followed by health facility deliveries were the 
most influential variables in determining the ICER 
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Figure 2: Differences in costs and effects, PMTCT uptake 
This figure shows a joint distribution of differences in costs and effects associated with uptake of PMTCT services. A total 4000 
replications of the original trial data were performed, and each dot in the graph represents one incremental cost-effectiveness ratio. 
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Figure 3: Differences in costs and effects, PMTCT retention 
This figure shows a joint distribution of differences in costs and effects associated with retention in PMTCT care. A total 4000 
replications of the original trial data were performed, and each dot in the graph represents one incremental cost-effectiveness ratio. 
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Figure 4: Society’s willingness-to-pay for uptake of PMTCT services and retention in PMTCT care 
This figure shows the uncertainty surrounding the mean incremental cost-effectiveness ratios (ICER) of the cash incentives with respect 
to PMTCT uptake and PMTCT retention. The steep slopes of the curves suggest a high degree of certainty surrounding the mean ICERs. 
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Appendices  
 
Appendix B1: Overview of search terms for cost estimates 
 
       
      
      
      
      
      
      
      
      
      
AND 
 
      
      
      
      
      
The study used these terms to search for cost estimates in 
Google, Google Scholar, Medline, and PubMed 
"prevention of mother-to-child transmission of HIV" 
OR "prevention of mother-to-child transmission" OR 
"PMTCT of HIV" OR "PMTCT" OR "vertical 
transmission of HIV" OR "Maternal and infant 
interventions in HIV" OR "prevention of vertical 
transmission of HIV" OR "mother-to-child 
transmission of HIV" OR "vertical transmission of 
HIV" OR "HIV" 
"cost" OR "cost analysis" OR "cost-effectiveness" OR 
"cost-utility" or "economic evaluation" or "cost-benefit 
analysis"  
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Appendix B2: Candidate cost sources  
Costs Cost source Country Currency 
and year 
Estimate  Original Unit  Common  
Derived 
Unit 
Estimate 
common 
unit 
Ref 
Recurrent costs 
     
 
 
 
Wages 
     
 
 
 
Clinical staff* IntraHealth 
International 
DRC 2016 USD 145.00 per nurse per m per visit 0.33 [228] 
 
Becker-Dreps DRC 2005 USD 1.15 per hour per visit 0.58 [225] 
 
Adebeyi & Waldron Zambia 2011 USD 1.32 per visit per visit 1.32 [137]  
Mccoy et al. Burkina 
Faso 
2006 USD 204.50 per nurse per m per visit 0.46 [229] 
 
Arise Project Zimbabwe 2012 USD 1.10 per patient per 
m 
per visit 1.10 [230] 
 
Scott et al. Zambia 2011 USD 0.52 per nurse visit per visit 1.04 [221]  
Maheswaran et al Malawi 2014 USD 1.00 per visit per visit 1.00 [139]  
Tagar et al. Malawi 2011 USD 365.00 per nurse per m per visit 0.83 [231]  
Tagar et al. Ethiopia 2011 USD 117.00 per nurse per m per visit 0.27  [231]  
Tagar et al. Zambia 2011 USD 386.00 per nurse per m per visit 0.88 [231]  
Tagar et al. Rwanda 2011 USD 806.00 per nurse per m per visit 1.83  [231]  
Jain et al. Uganda 2012 USD 240.00 per nurse per m per visit 0.55 [138] 
Support staff† Binagwaho et al. Rwanda 2009 USD 3.30 per 18 m per visit 0.55 [184] 
Bratt et al. Zambia 2008 USD 0.41 Per visit Per visit 0.41 [226] 
Lab tests‡ 
     
 
 
 
    CD4 count Toure et al. Rwanda 2009 USD 11.20 per test per test 11.20 [232] 
 Bikilla et al. Ethiopia 2005 USD 6.92 per person year per test 3.46 [233] 
 Jain et al.  Uganda 2012 USD 8.50 per test per test 8.50 [138] 
 Dutta et al. LIC 2014 USD  5.40 per person-year per test 2.70 [234] 
 Ishikawa et al. Zambia 2013 USD 5.00 per test per test 5.00 [235] 
 Scott et al. Zambia 2011 USD 10.60 per test per test 10.60 [221] 
DNA PCR Jain et al. Uganda 2012 USD 42.00 per test per test 42.00 [138] 
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Appendix B2: Candidate cost sources  
Costs Cost source Country Currency 
and year 
Estimate  Original Unit  Common  
Derived 
Unit 
Estimate 
common 
unit 
Ref 
 
Ishikawa et al. Zambia 2013 USD 10.00 per test per test 10.00  [235]  
Fasawe et al. Malawi 2010 USD 32.50 per test per test 32.50 [209]  
Khamadi et al. Kenya 2007 USD 21.50 per test per test 21.50 [223] 
Medications‡ 
     
 
 
 
HIV drugs (mothers) § 
     
 
 
 
  Zidovudine CHAI reference 
prices 
LMIC 2016 USD 6.30 60 tablets per m per m 6.30 [128] 
 
Perriens et al. LMIC 2012 USD 121.00 per patient per y per m 10.08 [236] 
Zidovir CHAI reference 
prices 
LMIC 2016 USD 6.30 60 tablets per m 6.30 [128] 
 
Perriens et al. LMIC 2012 USD 140.00 per patient per y per m 11.67 [236] 
Zidolam-N 
(AZT/3TC/NVP) 
CHAI reference 
prices 
LMIC 2016 USD 8.20 60 tablets per m per m 8.20 [128] 
 
Dutta et al. LMIC 2014 USD 96.00 per patient y per m 8.00 [234] 
 
Perriens et al. LMIC 2012 USD 118.00 per patient per y per m 9.83 [236] 
Zidolam (AZT/3TC) CHAI reference 
prices 
LMIC 2016 USD 6.60 60 tablets per m per m 6.60 [128] 
 
Scott et al. Zambia 2011 USD 8.41 per patient m per m 8.41 [221]  
Perriens et al. LMIC 2012 USD 140.00 per patient per y per m 11.67 [236] 
Efavirenz (EFV) CHAI reference 
prices 
LMIC 2016 USD 3.80 30 tablets per m per m 3.80 [128] 
 
Dutta et al. LIC 2014 USD 93.00 per patient y per m 7.75 [234]  
Scott et al. Zambia 2011 USD 4.30 per patient m per m 4.30 [221]  
Perriens et al. LMIC 2012 USD 183.00 per patient per y per m 15.25 [236] 
Cotrimoxazole 
(mothers) 
Fasawe et al. Malawi 2010 USD 0.40 per m per m 0.40 [209] 
 
Scott et al. Zambia 2011 USD 0.93 per patient m per m 0.93 [221] 
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Costs Cost source Country Currency 
and year 
Estimate  Original Unit  Common  
Derived 
Unit 
Estimate 
common 
unit 
Ref 
HIV drugs (infants) 
     
 
 
 
 Nevirapine CHAI reference 
prices 
LMIC 2016 USD 7.00 per infant m 6 w 9.80 [128] 
 
Maclean et al. Zambia 2003 USD 6.00 per m 6 w 8.40 [237]  
Kuznik et al. Uganda 2011 USD 11.20 per 6 w 6 w 11.20 [185]  
Ciaranello et al. Zimbabwe 2008 USD 4.50 per m 6 w 6.30 [238] 
Cotrimoxazole (infants) WHO LMIC 2006 USD 0.03 per d 6 w 1.26 [222]  
Binagwaho et al. Rwanda 2009 USD 12.30 per y 6 w 1.42 [184]  
Chitah Zambia 2015 USD 0.20 per dose 6 w 0.60 [239] 
Health facility 
deliveries‖ 
Kongo Emmanuel† DRC 2016 FC 15000.00 per delivery 
(normal, PHC, 
unemployed) 
per delivery 15000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 25000.00 per delivery 
(dystocia, PHC, 
unemployed) 
per delivery 25000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 300000.00 per delivery 
(cesarean, PHC, 
unemployed) 
per delivery 300000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 50000.00 per delivery 
(normal, PHC, 
employed) 
per delivery 50000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 100000.00 per delivery 
(dystocia, PHC, 
employed) 
per delivery 100000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 450000.00 per delivery 
(cesarean, PHC, 
employed) 
per delivery 450000.00 [224] 
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Costs Cost source Country Currency 
and year 
Estimate  Original Unit  Common  
Derived 
Unit 
Estimate 
common 
unit 
Ref 
 
Kongo Emmanuel DRC 2016 FC 150000.00 per delivery 
(normal, SHC, 
unemployed) 
per delivery 150000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 40000.00 per delivery 
(dystocia, SHC, 
unemployed) 
per delivery 40000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 870000.00 per delivery 
(cesarean, SHC, 
unemployed) 
per delivery 870000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 200000.00 per delivery 
(normal, SHC, 
employed) 
per delivery 200000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 100000.00 per delivery 
(dystocia, SHC, 
employed) 
per delivery 100000.00 [224] 
 
Kongo Emmanuel DRC 2016 FC 950000.00 per delivery 
(cesarean, SHC, 
employed) 
per delivery 950000.00 [224] 
 
The World Bank DRC 2005 USD 3.00 per delivery per delivery 3.00 [240]  
The World Bank DRC 2005 USD 10.00 per delivery per delivery 10.00 [240]  
The World Bank DRC 2005 USD 5.00 per delivery per delivery 5.00 [240]  
The World Bank DRC 2005 USD 15.00 per delivery per delivery 15.00 [240]  
The World Bank DRC 2005 USD 10.00 per delivery per delivery 10.00 [240]  
The World Bank DRC 2005 USD 125.00 per delivery per delivery 125.00 [240]  
Gibbons et al. DRC 2008 USD 131.40 per delivery 
(cesarean) 
per delivery 131.40 [241] 
Counseling after 
delivery 
Binagwaho et al. Rwanda 2009 USD 0.16 per session per session 0.16 [184] 
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Costs Cost source Country Currency 
and year 
Estimate  Original Unit  Common  
Derived 
Unit 
Estimate 
common 
unit 
Ref 
Transportation of DBS Khamadi et al. Kenya 2007 USD 0.50 per sample per sample 0.50 [223] 
Utilities Adebeyi & Waldron Zambia 2011 USD 3.15 per visit per visit 3.15 [137]  
Menzies et al. 5 PEPFAR 
countries¶ 
2009 USD 4.85 per y, minimum per visit 0.40 [227] 
 
Menzies et al. 5 PEPFAR 
countries¶ 
2009 USD 14.34 per y, mean per visit 1.19 [227] 
 
Jain et al. Uganda 2012 USD 0.50 per m per visit 0.50 [138]  
Galarraga et al. Benin 2009 USD 21.10 per y per visit 1.76 [242]  
Maheswaran et al Malawi 2014 USD 0.48 per visit per visit 0.48 [139] 
Opportunity cost of 
time # 
US Department of 
State 
DRC 2016 FC 1680.00 per day per day 1680.00 [141] 
Capital costs** 
     
 
 
 
Equipment (Office & 
Medical) 
Adebeyi & Waldron Zambia 2011 USD 2.01 per visit per visit 2.01 [137] 
Menzies et al. 5 PEPFAR¶ 
countries 
2009 USD 6.97 per y, minimum per visit 0.58 [227] 
Menzies et al. 5 PEPFAR 
countries¶ 
2009 USD 20.61 per y, mean per visit 1.72 [227] 
Abbreviations: DRC (Democratic Republic of the Congo); LMIC (Low-and-middle income countries); PCR (polymerase chain reaction); USD (United 
States Dollar); FC (Congolese Francs); WHO (World Health Organization); CHAI (Clinton Health Access Initiative); PEPFAR (Presidential Emergency 
Plan for AIDS Relief); PHC (primary health center); SHC (secondary health center). * We assumed that a patient was seen by one clinical staff (assumed 
to be a nurse) at each antenatal care (ANC) visit. We further assumed that a nurse takes care of 20 patients in a day and divided the monthly wage of a 
nurse by 22 because we also assumed that, as in many countries, normal work hours exclude weekends. The study by Becker-Dreps [225] provided an 
hourly cost estimate, so we assumed that each visit or interaction between the nurse and the patient lasted for 30 minutes and divided the hourly estimate 
by 2. † We assumed that one support staff was adequate at each ANC visit. ‡ Goods and services classified as tradable—goods that can be imported or 
exported[122], [124]; the rest were classified as non-tradable. § To estimate monthly costs for drugs, we divided annual costs by 12 or multiplied daily 
costs by 30. We assumed 15% for shipping and handling of the drugs [135] which we added to the estimates published by CHAI or Medicines Sans 
Frontier (MSF). We did not add the shipping and handling costs to estimates from peer-reviewed literature because these were assumed to have been 
included in the studies. ‖Estimates in local currency for health facility deliveries were not available, except for one study by Emmanuel Kongo [224] 
which did not indicate when the estimates were collected. So, we assumed that the estimates were collected in 2015—one year before the study was 
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Unit 
Estimate 
common 
unit 
Ref 
published. ¶ The 5 PEPFAR countries were Uganda, Nigeria, Botswana, Ethiopia, and Vietnam. # We assumed that both the patient and their support 
spent one day traveling and receiving (waiting plus actual interaction with a nurse) health care services at the clinic and quantified the cost of this time in 
terms of lost wages or earnings. Because there was no data on earnings, we assumed that the patient and her support each lost the equivalent of the 
statutory minimum wage (1680 Congolese Francs) for the DRC[141], [243], in 2016.   
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Appendix B3: Analytic decisions and recommendations for conducting cost-effectiveness analyses 
In this appendix, we outline a series of analytic decisions for estimating economic costs in the current study which were largely 
informed by CEA recommendations by WHO under the Cost Effectiveness and Strategic Planning[122], [124]. For completeness, we 
also present recommendations from two other organizations: The World Bank under the Disease Control Priorities Project (DCPP) 
[244], [245] and The US Panel on Cost-effectiveness in Health and Medicine[220], [246].  
Appendix B3: Recommendations for cost analysis and analytic decisions 
Analytic 
decision 
Concept Recommendations Debate/commentary Decision 
implemented 
Perspective This is the viewpoint 
for conducting a CEA. 
Examples include: 
societal, payer 
(including donor, 
employer, insurer, 
and/or government), 
healthcare, clinical 
provider, or patient. 
WHO: The study can be conducted from 
multiple perspectives, but the societal 
perspective should be primary. The 
societal perspective means that all costs 
associated with an intervention must be 
valued, regardless of who is paying for 
the intervention or service [122]. The 
rationale for this approach is that health 
and consumption of healthcare services 
contribute to social welfare [122]. 
 
World Bank/DCPP: The primary 
perspectives are the donor or partner and 
beneficiary (e.g., patient) perspective, 
although other perspectives like an 
implementer’s may also be specified 
[245]. The rationale is that the donor 
While many experts do not disagree with 
using the societal perspective as the 
primary perspective in CEA, they disagree 
on the extent of the societal perspective 
[247]. This is because including every 
aspect of the society affected by a health 
intervention may be burdensome to the 
analyst (thereby violating the “rule of 
reason”), particularly for interventions 
which extend survival or improve the 
quality of life. Additionally, while some 
experts do not agree with including future 
health-unrelated consumption or 
productivity benefits or losses, the 
position and guidance from other panels 
have been evolving on this matter. For 
example, the first US Panel (1996) on 
CEA recommended excluding 
We used  a societal 
perspective which 
was limited to the 
inclusion of 
transport costs and 
the opportunity 
cost of time for 
both the patient and 
her support. 
Productivity costs 
were not included 
because the RCT of 
the CCTs was not 
powered to 
estimate effects of 
the CCTs on 
averting new HIV 
infections or 
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Analytic 
decision 
Concept Recommendations Debate/commentary Decision 
implemented 
and the beneficiary of an intervention or 
program face different costs and an 
intervention which is cost-effective from 
the beneficiary’s perspective may not be 
cost-effective from the donor’s 
perspective [245].   
 
US Panel: CEA studies must be 
conducted from two perspectives: 
healthcare and societal perspectives 
[220]. 
productivity losses associated with an 
illness because such costs will have been 
captured in measures of quality life [246]. 
However, the second US Panel (2016) 
says that productivity gains or losses 
should be included whenever it is possible 
because there is no evidence suggesting 
that the quality of life measures reflect the 
productivity costs [220].   
quality of life 
through increased 
survival.  
Cost 
components 
This decision is about 
which cost 
components to include 
in the analysis. The 
question is: should the 
analysis include direct 
(health-related) costs 
only or direct and 
indirect (health-
unrelated) costs?  
WHO: Include both direct and indirect 
costs. The rationale is that costs like 
caregiving, travel time, and waiting time 
need to be valued as they can determine 
whether an intervention is effective or 
whether people will seek healthcare 
services. Additionally, health and 
healthcare also affect families’ 
consumption of other goods and 
services, either immediately or in the 
future[122], [124]. 
 
Many low-income countries, like the 
DRC, do not have properly functioning 
health systems or adequate healthcare 
infrastructure which pose barriers to 
accessing healthcare services[250], [251]. 
The trial of the CCTs was borne as an 
effort to help overcome barriers (e.g., 
transport costs) to accessing PMTCT 
services.  
We included both 
direct and indirect 
costs.  
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Analytic 
decision 
Concept Recommendations Debate/commentary Decision 
implemented 
World Bank/DCPP: Include direct costs 
only. The World Bank assumes that a 
properly functioning health system, 
defined as a health system that does not 
impose additional costs on consumers, is 
in place[244]. Furthermore, because 
some of the indirect costs can be higher 
than the cost of an intervention, some 
interventions may erroneously be 
deemed to be not cost-effective[244], 
[248].  
 
US Panel: Include both direct and 
indirect costs. The rationale is the same 
as with WHO[249].  
Price level This refers to whether 
resources consumed 
by the intervention 
should be valued at 
international or local 
prices. 
WHO: Two recommendations are made 
by the WHO. First, to value the cost of 
an intervention using local prices when 
detailed cost data about the intervention 
have been collected. Furthermore, to use 
local prices when the intervention is 
more local that international 
comparisons are not necessary or 
meaningful [122], [124]. Second, to 
value the costs of the intervention at 
The decision about price levels is often 
confused with the decision of currency 
choice[124], although in many cases the 
international prices are the US$ or the I$ 
(international dollar). Methods for 
deriving I$ are described below in a 
discussion of tradable and non-tradable 
and currency choice. 
 
We used 
international price 
levels (in I$) 
because the results 
of the CEA might 
also be relevant to 
other countries, 
particularly those 
in Sub-Saharan 
Africa, where 
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Analytic 
decision 
Concept Recommendations Debate/commentary Decision 
implemented 
international prices. The rationale is that 
the use of international prices can 
facilitate comparison of results from 
multiple studies across countries [122], 
[124].   
 
World Bank/DCPP: Like WHO, the 
recommendation is to value the costs of 
an intervention at international prices.  
The rationale is also to facilitate 
comparison of results from multiple 
studies across countries[244].   
 
 
mother-to-child 
transmission of 
HIV remains a 
challenge. 
Distinguishing 
between 
tradable vs. 
nontraded 
goods. 
Tradable goods—for 
example, 
medications—are 
those goods that can 
be imported or 
exported while non-
tradable goods (for 
example, labor) are 
those that are produced 
locally and cannot be 
imported or exported 
[122], [124]. 
WHO: Tradable goods should be 
distinguished from non-tradable goods. 
The rationale is that these goods must be 
costed differently to reflect the correct 
value of the good, otherwise non-
tradable goods will be undervalued if 
they are treated like tradable goods in 
countries with higher purchasing power 
[122], [124]. 
 
World Bank/DCPP: Distinguish 
between tradable and non-tradable 
The difference between the WHO and 
World Bank/DCPP recommendations is in 
the valuation of non-tradable goods. 
According to the World Bank, if the cost 
of a non-tradable good is in local 
currency, then it must be converted to 
US$ using the nominal (official) exchange 
rate of that country’s local currency to the 
US$. s that if the cost estimate of a non-
tradable good (e.g., buildings) is being 
extrapolated from another setting with the 
estimate already in US$, then no further 
conversion is required. On the other hand, 
We distinguished 
between tradable 
and non-tradable 
goods. 
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Analytic 
decision 
Concept Recommendations Debate/commentary Decision 
implemented 
 
 
goods. The rationale is that tradable 
(imported) goods are already in US$ 
while the cost of non-tradable goods 
must be converted to US$ using 
exchange rates[244]. 
 
US Panel: Not discussed 
the WHO recommendation is that all non-
tradable goods should be converted using 
purchasing power parity (PPP)—the 
number of units of a local currency 
required to buy the same quantities of 
goods and services as one US$ would do 
in the United States[122]. The unit cost of 
goods and services valued this way is the 
international dollar (I$) and 1I$=1US$. 
WHO also recommends that non-tradable 
goods quoted in US$ should be converted 
using the ratio of the PPP conversion 
factor to the official exchange rate of that 
country to the USD in the year of the cost 
estimate. Thus, using the PPP exchange 
rates eliminates price differences when 
converting or transferring costs across 
countries[123], [124]. The World Bank 
argues against using the PPP because the 
I$ is hypothetical and is not informative of 
how much an intervention costs which is 
important for budgeting purposes[244]. 
Currency 
choice 
This refers to the 
choice of currency for 
reporting costs. This is 
particularly important 
WHO: 1) When the analyst has decided 
to use international price levels and to 
distinguish between tradable and non-
tradable goods, the recommendation is 
While both the US$ and I$ may facilitate 
international comparisons of results from 
different studies, the World Bank notes 
that the I$ is hypothetical and is not 
We used I$ 
because, as argued 
by the WHO, the 
US$ only tells you 
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Analytic 
decision 
Concept Recommendations Debate/commentary Decision 
implemented 
as this study draws 
estimates from 
multiple sources with 
the cost estimates in 
different currencies. 
Furthermore, the 
choice of currency is 
informed by two 
analytic decisions 
presented above: price 
levels and 
distinguishing between 
tradable and non-
tradable goods. 
to use I$ which is derived when the PPP 
exchange rate is used (see discussion on 
tradable vs. non-tradable goods). The 
rationale is that using the PPP exchange 
rates eliminates price differences when 
converting or transferring costs across 
countries [122], [124]. 
  
World Bank/DCPP: To use the US$. 
The rationale is that the US$ is 
informative of how much an 
intervention actually costs[244].   
informative of how much an intervention 
costs and is not relevant to decision 
makers interested in budgeting or 
expanding interventions[244]. But the 
argument by WHO is that, in many cases, 
the I$ accurately reflects what people can 
purchase given a certain amount of 
resources and the US$ fails to convey this 
information.   
 
 
 
the cost of an 
intervention but it 
does not tell you its 
value. 
Year for 
reporting costs. 
This refers to the year 
for reporting results of 
the CEA 
This varies from study to study and 
depends on the analyst’s assessment of 
what the aims of the CEA are, so there 
are no clear guidelines on which year to 
use. 
For the current study, there are three 
options: 1) 2013: Start date of the RCT of 
the CCTs in the DRC; 2) 2015: End date 
of the RCT in the DRC; and 3) 2016: Year 
for which the most current data for 
inflation adjustment and currency 
conversion are available. 
 
 
We used 2016 as 
the base year 
because it is the 
year for which the 
most recent 
conversion data 
were available.  
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Analytic 
decision 
Concept Recommendations Debate/commentary Decision 
implemented 
Inflation 
adjustment  
Adjusting for inflation 
removes the effect of 
price changes and is 
necessary when the 
original cost data are 
reported in different 
years. Inflation 
adjustment will allow 
us to obtain estimates 
in a constant currency. 
Thus, the data from 
years prior to the 
chosen year will be 
inflated while data 
from later years will 
be deflated.  
WHO: Inflation adjustment to be done 
using the GDP (gross domestic product) 
deflator—an index number comparing 
real GDP to nominal GDP. The GDP 
deflator is recommended because it 
covers price changes in a broad range 
(almost everything) of economic 
activity, including health sector costs 
[122], [124], [252]. 
 
World Bank/DCPP: Not discussed 
 
US Panel: Inflation adjustment to be 
done using the medical price 
index[249]. The rationale is that, unlike 
the general consumer price index (CPI), 
the medical price index more accurately 
reflects changes in prices in the 
healthcare sector as it is specific to that 
sector.  
The main problem with the GDP deflator 
is that in many low-income countries, like 
the DRC, it fails to account for 
heterogeneity among sectors and can lead 
to wrong conclusions[253]. Although the 
medical CPI is recommended, it is not 
available for the DRC.  
We adjusted for 
inflation using the 
GDP deflator as it 
is the only 
recommended 
inflation-
adjustment method 
which is readily 
available. 
Order for 
inflation 
adjustment and 
When transferring 
costs across time and 
space, the order in 
which inflation 
WHO: Adjust for inflation before 
applying exchange rates. The rationale 
is that inflation in countries like the 
DRC also depends on exchange rates, 
The issue of whether inflation adjustment 
is done before currency conversion is 
almost a settled issue. 
We first adjusted 
for inflation before 
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Analytic 
decision 
Concept Recommendations Debate/commentary Decision 
implemented 
exchange rate 
application 
adjustment and 
exchange rates are 
applied can affect the 
eventual cost estimates 
and whether an 
intervention is cost-
effective. 
and because of weaker currencies, the 
inflation rate is much higher than in 
developed countries. This means that 
adjusting for inflation after currency 
conversion will more likely overvalue 
non-tradable goods[123].   
 
Julia Fox-Rushby, who has published 
some of the CEA guidelines by the 
World Bank, also recommend adjusting 
for inflation before applying exchange 
rates[254].  
 applying exchange 
rate conversion. 
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Appendix B4: Fieller’s theorem for estimating confidence intervals for incremental cost-
effectiveness ratios.  
Note: This appendix draws heavily from Glick, 2014. 
Fieller’s method is a parametric method for estimating confidence intervals for ratios like the 
incremental cost-effectiveness ratio (ICER). Compared to other parametric methods such as the 
normal distribution interval, Fieller’s method has one advantage: the method takes into account 
the skewness of the ratio as it does not require the distribution of the ICER to be normal or 
symmetrical [131], [159], [162]. Briefly, the parametric Fieller’s method proceeds as follows: let 
the bivariate normal distribution of the difference in mean costs and effects be represented by the 
expression RQ-C with a mean of zero [131]. In this expression, R=C/Q and Q is the difference in 
the mean effect and C is the difference in the mean cost [131]. Glick (2015) notes that when this 
expression is standardized using its standard error and setting it equal to a critical t-value, the result 
is a quadratic equation in R. If we take the square root of the quadratic equation in R, which also 
includes the Pearson correlation coefficient (ρ) between C and Q, we obtain the lower and upper 
confidence limits of the ICER [131]. The confidence intervals are as follows: 
𝐿𝑜𝑤𝑒𝑟 𝐿𝑖𝑚𝑖𝑡
=
[CQ − (𝑡𝛼
2
)2ρ𝑠𝑒𝑐 𝑠𝑒𝑞] − {[CQ −  (𝑡𝛼
2
)2ρ𝑠𝑒𝑐 𝑠𝑒𝑞] − [𝑄
2 −  (𝑡𝛼
2
)2𝑠𝑒2𝑞)(𝐶
2 −  (𝑡𝛼
2
)2𝑠𝑒2𝑐]}
0.5  
𝑄2 −  (𝑡𝛼
2
)2𝑠𝑒2𝑞
 
 
𝑈𝑝𝑝𝑒𝑟 𝐿𝑖𝑚𝑖𝑡
=
[CQ − (𝑡𝛼
2
)2ρ𝑠𝑒𝑐 𝑠𝑒𝑞] +  {[CQ − (𝑡𝛼
2
)2ρ𝑠𝑒𝑐 𝑠𝑒𝑞] − [𝑄
2 −  (𝑡𝛼
2
)2𝑠𝑒2𝑞)(𝐶
2 −  (𝑡𝛼
2
)2𝑠𝑒2𝑐]}
0.5  
𝑄2 −  (𝑡𝛼
2
)2𝑠𝑒2𝑞
 
In these equations: 
C and Q are the differences in mean costs and mean effects in the two groups. 
𝑡𝛼
2
 is the critical value from a student’s t-distribution; 𝑡𝛼
2
 = 1.96 for 95% C.I. 
 129 
ρ is the Pearson correlation coefficient between C and Q.  
𝑠𝑒𝑐 and 𝑠𝑒𝑞 are the standard errors for C and Q, respectively. 
Interpretation of the confidence limits: 
• A statistically significant difference in effects between the two groups exists only when the 
denominator is positive and the interval is lower to upper limit [131]. 
• Negative denominators mean there is no statistically significant difference between the two 
groups. In that case, the upper limit is smaller than the lower limit [131]. 
• If there is no statistically significant difference in both effects and costs part of the numerator 
for which we are taking the square root (the term in brackets) will likely be negative, making 
the lower and upper limits undefined as negative numbers do not have square roots [131]. 
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Stata do file 
 
/*capture log close 
set more off 
log using cea.log, text replace 
insheet using cea_new.csv, comma clear 
 
*listing all the variables  
ds 
 
format %12s observations 
 
*generating treatment 
gen treatment=. 
replace treatment=0 if group=="Soins habituels" 
replace treatment=1 if group=="Intervention - Cash" 
label define treatment 0 "Control" 1 "Treatment", replace 
label values treatment treatment 
tab treatment 
tab treatment group 
 
*working with the variables  
codebook marital_status 
encode marital_status, gen(marstatus) 
 
 
*transport cost has some values missing 
order transportcost transportcostart  
tab transportcost transportcostart , m 
 
replace transportcost=transportcostart if transportcost==. 
 
*multiple imputation of missing transport costs 
misstable patterns transportcost, bypatterns 
 
mi set mlong  
mi register imputed transportcost /*registers transportcost as the variable 
to be imputed*/ 
 
mi misstable summarize treatment ses transportcost 
 
mi impute pmm transportcost treatment uptakepmtct incaresixweek i.ses 
yearofeducation /// 
earlyancvisit traveltime i.transportmode i.marstatus age gestationalage, 
add(20) knn(5) rseed(2232) 
 
mi estimate: regress transportcost treatment uptakepmtct incaresixweek i.ses 
/// 
yearofeducation earlyancvisit traveltime i.transportmode i.marstatus age 
gestationalage 
 
*checking how the imputation worked 
mi estimate, vartable dftable /*as expected only travel time and SES 
siginificantly predicted transport cost*/ 
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*keeping a single dataset of imputed transport cost data 
keep if _mi_m > 0 
collapse (mean) transportcost , by( pidc) 
 
save cea_imputed, replace 
export excel using "cea_imputed", firstrow(variables) replace 
 
log close*/ 
 
***ANALYSIS BEGIN HERE 
capture log close 
set more off 
log using cea_analysis, replace 
 
insheet using cea_DRC_PPP_final.txt, tab clear 
 
*formatting column widths 
format %12s obs 
 
*listing all the variables  
ds 
 
*ordering variables 
order pidc group amountpaid ltfubydelivey incaresixweek ltfuat6wk uptakepmtct 
/// 
cost_pp cost_sp datepremierevisit visitnumber artstartdate aztstartdate 
cotrim_final /// 
deliverydate gestationalage 
 
*generating treatment 
gen treatment=. 
replace treatment=0 if group=="Control" 
replace treatment=1 if group=="Intervention" 
label define treatment 0 "Control (No CCTs)" 1 "Intervention (CCTs)" 2 
"Control (No CCTs)", replace 
label values treatment treatment 
tab treatment 
tab treatment group 
drop if treatment==. 
 
*correcting the variable incare at 6 wks postpartum. It seems 1s should be 0s 
ans 0s 1s 
tab treatment incaresixweek 
recode incaresixweek 0=2 
recode incaresixweek 1=0 
recode incaresixweek 2=1 
label define incaresixweek 0 "Not in care" 1 "In care", replace 
label values incaresixweek incaresixweek   
tab treatment incaresixweek 
 
*Uptake of PMTCT services 
tab treatment uptakepmtct 
label define uptakepmtct 0 "No uptake" 1 "Uptake", replace 
label values uptakepmtct uptakepmtct 
tab  uptakepmtct treatment 
 
*Early ANC visit 
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tab earlyancvisit treatment 
label define earlyancvisit 0 "Late ANC" 1 "Early ANC", replace 
label values earlyancvisit earlyancvisit 
tab earlyancvisit treatment 
 
*marital status and cohabitation  
codebook marital_status 
encode marital_status, gen(marstatus) 
codebook marstatus 
tab marstatus treatment 
replace marstatus=0 if marstatus!=1 
replace marstatus=1 if cohabitation=="yes" /*assumes that cohabiting is 
marriage*/ 
label define marstatus 1 "Married" 0 "Not married", replace 
label values marstatus marstatus 
tab marstatus treatment 
 
*first pregnancy 
tab primiparus 
rename primiparus firstpregnancy 
label define firstpregnancy 0 "Not first pregnancy" 1 "First pregnancy", 
replace  
label values firstpregnancy firstpregnancy 
 
*HIV disclosure 
codebook disclosure 
encode disclosure, gen(disclosure1) 
drop disclosure 
rename disclosure1 disclosure  
recode disclosure 1=0 2=1 
label define disclosure 0 "No" 1 "Yes", replace 
label values disclosure disclosure 
tab disclosure 
 
*Transport mode 
tab transportmode treatment 
recode transportmode 2=0 3=0  
label define transportmode 0 "Other means" 1 "Walk", replace 
label values transportmode transportmode 
tab transportmode treatment 
 
*education 
tab educlevel 
rename educlevel education 
label define education 0 "No education" 1 "Primary" 2 "Secondary or higher", 
replace 
label values education education 
tab education treatment 
 
*SES 
rename ses wealth 
codebook wealth 
label define wealth 4 "Fifth (richest)" 3 "Fourth" 2 "Third" 1 "Second" 0 
"First (poorest)", replace 
label values wealth wealth  
tab wealth treatment 
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*labelling variables 
label var pidc "Pateint ID" 
label var treatment "Intervention" 
label var amountpaid "Incentive paid" 
label var age "Age" 
label var incaresixweek "PMTCT Retention" 
label var cost_pp "Cost (Payer perspective)" 
label var cost_sp "Cost (Society perspective)" 
label var datepremierevisit "Enrollment date" 
label var disclosure "HIV disclosure" 
label var gestationalage "Gestational age" 
label var uptakepmtct "PMTCT Uptake" 
label var traveltime "Travel time" 
label var earlyancvisit "Early ANC visit" 
label var yearofeducation "Education (years)" 
label var wealth "Wealth quintile" 
label var incentive "Incentive paid" 
label var transportmode "Travel mode" 
      
 
*SUMMARIZING DATA 
*TABLE OF DEMOGRAPHIC CHARACTERISTICS 
 
*checking the distribution of costs 
sum cost_pp 
 
recode treatment 0=2 
 
hist cost_sp, by(treatment, note("")) freq subtitle(, size(medium)) /// 
 by(, title("Figure 1: Cost distribution in the intervention and Control 
groups, societal perspective", size(medium large) col(black))) /// 
 xtitle(Cost (2016 I$)) /// 
 legend(rows(1)) /// 
 graphregion(fcolor(white)) /// 
 ylab(, nogrid) 
 *graphregion(color(white)) 
 graph save "cost_distribution_sp", replace 
 
hist cost_pp, by(treatment, note("")) freq subtitle(, size(medium)) /// 
 by(, title("Figure 1: Cost distribution in the intervention and Control 
groups, payer perspective", size(medium large) col(black))) /// 
 xtitle(Cost (2016 I$)) /// 
 legend(rows(1)) /// 
 graphregion(fcolor(white)) /// 
 ylab(, nogrid) graphregion(color(white)) 
 graph save "cost_distribution_pp", replace 
  
*graph combine cost_distribution_sp.gph cost_distribution_pp.gph   
 
recode treatment 2=0 
 
count if cost_sp<200 & treatment==1 
count if cost_sp>=450 & treatment==1 
count if cost_sp>600 & treatment==1 
 
count if cost_sp<200 & treatment==0 
count if cost_sp>=450 & treatment==0 
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count if cost_sp>600 & treatment==0 
 
gen g_than_450=0 
replace g_than_450=1 if cost_sp>=450 
tab treatment g_than_450, row 
 
*dpplot costparticipant, dist(gamma) param(`e(alpha)' `e(beta)') 
 
*sample characteristics 
tabstat cost_pp cost_sp, by(treatment) stats(mean sd median p25 p75) 
tabstat cost_pp cost_sp age gestationalage yearofeducation traveltime, 
by(treatment) stats(mean sd median p25 p75) 
ttest cost_pp, by(treatment) 
ttest cost_sp, by(treatment) 
ranksum cost_pp, by(treatment) 
ranksum cost_sp, by(treatment) 
 
*summary of number of visits 
sum visitnumber, d 
tab treatment, sum(visitnumber) 
hist visitnumber, by(group) 
ttest visitnumber , by(treatment) level(90) 
tabstat visitnumber, by (treatment) stats(mean median sum) 
 
*cost per visit 
bysort treatment: egen cost_per_visit=mean(cost_sp/visitnumber)  
 
*TABLE SUMMARIZING COSTS 
*checking the distribution of continuous variables 
mvtest normal cost_pp cost_sp age traveltime yearofeducation incentive 
gestationalage , bivariate univariate stats(all) 
 
*performing the Mann-Whitney test 
 
foreach var of varlist incentive cost* { 
ranksum `var', by(treatment) 
} 
 
foreach var of varlist yearofeducation age traveltime gestationalage { 
ranksum `var', by(treatment) 
} 
 
 
 
foreach var of varlist  uptakepmtct incaresixweek education wealth marstatus 
earlyancvisit firstpregnancy disclosure transportmode { 
tab  `var' treatment, col chi2 
} 
*effectiveness 
 
*unadjusted risk ratios 
cs incare treatment, exact 
cs uptake treatment, exact 
 
order pid cost_* incare uptake treatment treatment incentive traveltime 
education marstatus firstpregnancy earlyancvisit  disclosure wealth 
transportmode 
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*exporting the dataset to SAS for comparing analyses in Stata and those 
performed in SAS 
save cea_analysed_forsas, replace 
saveold cea_analysed_forsasv12, version(12) replace  
fdasave cea_analysed_forsas, rename replace 
outsheet using cea_analysedforsas.txt, comma replace  
 
*putting controls in a global macro 
global controls "treatment earlyancvisit disclosure age i.marstatus 
i.education i.wealth firstpregnancy transportmode" 
 
 
*exploratory OLS multivariate model 
mvreg cost_sp cost_pp = $controls 
 
**GEE MODELS 
xtset clinic 
 
*EFFECTIVENESS  
xtgee incaresixweek $controls, family(poisson) link(log) corr(exch) robust 
eform 
*xtgee incaresixweek $controls, family(bin) link(log) corr(exch) 
 
estimates store incare 
estimates replay, eform 
 
/*xtgee uptake $controls, family(poisson) link(log) corr(exch) vce(robust) 
eform 
estimates store uptake*/ 
 
xtgee uptake $controls, family(poisson) link(log) corr(exch) robust 
estimates store uptake 
estimates replay, eform 
 
 
**Getting the number needed to treat (this will be used in the CEA) 
*incare 
global controls "treatment age i.marstatus yearofeducation" 
binreg incaresixweek $controls, rd vce(robust) 
gen rd_incare=_b[treatment] 
gen sd_rd_incare=0.0404129 
gen NNT_incare=1/_b[treatment] 
list NNT_incare in 1/1  
*predicting risk of being in care 
predict risk_incare, xb 
tab treatment, sum(risk_incare) 
 
*uptake 
binreg uptake $controls, rd vce(robust) 
gen rd_uptake=_b[treatment]  
gen sd_rd_uptake=0.0462205 
gen NNT_uptake=1/_b[treatment] 
list NNT_uptake in 1/1 
*predicting risk of taking up PMTCT services 
predict risk_uptake, xb 
tab treatment, sum(risk_uptake) 
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**COSTS 
*identifying the family using the modified park test 
global controls "treatment age i.marstatus i.education i.wealth 
transportmode" 
glm cost_pp $controls, family(gamma) link(identity) vce(robust) 
predict resid, dev 
predict yhat, xb 
gen resid_sq=resid^2 
glm resid_sq yhat, family(gamma) link(identity) vce(robust) 
test yhat=0 
test yhat=2 /*shows that the gamma should be used. See this link for this 
test: 
http://www.uphs.upenn.edu/dgimhsr/documents/ispor15.glmworkshop.glick.2.pdf*/ 
drop resid* yhat 
 
**Payer perspective 
xtgee cost_pp $controls, family(gamma) link(identity) corr(exch) vce(robust) 
estimates store cost_pp 
*incremental cost 
gen Inc_cost_pp=_b[treatment] 
gen sd_cost_pp=11.52162 /*standard errors*/ 
gen sample_size=217 /*sample size*/ 
 
*predicted costs 
predict pred_cost_pp, xb  
 
**Society perspective 
xtgee cost_sp $controls, family(gamma) link(identity) corr(exch) vce(robust) 
estimates store cost_sp 
*incremental cost 
gen Inc_cost_sp=_b[treatment] 
gen sd_cost_sp=13.29177 /*standard errors*/ 
*predicted costs 
predict pred_cost_sp, xb  
 
/*table of costs*/ 
esttab cost_pp cost_sp using costs.csv , plain nogaps b(a2) ci(a4)  wide 
replace  label obslast star /// 
 refcat (treatment "Ref: Control group" 1.wealth "Ref: First 
quintile(poorest)" /// 
 1.education "Ref: No education" 1.marstatus "Ref: Not married" 
transportmode "Ref: Other means") /// 
 collabels("2016 I$" "2016 I$") /// 
 drop (0.wealth 0.marstatus 0.education) brackets /// 
 addnote("95% Confidence intervals in brackets; * p<0.05, ** p<0.01, *** 
p<0.001") /// 
 title( "Table 5: Adjusted costs and effectiveness of conditional cash 
transfers") 
 
*table of effectiveness 
esttab uptake incare using effectiveness.csv, plain eform nogaps b(a3) ci  
replace  label wide obslast star /// 
 refcat (treatment "Ref: Control group" 1.wealth "Ref: First 
quintile(poorest)" /// 
 1.education "Ref: No education" 1.marstatus "Ref: Not married" 
transportmode "Ref: Other means") /// 
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 collabels("Relative risk" "Relative risk") /// 
 drop (0.wealth 0.marstatus 0.education) brackets /// 
 addnote("95% Confidence intervals in brackets; * p<0.05, ** p<0.01, *** 
p<0.001") /// 
 title( "Table 5: Adjusted effectiveness of conditional cash transfers") 
 
**generating incremental cost effectiveness ratios 
*incare 
*payer perspective 
gen ICER_pp_incare=Inc_cost_pp*NNT_incare 
 
*society perspective 
gen ICER_sp_inccare=Inc_cost_sp*NNT_incare 
 
*uptake 
*payer perspective 
gen ICER_pp_uptake=Inc_cost_pp*NNT_uptake 
 
*society perspective 
gen ICER_sp_uptake=Inc_cost_sp*NNT_uptake 
 
list NNT_incare NNT_uptake ICER_pp_incare ICER_sp_inccare ICER_pp_uptake 
ICER_sp_uptake in 1/1 
 
**caculating confidence intervals using the Fieller's theorem 
*payer perspective 
list Inc_cost_pp sd_cost_pp sample_size rd_uptake sd_rd_uptake sample_size in 
1/1 
list Inc_cost_pp sd_cost_pp sample_size rd_incare sd_rd_incare sample_size in 
1/1 
 
*society perspective 
list Inc_cost_sp sd_cost_sp sample_size rd_uptake sd_rd_uptake sample_size in 
1/1 
list Inc_cost_sp sd_cost_sp sample_size rd_incare sd_rd_incare sample_size in 
1/1 
 
***BOOTSTRAPPING 95% FOR THE ICER 
*recall that the following are the steps involved 
 
*1. Generate a sample of nt cost and effect pairs from the experimental group 
data with replacement. The cost and effect pairs need to be resampled 
together as they are inter-dependent. 
*2. Generate a sample of nc cost and effect pairs from the control group data 
with replacement 
*3. Calculate the ICER for this bootstrap resample. 
*4. Repeat this procedure 1000 times, to get 1000 bootstrap estimates of the 
ICER. These estimates then define the empirical sampling distribution of the 
ICER. 
 
*1&2. Bootsrapping to create treatment and control groups of sizes similar to 
the trial 
bootstrap pred_cost_pp pred_cost_sp  risk_incare risk_uptake  if 
treatment==0, reps(217) cluster(clinic) saving(control, replace) seed(1980): 
summarize 
bootstrap pred_cost_pp pred_cost_sp risk_incare risk_uptake if treatment==1, 
reps(216) cluster(clinic) saving(treat, replace) seed(1980): summarize 
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save cea_analysed, replace 
 
*combining the resampled datasets of treatment and control groups 
use control, clear 
gen treatment=0 
save control, replace 
 
use treat, clear 
append using control 
replace treatment=1 if treatment==. 
rename _bs_1 cost_pp 
rename _bs_2 cost_sp 
rename _bs_3 risk_incare 
rename _bs_4 risk_uptake 
 
*3. Calculating the ICER and 95% C.I. from the bootstrap resample 
program icer, rclass 
          version 14.2 
    ****costs 
    ***payer perspective 
    summarize cost_pp if treatment==0, meanonly 
          local a = r(mean) 
          summarize cost_pp if treatment==1, meanonly 
          local b = r(mean) 
    return scalar Inccost_pp=`b'-`a' 
    **incare 
    summarize risk_incare if treatment==0, meanonly 
    local c=r(mean) 
    summarize risk_incare if treatment==1, meanonly 
    local d=r(mean) 
    *NNT 
    return scalar diff_incare= `d'-`c' 
    return scalar NNT_incare=1/(`d'-`c') 
    *ICER 
    return scalar ICER_incarePP =(`b'-`a')/(`d'-`c') 
    **uptake 
    summarize risk_uptake if treatment==0, meanonly 
    local e=r(mean) 
    summarize risk_uptake if treatment==1, meanonly 
    local f=r(mean) 
    *NNT 
    return scalar diff_uptake=`f'-`e' 
    return scalar NNT_uptake=1/(`f'-`e') 
    *ICER 
    return scalar ICER_uptakePP =(`b'-`a')/(`f'-`e') 
    *society perspective 
    summarize cost_sp if treatment==0, meanonly 
    local g=r(mean) 
    summarize cost_sp if treatment==1, meanonly 
    local h=r(mean) 
    return scalar Inccost_sp=`h'-`g' 
    *in care 
    return scalar ICER_incareSP=(`h'-`g')/(`d'-`c') 
    *uptake 
    return scalar ICER_uptakeSP =(`h'-`g')/(`f'-`e') 
end 
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*4. Bootstrapping the ICERs. 
bootstrap r(Inccost_pp) r(Inccost_sp) r(diff_uptake) r(NNT_uptake) 
r(diff_incare) r(NNT_incare) r(ICER_incarePP) r(ICER_uptakePP) 
r(ICER_incareSP) r(ICER_uptakeSP), saving(trial, replace) bca reps(1000) 
seed(1980) strata(treatment) nodots: icer summarize 
program drop icer 
save CEA_with_CI, replace    
 
**GENERATING CEA ACCEPTABILITY CURVES 
*bootstraping differences in mean costs and mean effects. Note that above 
what was bootstrapped was the ICER itself. 
capture program drop bscer 
program define bscer 
 
  sum `1' if `5'==1,meanonly 
  scalar meancostpp=r(mean) 
  sum `1' if `5'==0,meanonly 
  scalar diffcostPP=meancostpp-r(mean) 
   
   
  sum `2' if `5'==1,meanonly 
  scalar meancostsp=r(mean) 
  sum `2' if `5'==0,meanonly 
  scalar diffcostSP=meancostsp-r(mean) 
 
  sum `3' if `5'==1,meanonly 
  scalar meanriskincare=r(mean) 
  sum `3' if `5'==0,meanonly 
  scalar diffriskincare=meanriskincare-r(mean) 
 
  sum `4' if `5'==1,meanonly 
  scalar meanriskuptake=r(mean) 
  sum `4' if `5'==0,meanonly 
  scalar diffriskuptake=meanriskuptake-r(mean) 
   
  scalar ICER_incarePP= diffcostPP/diffriskincare 
  scalar ICER_uptakePP=diffcostPP/diffriskuptake 
  scalar ICER_incareSP= diffcostSP/diffriskincare 
  scalar ICER_uptakeSP=diffcostSP/diffriskuptake 
 
end 
 
scalar exper=0 
 
clear 
use CEA_analysed 
bootstrap "bscer pred_cost_pp pred_cost_sp risk_incare risk_uptake treatment 
clinic " "diffcostPP diffcostSP diffriskincare diffriskuptake ICER_incarePP 
ICER_incareSP ICER_uptakePP ICER_uptakeSP", reps(4000) saving(Cost&Effects) 
replace strata(treatment) cluster(clinic) 
 
clear 
quietly do bsceaprogs 
use Cost&Effects 
sum 
corr 
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quietly do bsceagraphs 
*uptake 
bscicer _bs_2 _bs_4 .95 
bscicergraph 
bsaccept  _bs_2 _bs_4 .95 
bsaccgraph  
*incare 
bscicer _bs_2 _bs_3 .95 
bscicergraph 
bsaccept  _bs_2 _bs_3 .95 
bsaccgraph  
 
*CEA curve 
clear 
import excel "Willingess-to-pay_final.xlsx", sheet("Sheet1") firstrow 
case(lower) clear 
keep wtpacceptp retention uptake 
scatter retention uptake wtpacceptp,  connect(dot dot) msize(tiny tiny) /// 
    xtitle("Willingness-to-pay (WTP)", size(3.0)) /// 
 ytitle("% acceptable", size(3.0) height(7)) /// 
 graphregion(color(white)) /// 
 xline(402 803 1205) /// 
 yline(0.1 0.5 0.8) /// 
 legend(order(2 "Uptake" 1 "Retention")) /// 
 title("Figure 2: Willingness-to-pay for uptake of PMTCT services and 
retention in PMTCT care", size(3.5) col(black)) 
graph save WTP_final, replace 
 
log close 
log2html cea_analysis, replace  
**sensitivity analysis 
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Chapter 3: Guideline concordance of time to follow-up of anal cancer screening in women 
living with HIV at high-risk for acquiring anal cancer  
Abstract 
  Background: In the past 2-3 decades, the incidence of anal cancer has increased significantly 
among women with HIV. This calls for a better understanding of receipt of anal screening in this 
population, particularly among those at increased risk of acquiring anal cancer. While some 
evidence suggests that these women receive initial anal cancer screening, it is unclear whether 
they also receive follow-up screening consistent with the guidelines for anal cancer screening in 
this population. This study examines the guideline concordance of the time to follow-up for anal 
cancer screening in women with HIV with histories of abnormal cervical tests or genital warts.    
  Methods: Data for this analysis came from administrative claims of Medicaid beneficiaries 
ages 19–64 years who qualified for Medicaid based on income and disability and who were 
continuously enrolled for ≥ 24 months. We created a 4-year retrospective cohort (2009-2012) of 
high-risk women using ICD-9 codes for abnormal cervical tests or genital warts. We estimated 
the follow-up time as the time from the date of the first anal cancer screen (after a high-risk 
diagnosis) to the date of the second screen. Follow-up time was guideline-concordant if the 
follow-up screening was performed in ≤ 6 months for those with abnormal results on the first 
screen and ≤ 12 months for those with normal results on the first screen. We used the Kaplan-
Meier to estimate the follow-up time and modeled the guideline concordance of the follow-up 
time using logistic regressions. In sensitivity analysis, we restricted the sample to those 
continuously enrolled for 4 years, expanded the number of ICD-9 codes used to define a sample 
of high-risk women with HIV, and examined follow-up time of anal cancer screening at 
thresholds higher than those stipulated in the guidelines. 
  Results: A total of 3,779 high-risk women were eligible for follow-up screening and 
contributed 4,458 person-years. The median time to follow-up screening was 16.1 months (95% 
C.I.=15.2,17.6) and was shortest among women with histories of both risk factors (median=9.3, 
95% C.I.=7.6,11.0 months). The time to follow-up screening was guideline-concordant for 
47.3% (95% C.I.=42.0,53%) of high-risk women with abnormal results on the first screen and 
for 40.0% (95% C.I.=38.0,41.4%) for those with normal results. The time to follow-up screening 
was not guideline concordant for women with one risk factor. The odds that time to follow-up 
screening was guideline concordant were more than twice among women with two risk factors 
compared with those with a single risk factor for anal cancer (OR=2.06, 95% C.I.=1.73,2.46). 
These findings persisted in sensitivity analyses. 
  Conclusions: Time to follow-up anal cancer screening is not guideline-concordant overall and 
for nearly two-thirds of women with a single risk factor. Training providers in high-resolution 
anoscopy, gathering more evidence about the benefits of anal cancer screening to clarify the 
guidelines for anal cancer screening, and creating a billable procedural code for anal cancer 
screening could help to increase the rates of follow-up anal cancer screening in high-risk women.  
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1. Introduction 
Among all non-AIDS-defining cancers4, anal cancer has recorded the largest increase in 
incidence over the past 2-3 decades [256]. These increases have been observed in all groups of 
people living with HIV (PLWH), including women [257]–[259]. In that period, the incidence of 
anal cancer among women with HIV increased by 40% and is still increasing [257]–[260]. The 
high and rising incidence of anal cancer in women with HIV suggests that screening for anal 
cancer is critical in this population. This is particularly true in this era of combination 
antiretroviral therapy when PLWH have life expectancies similar to the general population but 
who are at a higher risk for many diseases, including anal cancer [261]–[263]. For example, data 
show that the incidence of anal cancer is 30 per 100,000 person-years in women with HIV, 
which is 15 times greater than in women without HIV [264].    
Anal cancer screening leads to early detection of abnormal anal cells otherwise known as anal 
intraepithelial neoplasia (AIN5), making effective secondary prevention possible [267], [268]. 
The evidence suggests that rates of abnormal anal test results range from 12 to 42% [269]–[275] 
and that AIN can develop quickly in women with HIV [273] even if the women have normal 
anal cells at baseline [270]. Further evidence suggests that untreated low-grade AIN can progress 
to high-grade AIN within 2 years in many PLWH [267] and that untreated high-grade AIN can 
progress to anal cancer in less than one year [268]. However, among those screened and treated 
for AIN, the rates of progression are much lower [267], [268]. Additional evidence also suggests 
                                                 
4 A cancer is AIDS-defining if its onset marks progression from HIV to AIDS [255] 
5 AIN is used to describe biopsy-confirmed results of anal cancer screening. Less severe lesions are classified as 
AIN1 while more severe ones are classified as AIN2 or AIN3 [265], [266]. On the hand, cytology results are 
reported as squamous intraepithelial lesions (SIL) and are classified as low-grade or high-grade SIL [265], [266]. 
These classifications are based off the terminology used in cervical cancer screening [265], [266]. 
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that early detection of cancerous anal cells has survival benefits. The 5-year survival rates for 
localized, regional, and metastatic anal cancers are 0.78, 0.56, and 0.18, respectively [276].   
While guidelines exist for anal cancer screening [277], little is known about the timing of 
screening for this cancer in women with HIV. This is particularly true for time to follow-up of 
anal cancer screening among women living with HIV at increased risk of acquiring anal cancer. 
Regular anal cancer screening is recommended for these at-risk women including those with 
histories of abnormal cervical tests or genital warts [277]–[279], two groups whom we 
collectively define as high-risk. Previous studies of anal cancer screening frequency in PLWH 
mainly focused on men who have sex with other men (MSM) [280]–[286], with women rarely 
included in those studies. While the few studies that included women provide some evidence of 
initial anal cancer screening in high-risk women with HIV [269]–[275], it is unclear whether 
high-risk women also receive follow-up screening and whether the timing of the follow-up 
screening is concordant with the guidelines. Studies that examined follow-up anal cancer 
screening in women with HIV had small sample sizes, were limited in geographic scope [270], 
[273], [275], [282], [283], or did not stratify findings by anal cancer risk factors [287], [288]. 
Guidelines for anal cancer screening by the HIV Medical Association recommend screening at 
baseline in all PLWH but thereafter, the screening depends on the outcome of the initial test and 
the risk of the individual [277]. When abnormal anal cells are detected at the initial test, follow-
up screening is recommended in 6 months. When the initial test is normal, a follow-up test is 
recommended in 12 months but only in PLWH at high-risk for acquiring anal cancer, figure 1. 
This includes women with histories of abnormal cervical tests or genital warts, two groups of 
women at the center of this study.  
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Given these guidelines and the limitations of previous studies, the goal of the current study is to 
examine the guideline concordance of the time to follow-up of anal cancer screening in high-risk 
women, and whether this varies by the risk factors for anal cancer. We overcome limitations of 
previous studies by creating a large retrospective cohort of high-risk women from Medicaid 
administrative claims data in the US South. 
1.1. Conceptual framework 
We adapted Andersen’s behavioral model of healthcare utilization to develop a conceptual 
framework for understanding the frequency of follow-up anal cancer screening in high-risk 
women [289], figure 2. The framework consists of three domains: individual and population 
characteristics, use of health services, and outcomes. It posits that health service utilization is a 
result of the interplay of three individual/population characteristics—predisposing factors, 
enabling resources, and need [289]. We emphasize that the focus of the current study is on the 
utilization of follow-up anal cancer screening services and not the benefits of the screening. 
From left to right, the first part of the framework consists of predisposing factors—factors which 
exist before a person’s need for healthcare arises. Although these factors do not define a person’s 
health service utilization, they suggest the propensity that a person will need health services. The 
predisposing factors—for example, age—are exogenous and only affect healthcare utilization 
through enabling resources [289]–[291]. Next, enabling resources are necessary—although 
insufficient—for health services utilization to occur [289], [290]. These resources, for example, 
income, can facilitate follow-up anal cancer screening if available or impede it if unavailable.  
Finally, individuals must have a need for healthcare if services are to be utilized. The need can 
be perceived (subjective) or evaluated (objective) [289]–[291]. While women with HIV have a 
need for anal cancer screening overall [292]–[296], the need is greater among those with one risk 
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factor for acquiring anal cancer and much greater among those with multiple risk factors [277]–
[279]. Therefore, we expect the timing of follow-up anal cancer screening to be shorter in high-
risk women with both risk factors for anal cancer but guideline-concordant in all high-risk 
women, regardless of the type or number of risk factors.   
2. Methods  
2.1. Overview 
We examined the guideline concordance of the time to follow-up anal cancer screening in a 
retrospective cohort of high-risk women with HIV continuously enrolled in Medicaid for ≥ 24 
months. Data for this analysis came from the Medicaid Analytic eXtract (MAX) files, which 
included administrative claims of beneficiaries ages 19–64 years and who qualified for Medicaid 
based on income and disability in the US South6 (2009-2012). We used the International 
Classification of Diseases, Ninth Revision (ICD-9) codes to identify women with HIV, genital 
warts, abnormal cervical tests, and abnormal anal cells. To identify high-risk women screened 
for anal cancer, we used Current Procedural Terminology (CPT) codes for anal cytology and 
high-resolution anoscopy. We estimated the time to follow-up screening as the time from the 
date of the first anal cancer screen after a high-risk diagnosis (henceforth, the first screen) to the 
date of the second (follow-up) screen. In each group, we estimated the percentage with 
guideline-concordant time to follow-up screening. To determine whether the time to follow-up 
was guideline-concordant for the whole group and to be consistent with the literature, we 
compared the median follow-up time in that group to the follow-up time in the guidelines. We 
compared the odds that time to follow-up screening was guideline-concordant across the groups 
                                                 
6 The US South encompasses 16 states (Delaware, Florida, Maryland, North Carolina, Georgia, South Carolina, 
Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma and Texas) 
plus the District of Columbia.   
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using logistic regressions. In sensitivity analysis, we redefined the sample of high-risk women 
and examined follow-up time at thresholds higher than recommended in the guidelines. 
2.2. Data sources 
MAX files, available through the Centers for Medicare and Medicaid Services (CMS), were the 
primary data source. These data contain person-level information on Medicaid eligibility, 
utilization of healthcare services, and payments [297]. We used three MAX files: the MAX 
Personal Summary (PS) file to obtain enrollees’ demographic information; MAX Other Therapy 
(OT) file to identify PLWH, high-risk women, those screened for anal cancer and outcomes of 
the screening; and the MAX Prescription Drug (RX) file to verify, using antiretroviral 
prescriptions, enrollees with HIV. Claims for services provided to PLWH are submitted to states 
by healthcare providers and in turn, each state’s health department sends the claims to CMS 
every quarter [297]. MAX data is a reliable source for services received by PLWH [298], [299], 
and CMS regularly validates these data [300].  
We supplemented the MAX data with data from the Area Health Resources File (AHRF) and 
AIDSVu for additional county-level information. In the MAX data, person-level socio-
demographic information is limited to age, sex, and race/ethnicity. The AHRF, maintained by the 
Health Resource Service Administration, has county-level data on income, education, and 
availability of healthcare workforce [301]. We controlled for county-level education, income, 
and the healthcare workforce because these variables are positively associated utilization of 
health services [289], [302], [303]. AIDSVu, constructed by the Centers for Disease Control and 
Prevention and maintained by Emory University, consists of county-level HIV surveillance data 
in the US [304]. We controlled for county-level HIV prevalence because PLWH in counties with 
a high HIV burden are more likely to access HIV providers and receive appropriate HIV care 
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[305]. The study was approved by the institutional review board of Virginia Commonwealth 
University and used the data in accordance with a data use agreement with the CMS (IRB#: 
HM20008091, DUA#: RSCH-2017-51616)  
2.3. Sample selection and eligibility criteria 
We identified high-risk women from a sample of people verified to be living with HIV. Briefly, 
the sample of PLWH was derived as follows: Enrollees with HIV/AIDS were identified using 
ICD-9 codes 042 (AIDS diagnosis) and V08 (HIV diagnosis) [306]. In this sub-sample of 
enrollees living with HIV, we excluded enrollees for whom we could not verify and confirm an 
HIV-positive diagnosis. These included enrollees who only received HIV counseling, had HIV-
associated ICD-9 codes that occurred <twice during the analytic time horizon or had first and last 
HIV-associated claims <30 days, only received Truvada—a pre-exposure prophylaxis for HIV. 
From this sample, we retained non-elderly women with HIV using the sex variable (el_sex_cd) 
and restricted ages of 19-65 years7. We also excluded women enrolled in both Medicare and 
Medicaid. Next, we identified high-risk women using ICD-9 codes for abnormal cervical tests 
and genital warts [307], [308],  Appendix C2. We also excluded those diagnosed as high-risk 
before the date of the first HIV-associated ICD-9 code or on their last verified date of service. 
Finally, we excluded women enrolled for <24 months to permit enough time to observe ≥2 anal 
cancer screens after a high-risk diagnosis. 
2.4. Identifying high-risk women screened for anal cancer 
We identified high-risk women who received anal cancer screening using CPT codes for anal 
cytology and high-resolution anoscopy, Appendix C3. We used these codes because there were 
                                                 
7 Although the data requested from the CMS was for Medicaid beneficiaries aged 19-64 years, we applied this 
exclusion because transitions from Medicaid to Medicare may not be instantaneous and some beneficiaries may 
receive services under Medicaid and Medicare during the transition period. 
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no CPT codes for anal cancer screening during the current study’s analytic time horizon, 2009-
2012 [309], [310]. At that time, the practice was for providers to bill payers for services and 
components that constituted anal cancer screening—for example, direct smear (CPT code 88104) 
or anoscopy (CPT code 46600). Although CPT code 88112 (anal cytology, liquid-based 
preparation) is the most commonly used for anal cytology [311], we included the other codes 
because specimens for anal cancer screening can be obtained in multiple ways and each of these 
codes reflects the method used [312]. 
2.5. Statistical analysis 
We estimated time to follow-up anal cancer screening as the time from the date of the first screen 
(after a high-risk diagnosis) to the date of the second screen. We used Kaplan-Meier to estimate 
the time to follow-up screening overall and by risk group to make our findings comparable to the 
literature. The Kaplan-Meier estimator produces unbiased estimates even if the data are censored 
or have gaps [313], [314]. Data are censored if the observation of time-to-event is incomplete 
while gaps mean that a participant disappears from the study and then reappears at a later date 
[315]. These issues were important because of some enrollees moving in and out of the Medicaid 
program (churning) or not receiving any follow-up screening at the end of the analytic time 
horizon. To report the time to any follow screening, we used the median because the follow-up 
time was right-skewed (χ2 =1777(2), p-value <0.001). We tested the statistical significance of 
the differences in the time-to follow-up screening between the groups using the log rank test. 
2.5.1. Guideline-concordant time to follow-up screening (unadjusted)  
In each of the groups of high-risk women, we report the percent of women receiving follow-up 
screening at the times stipulated in the guidelines for anal cancer screening. We report these 
percentages at 6 and 12 months if on the first screen the results were, respectively, abnormal and 
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normal. However, for comparability with previous studies, we also report the median time—the 
time at which 50% of the group received follow-up screening. We tested whether the median 
time to follow-up screening was guideline-concordant by comparing it to the follow-up time 
recommended in the guidelines. Therefore, a group of high-risk women (for example, women 
with both risk factors) was considered to have had guideline-concordant time to follow-up 
screening if the median time was ≤ 6 months for those with abnormal results on the first screen 
and ≤ 12 months for those with normal results on the first screen. To ascertain whether the result 
on the first screen was normal or abnormal, we used the ICD-9 codes in Appendix C4.   
2.5.2. Guideline-concordant time to follow-up screening (adjusted) 
We modeled the likelihood that time to follow-up screening was guideline-concordant using 
logistic regressions, adjusting for other factors that can potentially influence the time to follow-
up of anal cancer screening. We reported the results as odds ratios and probabilities. The odds 
ratios compared the guideline concordance of time to follow-up screening between groups while 
the probabilities determined if the time to follow-up in each group was guideline-concordant. 
Time to follow-up screening was guideline-concordant if the average predicted probability for a 
given group was ≥ 0.5. We created a binary variable “concordance” based on the follow-up time 
recommended in the guidelines. Concordance was equal to one if the time to follow-up screening 
was guideline-concordant and zero otherwise.  We specified the following model: 
𝑙𝑜𝑔 ( 
𝜋𝑖
[1−𝜋𝑖]
) = 𝛽0 +  𝜆𝑿𝑖 + 𝛼𝑷𝑗  + 𝜞 + ℇ𝑖 --- (1) 
Where;  
πi is the proportion with guideline-concordant time to follow-up screening; (1-πi) is the 
proportion with time to follow-up screening not guideline-concordant. 
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Xi is a vector of individual-level variables, for example, age (Appendix C1); λ is a vector 
of parameters corresponding to the individual-level characteristics.  
Pj is a vector of county-level variables, for example, the prevalence of HIV (Appendix C1); 
𝞪 is a vector of parameters corresponding to the county-level variables. 
Γ captures state fixed-effects for the 16 Southern states plus the District of Columbia. 
ℇi is residuals—assumed to be independent and normally distributed with zero means.  
Tests of model fitness using the Hosmer-Lemeshow test which compares observed vs. expected 
frequencies and deviance residuals which can identify outlying observations [316, p. 3] 
suggested the model was a good fit of the data: Hosmer-Lemeshow, χ2 (8) =6.29 (p>0.05) and 
<5% (129/3,779) of observations were outlying (±2 standard deviations of the residuals’ mean—
zero). Test of multicollinearity suggested this was not a problem (mean VIF=6.10) [316], [317]. 
2.6. Sensitivity analysis  
We conducted three sensitivity analyses. First, we restricted the sample of high-risk women to 
only those continuously enrolled in Medicaid for the entire study period (2009-2012). Redefining 
the sample this way helped to understand whether Medicaid enrollment length and churning 
influenced the frequency of anal cancer screening. In the second sensitivity analysis, we 
redefined the sample of high-risk women by including additional ICD-9 codes that might also be 
used to indicate a diagnosis of abnormal cervical test or genital warts. We conducted this 
sensitivity analysis to account for differences in practices in deciding which diagnoses might 
qualify an individual for anal cancer screening. For example, women with a diagnosis of “other 
abnormal Pap smear of cervix and cervical HPV (ICD-9 code 795.09)” may be considered as 
high-risk by some practitioners but not by others. All the supplementary codes used in the 
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sensitivity analysis are presented in Appendix C2. In the third sensitivity analysis, we modeled 
the time to follow-up screening at thresholds higher than stipulated in the guidelines to account 
for logistical delays in seeking care. We assumed a 2-month delay. Thus, in equation 1, we 
examined the likelihood of follow-up screening at ≤ 14 months among women with normal 
results and ≤ 8 months among those with abnormal results on the first screen.    
3. Results  
3.1. Descriptive statistics 
Overall, we identified 6,086 high-risk women continuously enrolled in Medicaid for ≥ 24 
months. Sixty-two percent (3,779/6,086) were screened for anal cancer after a high-risk 
diagnosis. Therefore, we examined time to follow-up screening in 3,779 high-risk women who 
accounted for a total of 4,458 person-years, table 1. Approximately three-quarters qualified for 
Medicaid via the disability path, with nearly two-thirds continuously enrolled in Medicaid for 4 
years. The mean (±SD) age (years) was 41.5±10.4. The sample largely comprised women with 
histories of abnormal cervical tests (74%) followed by those with histories of both risk factors 
(18%). Most were non-Hispanic black (68%) followed by other races/ethnicities (for example, 
Pacific Islanders, Hawaiians, and Asians) (15%), non-Hispanic whites (12%), and Hispanics 
(5%). The incidence of anal cancer screening was 0.39 (95% C.I.=0.26,0.37) per person-year 
overall but much higher among high-risk women with both risk factors (0.62 (95% 
C.I.=0.57,0.68) per person-year). The time to follow-up screening was guideline-concordant for 
46% of those with abnormal results and 37% among those with normal results. Women with both 
risk factors were highest in the proportion with guideline-concordant time to follow-up 
screening, regardless of the result on the first screen. 
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3.2. Time to any follow-up anal cancer screening (unadjusted) 
The overall median time to any follow-up screening was 16.1 months (95% C.I.=15.2,17.6) but 
differed by risk group (χ2(2) =115.8, p-value<0.001). The follow-up time was shortest among 
women with histories of both risk factors, with a median time almost half that of the next most 
screened group (women with histories of abnormal cervical tests only) (median=9.3, 95% 
C.I.=7.6,11.0 months vs. median=18.6, 95% C.I.=17.6,19.9 months). Among women with 
histories of genital warts only, the median follow-up time was two years (median=24.4, 95% 
C.I.=16.3,39.0 months). When examined collectively, the median time to follow-up screening for 
women with any single risk history was 18.9 (95% C.I.=17.8,20.3) months, figure 3. By 24 
months, >75% of women with both risk histories had received follow-up screening compared 
with <60% among women with only one risk factor.  
3.3. Guideline concordance of the time to follow-up screening (unadjusted) 
Receipt of guideline-concordant follow-up anal cancer screening—defined as receiving follow-
up screening within 6 months and 12 months for those with normal and abnormal results after the 
first screen, respectively—also differed by risk group. The time to follow-up screening was 
guideline-concordant for 47.3% (95% C.I.=42.0,53%) of high-risk women with abnormal results 
on the first screen and for 40.0% (95% C.I.=38.0,41.4%) for those with normal results. When 
stratified by risk group, the time to follow-up screening was guideline-concordant for more than 
half of high-risk women with both risk factors, figure 4 (points A and C). The percent of 
women with guideline-concordant time to follow-up screening was lowest for women with a 
single risk factor and normal results on the first screen (36.8%, 95% C.I.=35.0,38.7%), figure 4 
(point D).   
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3.4. The odds of any follow-up anal cancer screening (adjusted) 
In adjusted analyses, the odds of receiving any follow-up anal cancer screening differed by the 
number of risk factors, table 2 (panel 1). The odds were significantly higher in women with both 
risk factors than in women with one factor (OR=2.57, 95% C.I.=2.12,3.12). At the same time, 
high-risk women with an abnormal anal test on the first screen had significantly higher odds of 
receiving any follow-up screening compared with those who had normal results (OR=3.22, 95% 
C.I.=2.39,4.34). We also found that the odds of receiving any follow-up screening were 
significantly higher among those who qualified for Medicaid via the disability path and increased 
with increasing years of enrollment and age. Compared to non-Hispanic whites, Hispanics had 
significantly higher odds of receiving any follow-up anal cancer screening. Non-Hispanic blacks 
had similar odds of receiving any follow-up screening as non-Hispanic whites.     
3.5. The odds and probability of guideline-concordant follow-up screening (adjusted) 
The odds that the time to follow-up of anal cancer was guideline-concordant differed by risk 
group, table 2 (panel 2). Compared with women with a single risk factor, women with both risk 
factors had double the odds of having guideline-concordant time to follow-up screening 
(OR=2.06, 95%=1.73,2.46). The odds were also higher among women with abnormal results on 
the first screen compared with women with normal results (abnormal vs. normal,  OR=1.27, 
C.I.=1.00,1.63).  
These results are also presented as predicted probabilities in table 3 (base case analysis). From 
first to last, the average probabilities that the timing of the follow-up screening was guideline-
concordant were as follows: both risk factors and abnormal result, 56.7% (95% 
C.I.=50.7,62.8%); both risk factors and normal result, 50.9 (95% C.I.=47.0-54.8%); one risk 
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factor and abnormal result, 39.3% (95% C.I.=33.7,44.9%); one risk factor and normal result, 
33.8% (95% C.I.=32.2,35.6%).  
We also found that the odds that time to follow-up screening was guideline-concordant differed 
on some individual- and county-level variables. The odds were significantly higher for older 
enrollees and those who qualified for Medicaid via the disability path. However, the odds did not 
significantly differ by years of continuous enrollment or race/ethnicity. In terms of county-level 
variables, the odds were higher for those living in counties with higher HIV prevalence but lower 
for those living in counties with more specialists. Finally, the odds were lower for high-risk 
women in states with higher proportions of Medicaid managed care enrollment although the 
difference was not significant.   
3.6. Sensitivity analysis 
When we restricted the sample of high-risk women to only those continuously enrolled in 
Medicaid for the entire study period (2009-2012), the percent of women with guideline-
concordant time to follow-up screening increased but only marginally (within five percentage 
points), table 3 (continuously enrolled for 4 years). For example, among women with both risk 
factors and abnormal results the percent with guideline-concordant follow-up time to screening 
increased from 57% (95% C.I.=51%,63%) in the main analysis to 62% (95% C.I.=56%,68%) in 
the sensitivity analysis.  
Table 4 presents the results of the second sensitivity analysis in which we increased the number 
of ICD-9 codes used to create a sample of high-risk women, thereby relaxing the approach for 
constructing our sample. The pattern suggests that the percent with guideline-concordant time to 
follow-up screening decreased but was still higher in high-risk women with both risk factors. 
The decreases ranged from zero to three percentage points. Overall, the percent with guideline-
 155 
concordant time to follow-up decreased by two percentage points among high-risk women with 
normal results on the first screen after a high-risk diagnosis but did not decrease among those 
with abnormal results. Similar patterns were observed when the time to follow-up was analyzed 
by risk group.  
In the third sensitivity analysis, which examined follow-up screening at the guideline-
recommended times plus 2 months, the probability of follow-up anal cancer screening increased 
but marginally. The increases were by three to five points in each group, table 5. As in the main 
analysis, the probability of receiving follow-up screening at the higher thresholds was highest 
among women with both risk factors and abnormal results on the first screen, followed by those 
with both risk factors and normal results. In these two groups, the probabilities were >0.5. In 
high-risk women with one risk factor, the probabilities were <0.5, regardless of the result on the 
first screen. 
4. Discussion 
To our knowledge, this is the first study to examine and report, by anal cancer risk factors and 
screening result, the guideline concordance of the time to follow-up of anal cancer screening in 
women with HIV at high-risk for acquiring anal cancer. These women include those with 
histories of abnormal cervical tests or genital warts. We found that the time to any follow-up of 
anal cancer screening was longer overall, although shorter among high-risk women with histories 
of both risk factors. The time to follow-up screening was not guideline-concordant for most 
high-risk women although it was for most high-risk women with both risk factors. These 
findings persisted in sensitivity analyses. Among women at high risk of acquiring anal cancer, 
the odds of guideline-concordant screening are lower in those who are younger and qualified for 
Medicaid through the disability pathway.  
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Overall, we found that the time to follow-up of anal cancer screening was much longer among 
high-risk women with one risk factor, and it was not guideline-concordant for nearly two-thirds 
of them. However, the time to follow-up was guideline-concordant for high-risk women with 
both risk factors, regardless of the result on the first screen after a high-risk diagnosis. The lack 
of guideline concordance of the time to follow-up overall and among high-risk women with one 
risk factor is not surprising and might be for several reasons. One possible explanation is that the 
guidelines for anal cancer screening are not very clear on what to do next after the initial 
screening, particularly when a positive test is obtained [277], [318]. As a result, opinions and 
practice patterns of experts tend to influence institutions’ anal cancer screening processes. For 
example, for people treated for severe lesions (AIN2/3), the University of San Francisco’s 
screening protocol recommends follow-up screening every six months with high-resolution 
anoscopy (HRA)—the same as for those with untreated AIN1 [319], [320]. On the other hand, 
John’s Hopkins does not have formal recommendations on follow-up time for those treated for 
AIN2/AIN3 but does recommend that follow-up screening with HRA be performed every six 
months in those with AIN1 [318]. Another area of uncertainty and debate is when the result of a 
pap smear is determined to be ASC-US—atypical squamous cell of undetermined significance or 
ASC-H— atypical squamous cell, cannot rule out high-grade lesion. For ASC-US, the University 
of San Francisco recommends follow-up screening with HRA screening and if lesions not found, 
an annual Pap test is recommended [319]. On the other hand, Johns Hopkins does not make any 
recommendations on ASC-US. However, if the result is ASC-H, it recommends HRA and if 
there is no lesion or AIN1, repeat HRA should be performed every 3 months [318]. The 
University of San Francisco has no formal recommendations for ASC-H. The position of the 
HIV Medical Association is unclear on these grey areas. This lack of clarity in the guidelines 
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suggests that the time to follow-up will vary by providers and some providers may not 
recommend follow-up screening to their clients even if the results on the initial screen are 
positive.  
Given the lack of clarity in the guidelines, another possible explanation is that the guidelines may 
not have been sufficiently popularized and therefore, some providers may not be fully aware of 
the guidelines for anal cancer screening. This lack of awareness about the guidelines would most 
likely affect rates of anal cancer screening among women with histories of abnormal cervical 
tests or genital warts. This is because these risk factors for anal cancer are not the most well-
known or most extensively studied. Receptive anal intercourse is [321] and hence the large 
literature on anal cancer screening in MSM with HIV [267], [280]–[283]. Thus, it is probable 
that providers not aware of the guidelines may prioritize anal cancer screening in MSM and 
overlook high-risk women, particularly those with a single risk factor.   
Another potential explanation for the low rates of follow-up screening is that while HRA is 
considered the gold standard for anal cancer screening and strongly recommended for follow-up 
screening [318], [320], [322], several challenges limiting its use remain. These challenges 
include a shortage of colposcopies, shortage of well-trained personnel, and a long learning curve 
for the technique [278], [323], [324]. For example, data show that it takes examining about 200 
cases for a provider to competently detect all high-grade lesions using HRA [324]. These 
technological limitations suggest that high-risk women, particularly those with abnormal results 
on the first screen after a high-risk diagnosis, may not receive the follow-up screening even if 
they want to.  
An additional potential explanation is that physicians, particularly specialists, may not have 
enough time to provide the follow-up screening services. In multivariable regressions, we found 
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that high-risk women in counties with more specialists are significantly less likely to have 
guideline-concordant time to follow-up screening. At the same time, the likelihood of receiving 
guideline-concordant follow-up screening is higher, although not significant, in counties with 
more primary care physicians. This suggests that high-risk women relying on specialists, vs. 
primary care physicians, may face delays in receiving the follow-up anal cancer screening. These 
delays could be due to the involvement of multiple specialties vs. a single specialty in providing 
this care [325], [326]. Finally, it is possible that those with one risk factor may downplay the risk 
of anal cancer given that they have one and not multiple risk factors. Therefore, they may 
procrastinate in seeking follow-up screening, thinking the problem is not serious enough and 
may naturally disappear.  
The pattern of the time to follow-up screening among those with abnormal and normal results 
(on the first screen) is consistent with reports from previous studies, although we emphasize that 
the overall median follow-up time in this study is not always consistent with those studies. 
Similar to the current study, previous studies reported higher follow-up screening frequencies 
among women with abnormal results compared to those with normal results [273], [275], [287]. 
The study’s overall median follow-up time (18 months) compares favorably with findings from a 
study in California which reported a follow-up time of 17 months in women with HIV [287]. In 
New York, women with HIV and normal results on the previous screen received follow-up anal 
cancer screening in 12 months [275], which is guideline-concordant but inconsistent with this 
study’s findings. Studies of women with HIV in Boston, Connecticut, and Massachusetts, 
reported a follow-up time of 6 months if the previous screen was normal [270], [273]. We 
emphasize that comparisons with these studies are limited because the studies did not restrict 
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their samples to women at high risk for anal cancer, had smaller sample sizes (<100 in many 
cases) or were limited in geographic scope.  
Finally, the finding that time to follow-up screening was guideline-concordant for <50% of the 
high-risk women is consistent with other studies on the guideline concordance of care among 
PLWH. Among women with HIV, <50% receive guideline-concordant depression care [328] and 
<40% receive guideline-concordant cervical cancer screening [329]. Among PLWH,  <40% 
receive guideline-concordant opioid therapy [330], <30% receive timely medical care for HIV 
symptoms [331], and <50% receive regular HIV care [332]. Therefore, this study contributes to a 
broader literature suggesting that there is room for improvement in the delivery of HIV-related 
care. 
4.1. Limitations 
This study has limitations. First, we were unable to examine the guideline concordance of the 
time to follow-up screening in women with HIV and histories of receptive anal intercourse due 
to data limitations. These women are also at high risk of acquiring anal cancer and are 
recommended for regular follow-up screening [277]. Although ICD-9 codes for high-risk sexual 
behaviors were available, we could not identify specific diagnoses of receptive anal intercourse 
in the MAX data. Despite this limitation, it is likely that we captured some of these women 
among those with histories of genital warts. This is because individuals with high-risk sexual 
behaviors like receptive anal intercourse are more likely to acquire sexually transmitted 
infections, including genital warts [333].  
Second, we were unable to know if any women received follow-up anal cancer screening not 
paid for by Medicaid and therefore, not captured in the MAX data. This problem was likely to 
occur because of churning. Data show that individuals who churn tend to have health service 
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utilization patterns different from those continuously enrolled in Medicaid [334], [335]. Thus, 
the estimates are biased to the extent that the frequency of follow-up screening among those who 
churned systematically differed by risk group. To mitigate this problem, we limited the study’s 
sample to high-risk women continuously enrolled in Medicaid for ≥ 24 months. Moreover, the 
study’s findings were robust in sensitivity analysis when we restricted the sample to only those 
continuously enrolled for the entire study period (48 months).  
Third, we did not have access to individual-level socio-economic data like education and 
income—two factors that influence the utilization of preventive care and health outcomes among 
PLWH [302], [303]. To address this limitation, we supplemented the MAX data with the AHRF 
and controlled for county-level education and income. 
Finally, the findings may not be generalizable to all women with HIV at high-risk of acquiring 
anal cancer. This is particularly true as we used a cohort of Medicaid enrollees in the US South 
and not a nationally representative sample. Thus, the time to follow-up screening reported here 
may not be observed in the country’s other regions or among those privately insured or rely on 
Ryan White HIV clinics. Despite these limitations, it is likely the study adequately captured the 
frequency of follow-up anal screening in high-risk women with HIV given the large sample for 
the study and likely reflects regional trends in the receipt of follow-up screening in this 
population. 
4.2. Implications for practice and policy  
Time to follow-up anal cancer screening is not guideline-concordant for most high-risk women 
with histories of abnormal cervical tests or genital warts, although it is for most high-risk women 
with both risk factors. This problem can be addressed in several ways, including enhancing 
partnerships between primary care physicians and specialists and training more providers in 
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using HRA—a specialized test for anal cancer screening and recommended for follow-up 
screening particularly among those with abnormal cytologic results. Use of HRA in follow-up 
screening is critical because, unlike cytology, HRA can distinguish between low-grade and high-
grade lesions and therefore, allows for the appropriate treatment and follow-up recommendations 
[318], [320], [322].  
Second, it is critical to clarify the guidelines for anal cancer screening. This can be achieved by 
gathering more compelling evidence on the benefits of anal cancer screening, particularly in 
individuals at high-risk for acquiring anal cancer. While experts agree that anal cancer screening 
in high-risk individuals can prevent anal cancer or at least detect it early, the guidelines for anal 
cancer screening have not been adopted universally [336], [337]. This is mainly because of the 
lack of compelling evidence about the benefits of anal cancer screening [336], [337]. To address 
this gap, a randomized controlled trial evaluating the benefits of treating high-grade lesions in 
PLWH is currently in progress in the USA [338]. Thus, the evidence from that trial and perhaps 
additional observational studies can help to clarify the guidelines, lead to their universal adoption 
and popularization, and eliminate any confusions about the timing of follow-up screening.  
Furthermore, re-examining the payment policy for anal cancer screening services can be useful 
since there is no CPT code for anal cancer screening [309], [310], [312]. Thus, clinicians cannot 
bill payers for anal cancer screening as a single service. The status quo is that clinicians bill 
payers the bits and pieces that comprise anal cancer evaluation and management (for example, 
anoscopy) [339], [340]. Payers argue that they cannot pay for anal cancer screening because its 
benefits have not been evaluated in any randomized controlled trial and the screening is not 
universally recommended [278], [336], [340]. It is noteworthy that payers reimburse clinicians 
for cervical cancer screening despite cervical and anal cancers having many similarities and both 
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lacking evidence of screening benefits from randomized controlled trials [336], [339]. The lack 
of a single CPT code for anal cancer screening creates difficulties in reimbursement for the 
services [309], [312] and therefore, a disincentive to the continued provision of anal cancer 
screening services. Thus, it is probable that creating a billable CPT code for anal cancer 
screening could eliminate the difficulties in reimbursements and increase rates of anal cancer 
screening overall. 
Finally, high-risk women should be made aware of the benefits of anal cancer screening, 
regardless of the number of risk factors for anal cancer. Data show that 63% of people at risk for 
anal cancer do not know that anal cancer screening is recommended [341], a sizable proportion 
refuses the screening [341]–[343], and not all clinicians discuss this with their patients [344]. 
Therefore, discussions between providers and their clients at a high-risk for acquiring anal cancer 
about the benefits of anal screening can increase the uptake of anal cancer screening services.   
4.3. Future research 
While this study contributes to a broader literature suggesting that most PLWH do not receive 
guideline-concordant care, much remains to be done. Future research should focus on whether 
the timing of follow-up anal cancer screening varies by health service delivery model (managed 
care) or payment model (fee-for-service). This is important as many states have moved from 
Medicaid fee-for-service to Medicaid managed care [345]. However, it is unclear how such 
changes affect the receipt of anal cancer screening specifically and HIV-related preventive care 
in general. Future research should also examine racial/ethnic disparities in the timing of follow-
up anal cancer screening overall and in each group of high-risk women. Evidence suggests that 
racial/ethnic minorities are less likely to receive HIV-related preventive care [346]–[348], be 
treated for anal cancer [349], and more likely to present with advanced disease stage [350], 
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[351], compared with non-Hispanic whites. Among MSM with HIV, non-Hispanic blacks are 
less likely to be screened for anal cancer [286], [343], [352]. It is unclear whether these 
disparities extend to follow-up anal cancer screening of high-risk women. We were unable to 
investigate this question because of inadequate sample sizes for high-risk non-Hispanic whites 
and Hispanics.  
5. Conclusion 
In the past 2-3 decades, the incidence of anal cancer among PLWH has increased significantly. 
We examined the guideline concordance of the timing of follow-up anal cancer screening in two 
groups of women at high-risk for acquiring anal cancer: women with HIV and histories of either 
abnormal cervical tests or genital warts. The timing of the follow-up screening is not guideline-
concordant overall and among high-risk women with a history of one risk factor. However, it is 
guideline-concordant among those with histories of both risk factors. These findings suggest that 
high-risk women with one risk factor are in danger of being overlooked as also being at risk for 
anal cancer. As a result, they may present for screening with advanced disease, making 
secondary prevention difficult, and thereby limiting the chance of survival. In all, these findings 
provide support for efforts, including training providers in how to effectively use HRA and 
generating more evidence to help push for the universal adoption of the guidelines for anal 
cancer screening, to increase rates of follow-up anal cancer screening in those at high-risk of 
acquiring anal cancer.  
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Table 1: Summary statistics for high-risk women living with HIV followed-up for anal cancer screening, by risk group   
Variable  
All high-risk women 
(n=3,779) 
Genital warts only 
(n=292) 
Abnormal cervical only 
(n=2,809) 
Abnormal cervical and 
genital warts (n=678) 
  Frequency Percent Frequency Percent Frequency Percent Frequency Percent 
First screen after a high-risk diagnosis***                 
Abnormal 326 9% 34 12% 162 6% 130 19% 
Normal 3453 91% 258 88% 2647 94% 548 81% 
Time at risk (person-years)† 4458 100% 349 8% 3438 77% 672 15% 
Received follow-up screening*** 2086 55% 129 44% 1454 52% 503 74% 
Incidence of follow-up screening (per person-year) 0.39   0.31   0.35   0.62   
Time to follow-up screening guideline-concordant‡ 1414 37% 91 31% 972 35% 351 52% 
Abnormal anal test at first screening*** 150 46% 10 29% 73 45% 67 52% 
Normal anal test at first screening*** 1264 37% 81 31% 899 34% 284 52% 
Race/ethnicity***                 
Non-Hispanic white 454 12% 45 15% 324 12% 85 13% 
Non-Hispanic black 2570 68% 175 60% 1949 69% 446 66% 
Hispanic 174 5% 28 10% 99 4% 47 7% 
Others 581 15% 44 15% 437 16% 100 15% 
Medicaid qualification***                 
Income 994 26% 58 20% 788 28% 148 22% 
Disability 2785 74% 234 80% 2021 72% 530 78% 
Enrollment length***                 
Continuously enrolled for 2 years 788 21% 62 21% 602 21% 124 18% 
Continuously enrolled for 3 years 585 15% 48 16% 444 16% 93 14% 
Continuously enrolled for 4 years 2406 64% 182 62% 1763 63% 461 68% 
Age (mean and standard deviation) ***, years 41.9 10.2 42.2 9.9 41.6 10.6 40.7 9.9 
*p-value<0.05; **p-value<0.01; ***p-value<0.001. †Percentages are by row, otherwise, percentages are by column. ‡ Receipt of follow-up anal cancer screening 
within 6 months for those with an abnormal anal test at the first test and within 12 months for those with normal results at the first test. §First column=mean and 
second column= standard deviation. For these variables tests of statistical significance were performed using the F-test; otherwise, Chi-square were tests used.      
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Table 2: Odds of guideline-concordant time to follow-up anal cancer screening in high-risk women with HIV  
 Panel 1 Panel 2 
 Any follow-up anal cancer 
screening 
Guideline-concordant follow-
up anal cancer screening† 
  Odds Ratio 95% C.I. Odds Ratio 95% C.I. 
Individual-level factors     
Number of risk factors (ref: one risk factor)‡     
Both factors 2.57*** [2.12,3.12] 2.06*** [1.73,2.46] 
Result at first anal cancer screen (ref: normal)     
Abnormal 3.22*** [2.39,4.34] 1.27* [1.00,1.63] 
Qualification for Medicaid (ref: income)     
Disability 1.23** [1.03,1.47] 1.28*** [1.06,1.53] 
Years of continuous enrollment (ref: 2 years)     
3 years 1.29** [1.03,1.62] 1.11 [0.88,1.39] 
4 years 1.37*** [1.16,1.64] 0.97 [0.81,1.16] 
Age (ref: 19-34 years)     
35-44 years 1.39*** [1.16,1.67] 1.40*** [1.16,1.68] 
45-54 years 1.30*** [1.07,1.58] 1.24** [1.02,1.51] 
55-64 years 1.58*** [1.22,2.04] 1.66*** [1.28,2.14] 
Race/ethnicity (ref: non-Hispanic whites)     
Non-Hispanic Black 1.07 [0.86,1.34] 0.89 [0.71,1.11] 
Hispanic 1.63** [1.11,2.41] 1.14 [0.79,1.66] 
Others 1.22 [0.87,1.70] 0.83 [0.59,1.16] 
County/state level controls§     
Diagnosed HIV cases per 100,000 adults (ref: 0-54)     
55-138 1.84 [0.61,5.55] 2.82 [0.81,9.76] 
139-2426 1.27 [0.44,3.69] 1.98 [0.59,6.65] 
Primary care physicians per 10,000 population (ref: 
0-3.7) 
    
3.8-6.3 1.35 [0.90,2.03] 1.22 [0.81,1.85] 
6.4-47.6 1.22 [0.78,1.91] 1.18 [0.75,1.85] 
Specialists per 10,000 population (ref: 0-0.92)     
0.93-3.4 0.43*** [0.24,0.76] 0.41*** [0.24,0.72] 
3.5-147.8 0.45** [0.24,0.83] 0.50** [0.27,0.91] 
Percent living the federal poverty level (ref:0.9%-
13.5%) 
    
13.6%-18.9% 0.84 [0.60,1.17] 1.13 [0.81,1.59] 
19%-63.2% 0.82 [0.56,1.20] 0.94 [0.64,1.37] 
Percent with less than high school education (ref: 
1%-11.4%) 
    
11.5%-18% 0.80* [0.63,1.03] 0.86 [0.67,1.09] 
18.1%-55 0.91 [0.66,1.27] 1.08 [0.78,1.51] 
Percent with Medicaid managed care enrollment 
(ref: <=60%)¶ 
    
61%-80% 1.02 [0.29,3.54] 0.33 [0.08,1.27] 
>80% 1.1 [0.34,3.58] 0.38 [0.10,1.41] 
Observations 3779   3779   
* p < 0.10, ** p < 0.05, *** p < 0.01. †Receipt of follow-up anal cancer screening in 6 months for those with an abnormal 
anal test at the first test and within 12 months for those with normal results at the first test. ‡The risk factors are histories 
of abnormal cervical tests or genital warts. §The county and state control variables are tertiles. ¶State-level variable.  
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Table 3: The percent of women living with HIV with guideline-concordant time to follow-up screening at varying restrictions of years 
of continuous enrollment in Medicaid  
Base case analysis† (n=3,779) Sensitivity analysis‡ (n=2,406) 
 
Continuously enrolled for at least 2 years Only those continuously enrolled for 4 years 
 
Normal (≤12 months) Abnormal (≤6 months) Normal (≤12 months) Abnormal (≤6months) 
Risk factors* Estimate (%) 95% C.I. Estimate (%) 95% C.I. Estimate (%) 95% C.I. Estimate (%) 95% C.I. 
Overall 37 [35-39] 42.00 [42-52] 39.61 [37-42] 46.96 [41-54] 
One risk factor 34 [32-36] 39.33 [34-45] 36.30 [34-39] 44.39 [36-53] 
Both risk factors 51 [47-55] 56.76 [51-63] 55.24 [50-61] 50.37 [41-61] 
*Risk factors: a history of abnormal cervical tests or a history of genital warts. †The base case (main) analysis uses a sample of women living 
with HIV continuously enrolled in Medicaid for at least two years. ‡ This is a sensitivity analysis in which the guideline concordance of the 
follow-up time to anal cancer screening was examined only in women living with HIV continuously enrolled in Medicaid for 4 years (2009-
2012)-the study's analytic time horizon.  
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Table 4: The percent of women living with HIV with guideline-concordant time to follow-up screening, using varying numbers of 
ICD-9 codes to define high-risk women 
  Base case analysis† (n=3,779) Sensitivity analysis (n=4,960) 
 
Percent receiving follow-up screening† Percent receiving guideline-concordant‡  
 
Normal (≤12 months) Abnormal (≤6 months) Normal (≤12months) Abnormal (≤6months) 
Risk factors* Estimate (%) 95% C.I. Estimate (%) 95% C.I. Estimate (%) 95% C.I. Estimate (%) 95% C.I. 
Overall 40 [38-41] 47 [42-53] 38 [37-40] 47 [42-52] 
One risk factor 37 [35-39] 44 [37-51] 36 [34-38] 42 [36-49] 
Both risk factors 54 [50-58] 53 [44-61] 51 [47-55] 56 [48-64] 
Abbreviation: ICD-9, International Classification of Diseases, Ninth Revision. *Risk factors: a history of abnormal cervical tests or a history 
of genital warts. †Estimates in the base case analysis were derived from a sample of high-risk women created using a more conservative 
definition (fewer ICD-9 codes) of high-risk. ‡In the sensitivity analysis, a sample of high-risk women was created using additional codes that 
may or may not conclusively suggest that an individual is high-risk. ‡Receipt of follow-up anal cancer screening within 6 months for those 
with an abnormal anal test at the first test and within 12 months for those with normal results at the first test 
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Table 5: Average predicted probability of receiving follow-up anal cancer screening in women with HIV at different cut-off points 
  Base case analysis† (n=3,779) Sensitivity analysis (n=3,779)‡ 
 
Normal (≤12 months) Abnormal (≤6 months) Normal (≤14 months) Abnormal (≤8 months) 
Risk factors* Probability 95% C.I. Probability 95% C.I. Probability 95% C.I. Probability 95% C.I. 
Overall 0.37 [0.35-0.39] 0.42 [0.42-0.52] 0.40 [0.39-0.42] 0.47 [0.42-0.53] 
One risk factor 0.34 [0.32-0.36] 0.39 [0.34-0.45] 0.37 [0.35-0.39] 0.44 [0.38-0.50] 
Both risk factors 0.51 [0.47-0.55] 0.57 [0.51-0.63] 0.55 [0.51-0.59] 0.62 [0.56-0.68] 
*Risk factors: a history of abnormal cervical tests or history of genital warts. †The base case analysis represents the time to follow-up 
recommended in the guidelines for follow-up anal cancer screening. ‡ The sensitivity analysis represents a relaxed threshold to account for 
logistical delays that may happen is seeking follow-up anal cancer screening services. 
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Adapted from Chin-Hong and Palefsky. Clin Inf Dis (2002) and Leeds and Fang. World J Gastrointest Surg (2016). 
Thick boxes highlight the groups of people living with HIV and anal cancer screening frequencies of interest in this study. 
*Both men and women with genital warts are recommended for regular screening, but the focus is on women with genital 
warts 
Figure 1: Recommendations for anal cancer screening in people living with HIV at high risk for anal cancer 
This figure summarizes recommendations for anal cancer screening in people with HIV at high-risk of acquiring 
anal cancer. Guidelines for anal cancer screening recommend regular screening in those with histories of high-
risk sexual behaviors, abnormal cervical tests, or genital warts. Follow-up screening is recommended every 12 
months if the initial result is normal or every 6 months if the result is abnormal. 
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Individual and population characteristics 
 
  Use of health services   
 
    Outcomes 
                                
 
  
 
                              
                                
                                
                                
                                
                                
                                
                                
                                
                                
                                
                                
                                
Adapted from Andersen, J. Health Soc. Behav., 1995                   
The thick box highlights that the present study is interested in the frequency of anal cancer screening (utilization of health services) in high-
risk people living with HIV. *Variable is only available at the county- and not individual-level. †The guidelines for anal cancer screening 
recommend screening of all people diagnosed with HIV at baseline and then those with histories of abnormal cervical Pap or genital warts 
should be screened annually if the anal cancer screening results are normal or bi-annually if the results are abnormal. 
Figure 2: A framework for understanding the frequency of follow-up anal cancer screening in high-risk women living with HIV 
This figure shows the interplay of individual/population factors and how they affect the utilization of anal cancer screening services. It also 
shows that while people living with HIV people have a need for anal cancer screening, risk factors like having a history of genital warts 
increase this need.  
 
Need factors 
  Living with HIV 
   Anal cancer screening† 
     Baseline 
     Every 6 months 
     Every 12 months 
    
Prevention of anal cancer 
Lower morbidity mortality 
due to anal cancer 
  History of abnormal   
  cervical Pap 
  History of genital warts 
Enabling resources 
  Income* 
  PCPs/population ratio* 
  Specialists/population* 
  Insurance  
   
Predisposing 
characteristics 
  Age 
  Sex 
  Education* 
  Race/ethnicity 
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Figure 3: Kaplan-Meier estimates of the frequency of follow-up anal cancer screening, by risk group 
This figure shows that the frequency of follow-up anal cancer screening was higher in women with HIV and histories of both 
abnormal cervical tests and genital warts.  
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The risk factors are 1) history of abnormal cervical tests; 2) history of genital warts.
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Figure 4: Percent receiving guideline-concordant follow-up anal cancer screening, by risk group and the result of the first screen 
This figure shows that the percent of women receiving guideline-concordant follow-up screening was highest among those with both 
risk factors, regardless of the result of the first anal cancer screen after a high-risk diagnosis (points A and C). The percent was lowest 
among those with a single risk factor and a normal result on the first test (point D). 
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Appendices 
Appendix C1: Variable definitions 
Table C1: Definition of variables in a study of guideline concordance of follow-up anal screening in high-risk women living with HIV 
Variables  Type Definition Justification  Source Year 
Individual-level 
variables 
     
Frequency  Continuous Time from first anal cancer screen after a 
high-risk diagnosis to the next screen. 
Dependent variable. MAX files 2008-2012 
Concordance Binary Receipt of guideline-concordant follow-
up screening: concordance=1 if 
guideline-concordant, concordance=0 
otherwise 
Dependent variable MAX files 2008-2012 
Risk group Categorical 1=history of abnormal cervical tests, 
2=history of genital warts, 3=history of 
abnormal cervical tests and genital warts 
Key explanatory variable. Anal cancer screening likely 
higher among women with both risk factors. 
MAX files 2008-2012 
Qualification for 
Medicaid  
Binary 1= via income, 2= via disability. Anal cancer screening likely higher among those 
qualified via the disability path. 
MAX files 2008-2012 
Continuous enrollment 
(years) 
Ordinal Years continuously enrolled in Medicaid: 
1=2 years, 2=3 years, 3=4 years. 
Anal cancer screening likely higher among those 
enrolled in Medicaid for longer periods. 
MAX files 2008-2012 
Age (years) Categorical 1=19-34 years, 2=35-44 years, 3=45-54 
years, 4=55-64 years. 
Older participants more likely to be screened for anal 
cancer. 
MAX files 2008-2012 
Race/ethnicity Categorical 1=non-Hispanic white, 2=non-Hispanic 
black, 3=Hispanic, 4=Others 
Use of healthcare services differs by race [286], [343], 
[352]. 
MAX files 2008-2012 
County-level       
HIV prevalence  Ordinal (tertiles) HIV cases per 100,000 adult population. People in high-burden HIV counties are more likely to 
receive HIV appropriate care as HIV providers are more 
likely to locate there [305]. 
AIDSVu*  2010 
Primary care physician 
population (PCP) ratio 
Ordinal (tertiles) The ratio of primary care physicians per 
10,000 population 
Anal cancer screening services are more likely to be 
available in areas with a higher supply of PCPs. 
AHRF 2010 
Specialist population 
ratio 
Ordinal (tertiles) The ratio of specialists per 10,000 
population 
Anal cancer screening more likely to be available in 
areas with a higher supply of specialists. 
 
AHRF 2010 
Poverty Ordinal (tertiles) The percent of people in poverty. Income is an enabler of health services use [289]. AHRF† 2010 
Education Ordinal (tertiles) The proportion of residents with at least a 
high school education. 
Education predisposes an individual to use healthcare 
services [289]. 
AHRF 2010 
State-level      
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Medicaid managed care 
enrollment. 
Ordinal (tertiles) The percent of Medicaid beneficiaries 
enrolled in managed care. 
Beneficiaries in managed care are more likely to receive 
preventive care [353], like anal cancer screening.  
KFF 2012 
Abbreviations: MAX, Medicaid Analytic eXtract file; AHRF, AHRF Area Health Resources File; KFF, Kaiser Family Foundation. *AIDSVu, maintained by 
Emory University, consists of county-level surveillance data on diagnosed HIV cases in the US [304]. †AHRF is maintained by the Health Resource 
Service Administration [301]. 
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Appendix C2: Identifying high-risk women from a sample of women living with HIV 
To identify high-risk women among those with HIV, we used diagnosis codes for abnormal 
cervical tests or genital warts [307], [308]. We searched Google for commonly used ICD-9 codes 
for abnormal cervical tests or genital warts which we validated using the literature and expert 
opinions. For abnormal cervical tests, codes traditionally used for abnormal cervical Pap smears 
or cervical intraepithelial neoplasia were the main codes [354]–[357], table C2. However, other 
codes such as 795.01 (Papanicolaou smear of cervix with atypical squamous cells of 
undetermined significance) were also included to account for coding errors or misdiagnoses. The 
supplementary codes in table C2 were used in sensitivity analysis only. For genital warts, while 
ICD-9 code 078.11 is specific to genital warts, two codes are also commonly used: 078.10 for 
unspecified viral warts and 078.19 for other specified viral warts [358]. The supplementary 
codes were used in sensitivity analyses only. We did not restrict the ICD-9 code to a specific 
position. 
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Table C2: Codes for identifying women with HIV at high-risk for acquiring anal cancer 
Identifying women living with HIV* 
ICD-9 Code Description 
042 AIDS diagnosis 
V08 HIV diagnosis 
Abnormal cervical Pap test/cervical intraepithelial neoplasia 
ICD-9 Code (Main)† Description 
795.02 Papanicolaou smear of cervix with atypical squamous cells cannot exclude high grade squamous 
intraepithelial lesion (ASC-H) 
795.03 Papanicolaou smear of cervix with low grade squamous intraepithelial lesion (LGSIL) 
795.04 Papanicolaou smear of cervix with high grade squamous intraepithelial lesion (HGSIL) 
795.05 Cervical high-risk human papillomavirus (HPV) DNA test positive 
795.06 Papanicolaou smear of cervix with cytologic evidence of malignancy 
622.10 Dysplasia of cervix, unspecified 
622.11 Mild dysplasia of the cervix 
622.12 Moderate dysplasia of the cervix 
233.1 Carcinoma in situ of cervix uteri 
233.32 Carcinoma in situ vulva 
V13.22 History of cervical dysplasia 
ICD-9 Code 
(Supplementary)‡ 
Description 
622.1 Dysplasia of cervix, uteri 
623 Dysplasia of vagina 
79.4 HPV infection, unspecified site 
795.00 Abnormal glandular Papanicolaou smear of cervix 
795.01 Papanicolaou smear of cervix with atypical squamous cells of undetermined significance (ASC-
US) 
795.07 Satisfactory cervical smear but lacking transformation zone 
795.08 Unsatisfactory cervical cytology smear 
795.09 Other abnormal Pap smear of cervix and cervical HPV 
History of genital warts 
ICD-9 Code (Main) Description 
078.11 Condyloma acuminatum 
078.10 Viral warts, unspecified 
078.19 Other specified viral warts 
ICD-9 Code 
(Supplementary)‡ 
Description 
078.12 Plantar warts 
Abbreviations: ICD-9, International Classification of Diseases, Ninth Revision. *ICD-9 codes V01.79 (exposure to HIV 
virus) and 795.71 (nonspecific serologic evidence of HIV) were not included in identifying women with HIV because 
these codes do not confirm HIV disease. †These are the main codes for this diagnosis but added supplementary codes to 
account for coding errors. ‡ The supplementary codes were used in sensitivity analysis only. 
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Figure C2: Algorithm for identifying high-risk HIV-infected women from Medicaid Analytic eXtract (MAX) files  
This figure shows the process of deriving a sample of women at high-risk for acquiring anal cancer from a sample of women enrolled in 
Medicaid and validated to be living with HIV. The analytic sample comprised 6,086 of whom 5,977 had a history of abnormal cervical 
tests, 889 had a history of genital warts, and 1,051 had histories of both abnormal cervical tests and genital warts.  
Exclusions
Sample of high risk non-elderly women living with HIV 
N=7,917
Analytic sample of high-risk non-elderly women living 
with HIV continuously enrolled for at least 24 months 
N=6,086
History of genital warts 
N=889
Sample of people living with HIV
N=71,090
1. Not high-risk for anal cancer (without histories of  
abnormal cervical test or genital warts); N=25,751
2. Maximum date for a high-risk diagnosis less than 
minimum date of HIV-associated ICD-9 code; N=638
3. Diagnosed high-risk on the last service date, N=12
Sample of  non-elderly women living with HIV
N=34,318
1. Males; N=34,560
2. Unknown sex=583
3. Women 19 years ≤ age ≤  64 years, N=87
4. Eligible for Medicare and Medicaid. N=1,549
1. Not continuously enrolled for ≥24 months; N=1,831
History of abnormal cervical tests 
N=5,977
History of both abnormal cervical 
tests and of genital warts 
N=1,051
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Appendix C3: Identifying high-risk women screened for anal cancer 
To identify high-risk women screened for anal cancer, we used CPT codes that suggest that an 
anal cancer screen was performed, table C3. Unlike similar services such as cervical cancer 
screening, there is no single CPT code for anal cancer screening [309], [310], [312]. For 
example, CPT code 88104 “fluid requiring simple smear preparation” suggests that anal cancer 
screening was performed using a Pap smear. We searched Google, Google Scholar, and PubMed 
for commonly used CPT codes that suggest anal cancer screening was performed. Examples of 
terms used include “CPT code” used in combination with “anal cytology” or “anal cancer 
screen” or “high-resolution anoscopy”. 
  
  
179 
 
Table C3: CPT codes for anal cancer screening 
Anal cytology 
CPT* code Description 
87207 Stain for inclusion bodies 
88104 Fluid requiring simple smear preparation 
88108 Fluid requiring concentration technique 
88112 Fluid requiring thin layer preparation 
88160 Smear prepared by the client 
88161 Smear requiring preparation 
88162 Multiple smears (5 or more) requiring extended study 
88172 Determination of adequacy of specimen 
88173 FNA (fine needle aspiration) interpretation 
88305 Fluid requiring cell block preparation 
Anoscopy 
CPT code  
46600 Anoscopy, with or without collecting a specimen 
46601 Anoscopy; diagnostic, with high-resolution magnification (HRA) 
46606 Anoscopy with multiple biopsy specimens 
46607 Diagnostic anoscopy and biopsy 
HCPCS code† Description 
G2078 Anoscopy, high resolution (with magnification and chemical agent enhancement) 
G6027 High-resolution anoscopy with specimen collection 
G6028 High-resolution anoscopy with biopsy 
Abbreviations: CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System. 
*CPT codes are used to report medical, surgical and diagnostic procedures rendered by physicians and other 
healthcare professionals. †HCPCS codes are in two levels. Level 1 comprises CPT codes while level 2 is for 
supplies, medications, and services provided to patients outside the physician's office and not included in the 
CPT code.  
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Appendix C4: Ascertaining whether a result of an anal cancer screen was abnormal 
To ascertain whether the outcome of the anal cancer screen was abnormal, we used ICD-9 codes 
suggesting that an abnormal result was found during the screening. If an enrollee received the 
screening but none of the codes we found were recorded, we assumed that abnormal or 
suspicious anal cells were not found. We searched Google, Google Scholar, and PubMed for the 
ICD-9 codes. For the search, we used the terms “ICD-9 or in combination with “anal squamous 
intraepithelial lesion” or “dysplasia of anus” or “anal intraepithelial neoplasia”, among other 
terms.   
Table C4: ICD-9 codes for identifying women with abnormal results after anal cancer screening 
ICD-9 Code Description 
796.70 Abnormal glandular Papanicolaou smear of anus 
796.71 Papanicolaou smear of anus with atypical squamous cells of undetermined significance 
(ASC-US) 
796.72 Papanicolaou smear of anus with atypical squamous cells cannot exclude high grade 
squamous intraepithelial lesion (ASC-H) 
796.73 Papanicolaou smear of anus with low grade squamous intraepithelial lesion (LGSIL) 
796.74 Papanicolaou smear of anus with high grade squamous intraepithelial lesion (HGSIL) 
796.75 Anal high-risk human papillomavirus (HPV) DNA test positive 
796.76 Papanicolaou smear of anus with cytologic evidence of malignancy 
796.77 Satisfactory anal smear but lacking transformation zone 
796.78 Unsatisfactory anal cytology smear 
796.79 Other abnormal Papanicolaou smear of the anus and anal HPV 
569.44 Dysplasia of anus (mild, moderate, AINI and II) 
230.5 Carcinoma in situ of the anal canal 
230.6 Carcinoma in situ of anus, unspecified 
211.4 Benign neoplasm of rectum and anal canal 
569.49 Other specified disorders of rectum and anus 
Abbreviation: ICD-9, International Classification of Diseases, Ninth Revision. 
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Stata do file 
///Analysis of initial anal cancer screening 
cd /mnt/isilon/data/hpr/yang/HIV/STEVEN/DATA/CLAIM/Working_folder/Stata/ 
 
log using summaries, replace 
 
set more off 
 
use hiv+_hirsk_patient_analysis, clear 
 
 
*examining the characteristics of those enrolled for two years and those who 
were not 
tab continuously_2yr riskgroup, chi exp row 
tab continuously_2yr race, chi exp row 
tab continuously_2yr scrnd_for_AC, chi exp row 
tab race scrnd_for_AC if continuously_2yr==0, chi exp row 
tab race scrnd_secondtime if continuously_2yr==0, chi exp row 
 
 
*keeping only those enrolled for at least two years 
tab continuously_2yr, m 
keep if continuously_2yr==1 
 
*checking the association between routine care and anal cancer screening 
tab routinecare 
tab routinecare scrnd_for_AC, chi 
tab routinecare scrnd_for_AC, col 
tab routinecare scrnd_for_AC, col row 
 
*setting the font 
graph set window fontface "Times New Roman" 
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*********** 
*Initial anal cancer screening 
 
**understanding the data 
 
*tsetting the data 
stset time_exit1, origin(time_entry1) failure(scrnd_for_AC ==1) id(msis_id) 
scale(30) 
 
tab _d, m 
*tab _d scrnd_for_AC, m 
gsort- _d 
order scrnd_for_AC srvc_bgn_dt srvc_end_dt time* date_first_hirsk _d 
srvc_date_first srvc_date_last 
 
 
*describing the data 
stdescribe 
 
forval i=1/3 { 
stdescribe if riskgroup==`i' 
} 
 
forval i=1/4 { 
stdescribe if race==`i' 
} 
 
*summarizing the data 
stsum, by(riskgroup) 
stsum, by(race) 
stsum, by(riskgroup race) 
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*checking if any of the variables are timevarying 
stvary 
 
 
*using the log-rank and unadjusted cox model to check variables for inclusion 
/// 
*usually if p value >.2, the variable should not be included 
*log rank test is for categorical variables, while Cox is for continuous one 
*log rank 
foreach var of varlist riskgroup race eligibility { 
sts test `var' 
}  
* Cox 
stcox age 
stcox enrollment 
 
***summary statistics 
summarize  enrollment age  
 
*Oneway ANOVA 
oneway age riskgroup, tab 
oneway enrollment riskgroup, tab 
 
 
*kruskall Wallis test, by risk group 
tabstat enrollment age, by(riskgroup) stats(p50 iqr) 
kwallis enrollment, by(riskgroup) 
kwallis age, by(riskgroup) 
 
 
foreach var of varlist scrnd_for_AC scrnd_secondtime abnanal race eligibility 
continuously_3 continuously_4 { 
tab `var' riskgroup, chi 
  
184 
 
} 
 
*ranksum tests 
median age, by (riskgroup) 
** 
**table 2 of descriptives (by race) 
*kruskall Wallis test, by race 
tabstat enrollment age, by(race) stats(p50 iqr) 
kwallis enrollment, by(race) 
kwallis age, by(race) 
 
oneway age race, tab 
oneway enrollment race, tab 
 
 
foreach var of varlist scrnd_for_AC scrnd_secondtime abnanal riskgroup 
eligibility continuously_3 continuously_4 { 
tab `var' race, chi 
} 
**the bivariate analyses  
*the bivariate analyses will be only among those continuously enrolled for at 
least 24 months 
 
*table 3: bivariate analyses 
foreach var of varlist riskgroup race continuously_3 continuously_4 { 
stsum, by(`var') 
stci, by(`var') 
stci, rmean by(`var') 
sts test `var' 
} 
 
*drawing Kaplan-Meier graphs: interest is in failure (success) and not 
survival 
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sts graph, gwood failure risktable(, color(black) size(2.5) order(1 "All 
women")  title("Risk table", size(3.0))) /// 
yline(0.5, lwidth(0.002) lcolor(black) lpattern(-)) ylab(, labsize(2.5)) 
xline(13.6, lwidth(0.002) lcolor(black) lpattern(-)) /// 
xtitle("Analysis time (months)", size(3.0)) ytitle("% screened for anal 
cancer", size(3.0) height(7)) xlabel(,labsize(3.0)) /// 
xlabel(0 (12) 48) /// 
graphregion(fcolor(white)) /// 
legend(rows(1) label(1 "(95% C.I.") label(2 "Screening function") size(2.5) 
order(2 "Screening function" 1 "95% C.I.")) /// 
title("Figure 1: Kaplan-Meier (KM) estimates of initial anal cancer screening 
rates", size(3) color(black)) /// 
graphregion(color(white))  
graph save all_women, replace 
 
*by riskgroup but I start by estimating unadjusted relative risks to see if 
separate failure (sucess) curves are warranted 
glm scrnd_for_AC i.riskgroup, fam(bin) link(log) eform /*shows that separate 
success curves are warranted*/ 
stcox i.riskgroup 
 
sts graph, failure by(riskgroup) risktable(, color(black) size(2.5) order(1 
"Warts only" 2 "Abn. cerv only" 3 "Both")  title("Risk table", size(3.0))) 
/// 
yline(0.5, lwidth(0.002) lcolor(black) lpattern(-)) ylab(, labsize(2.5)) /// 
xline(4.2 14.8 43.9, lwidth(0.002) lcolor(black) lpattern(-)) /// 
legend(rows(1) subtitle("Risk group", size(3.0)) label(1 "Warts only") 
label(2 "Abn. cerv only") label(3 "Both") size(2.5)) /// 
xtitle("Analysis time (months)", size(3.0)) ytitle("% screened for anal 
cancer", size(3.0) height(7)) xlabel(,labsize(3.0)) /// 
graphregion(fcolor(white)) /// 
xlabel(0 (12) 48) /// 
plot1opts(lpattern(longdash_dot) lcolor(blue)) /// 
plot2opts(lpattern(dash) lcolor(maroon)) /// 
plot3opts(lpattern(dash_dot) lcolor(green)) /// 
caption("Abnormal cervical: HR=1.48, 95% C.I.=1.30-1.69; Both: HR=2.28, 95% 
C.I.=1.97-2.63", size(3.0)) /// 
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title("Figure 1: KM estimates of initial anal cancer screening rates" "after 
a high-risk diagnosis, by risk group", size(3.0) color(black)) /// 
graphregion(color(white))  
graph save byriskgroup_kaplan, replace 
 
*estimating baseline hazards (read about this on page 142 and 143 of intro to 
survival analysis using stata) 
stcox i.riskgroup i.race i.eligibility log_enrol age number_pcp specialists 
proportion_college med_hh_inc countycases 
 
*stcurve, hazard at(riskgroup=1) at(riskgroup=2) at(riskgroup=3) 
kernel(gaussian) width(4) noboundary  
 
stcurve, cumhaz at(riskgroup=1) at(riskgroup=2) at(riskgroup=3) ///  
legend(rows(1) subtitle("Risk group", size(3.0)) label(1 "Warts only") 
label(2 "Abn. cerv only") label(3 "Both") size(2.5)) /// 
xtitle("Analysis time (months)", size(3.0)) ytitle("Cumulative risk (hazard) 
of anal cancer screening", size(2.5) height(7)) xlabel(,labsize(3.0)) /// 
clpattern(longdash dash longdash_dot) clcolor(blue maroon green) /// 
xlabel(0 (12) 48) /// 
caption("Abnormal cervical: HR=1.51, 95% C.I.=1.32-1.72; Both: HR=2.48, 95% 
C.I.=2.15-2.87", size(2.8)) /// 
title("Figure 2: Adjusted risk of initial anal cancer screening (CPH)" "after 
a high-risk diagnosis, by risk group", size(3.5) color(black)) /// 
graphregion(color(white)) 
graph save byriskgroup_CPH, replace 
 
*by race 
glm scrnd_for_AC i.race, fam(bin) link(log) eform /*shows that separate 
success curves are not warranted*/ 
stcox i.race 
stcox i.riskgroup i.race i.eligibility log_enrol age number_pcp specialists 
proportion_college med_hh_inc countycases 
 
*unadjusted (KM) 
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sts graph, failure by(race) risktable(, color(black) size(2.5) order(1 
"Whites" 2 "Blacks" 3 "Hispanics" 4 "Others")  title("Risk table", 
size(3.0))) /// 
yline(0.5, lwidth(0.002) lcolor(black) lpattern(-)) ylab(, labsize(2.5)) 
xline(6.3 8.2 8.5, lwidth(0.002) lcolor(black) lpattern(-)) /// 
legend(rows(1) subtitle("Race/ethnicity", size(3.0)) label(1 "Whites") 
label(2 "Blacks") label(3 "Hispanics") label(4 "Others")size(2.5)) /// 
xtitle("Analysis time (months)", size(3.0)) ytitle("% screened for anal 
cancer", size(3.0) height(7)) xlabel(,labsize(3.0)) /// 
xlabel(0 (12) 48) /// 
graphregion(fcolor(white)) /// 
caption("Blacks: HR=0.95, 95% C.I.=0.87-1.04; Hispanics: HR=0.89, 95% 
C.I.=0.76-1.04 Others: HR=0.45, 95% C.I.=0.41-0.51", size(2.2)) /// 
title("Figure 2: KM estimates of initial anal cancer screening rates, by 
race", size(3) color(black)) /// 
plot1opts(lpattern(longdash_dot) lcolor(blue)) /// 
plot2opts(lpattern(dash) lcolor(maroon)) /// 
plot3opts(lpattern(dash_dot) lcolor(green)) /// 
plot4opts(lpattern(longdash) lcolor(black)) /// 
graphregion(color(white)) 
graph save byrace_kaplan, replace 
 
*adjusted (CPH) 
stcurve, cumhaz at(race=1) at(race=2) at(race=3) at(race=4) /// 
legend(rows(1) subtitle("Race/ethnicity", size(3.0)) label(1 "Whites") 
label(2 "Blacks") label(3 "Hispanics") label(4 "Others")size(2.5)) /// 
xtitle("Analysis time (months)", size(3.0)) ytitle("Cumulative risk (hazard) 
of anal cancer screening", size(2.5) height(7)) xlabel(,labsize(3.0)) /// 
xlabel(0 (12) 48) /// 
clpattern(longdash_dot dash dash_dot longdash) clcolor(blue maroon green 
black) /// 
caption("Blacks: HR=0.97, 95% C.I.=0.88-1.06; Hispanics: HR=0.84, 95% 
C.I.=0.72-0.99; Others: HR=0.65, 95% C.I.=0.57-0.73", size(2.2)) /// 
title("Figure 7: CPH adjusted risk of anal cancer screening, by 
race/ethnicity", size(3.5) color(black)) /// 
graphregion(color(white)) 
graph save byrace_CPH, replace 
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stci, rmean by(riskgroup) 
stci, emean by(riskgroup) 
stci, p(20) by(riskgroup) 
stci, by(riskgroup) 
stci, by(riskgroup abnanal) 
stci, emean by(riskgroup) /*gives the extended mean*/ 
 
stci,  emean graph 
stci,  emean tmax(100) graph 
 
 
*estimating the hazard function using the adjusted Cox PH model 
stcox i.riskgroup i.race i.eligibility enrollment age 
 
*finding the correct functional form 
predict mg, mgale 
lowess mg age /*no major concerns here*/ 
lowess mg enrollment /*no major concerns here*/ 
drop mg 
 
 
******overall hazards 
stcox i.riskgroup i.race i.eligibility log_enrol age number_pcp specialists 
proportion_college med_hh_inc countycases 
estimates store overall 
 
esttab overall using overall.rtf, nogaps wide eform b se  aic bic replace  
nonum label 
 
**hazards at different time periods 
*estimating hazard rates at different time intervals 
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log using summaries1, replace 
stptime,  by(riskgroup) at (1 6 12 24 48) 
stptime,  by(race) at (1 6 12 24 48) 
stsplit time, at(1 6 12 24) 
stcox i.riskgroup i.race eligibility age log_enrol  number_pcp specialists 
med_hh_inc proportion_college countycases 
bysort time: stcox i.riskgroup i.race eligibility age log_enrol  number_pcp 
specialists med_hh_inc proportion_college countycases 
drop time 
log2html summaries1, replace 
 
 
*estimating the cumulative baseline hazard 
stcox i.riskgroup i.race i.eligibility log_enrol age 
predict H0, basechazard 
line H0 _t, c(J) sort 
label variable H0 "Warts only" 
label variable _t "Analysis time (months)" 
  
*getting the baseline hazard for each risk group 
gen H2=H0*(exp(_b[2.riskgroup])) 
label variable H2 "Abnormal cervical only" 
 
gen H3=H0*(exp(_b[3.riskgroup])) 
label variable H3 "Both warts and abnormal cervical"  
 
line H0 H2 H3 _t, c(J J J) sort /// 
legend(rows(1) size(2.0)) /// 
xtitle(, size(3.0)) ytitle("Cumulative risk (hazard) of anal cancer 
screening", size(2.5) height(7)) xlabel(,labsize(3.0)) /// 
title("Figure 5: Adjusted risk of anal cancer screening", size(3.5) 
color(black)) 
 
drop H0 H2 H3 
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*stcurve, cif at(riskgroup=1) at(riskgroup=2) at(riskgroup=3)  
 
/*survivor functions (these might not be needed) 
predict S0, basesurv 
line S0 _t, c(J) sort 
 
gen S2=S0*exp(_b[2.riskgroup]) 
gen S3=S0*exp(_b[3.riskgroup]) 
line H0 H2 H3 S0 S2 S3 _t, c(J J J J J J) sort 
*/ 
 
*testing the PH assumption  
 
*Global test for all and each variable after Cox regression 
stphtest, rank detail 
 
 
*graphs for each variable 
stphtest, plot(age) /// 
title("Age", position(12) ring(0) size(3.5) color(black)) /// 
xtitle("Analysis time (months)", height(4) size(2.8) ) /// 
xlabel(0 (12) 48) /// 
ytitle(, height(7) size(2.8)) /// 
graphregion(color(white)) /// 
note("")  
graph save age_ph.gph, replace 
 
stphtest, plot(log_enrol) /// 
title("Enrollment", position(12) ring(0) size(3.5) color(black)) /// 
xtitle("Analysis time (months)", height(4) size(2.8)) /// 
xlabel(0 (12) 48) /// 
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ytitle("scaled Schoenfeld - enrollment", height(7) size(2.8)) /// 
graphregion(color(white)) /// 
note("")  
graph save enrollment_ph.gph, replace 
 
stphplot, by(riskgroup) /// 
title("Risk group", position(12) ring(0) size(3.5) color(black)) /// 
ytitle(, height(7) size(2.8)) /// 
xtitle(, height(4) size(2.8)) /// 
plot1opts(lwidth(thin) msize(vsmall)) /// 
plot2opts(lwidth(thin) msize(vsmall)) /// 
plot3opts(lwidth(thin) msize(vsmall)) /// 
graphregion(color(white)) /// 
legend(off) 
graph save riskgroup_ph.gph, replace 
 
stphplot, by(race) /// 
title("Race/ethnicity", position(12) ring(0) size(3.5) color(black)) /// 
ytitle(, height(7) size(2.8)) /// 
xtitle(, height(4) size(2.8)) /// 
plot1opts(lwidth(thin) msize(vsmall)) /// 
plot2opts(lwidth(thin) msize(vsmall)) /// 
plot3opts(lwidth(thin) msize(vsmall)) /// 
plot4opts(lwidth(thin) msize(vsmall)) /// 
graphregion(color(white)) /// 
legend(off) 
graph save race_ph.gph, replace 
 
graph combine riskgroup_ph.gph race_ph.gph age_ph.gph enrollment_ph.gph, 
title("Figure 5: Test of PH assumption", size(4.0) color(black)) /// 
graphregion(color(white)) 
graph save combined_ph.gph, replace 
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****** 
*testing overall fitness of the model 
*Cox-snell residuals  
*note that without the mgale option the results would be different 
set more off 
 
*before transforming enrollment 
stcox i.riskgroup i.race i.eligibility enrol age, mgale(mg) 
 
predict cs, csnell 
stset cs, failure(scrnd_for_AC ==1) 
sts generate H = na 
line H cs cs, sort xlab(0 1 to 4) ylab(0 1 to 4) /// 
title("Figure 7a: Overall model fitness using Cox-snell residuals" /// 
"Before variable transformation", linegap(2) size(3.5) color(black)) /// 
graphregion(color(white)) 
graph save gof_ph.gph, replace 
drop mg cs H 
 
*after transforming enrollment 
 
stcox i.riskgroup i.race i.eligibility log_enrol age, mgale(mg) 
 
predict cs, csnell 
stset cs, failure(scrnd_for_AC ==1) 
sts generate H = na 
line H cs cs, sort xlab(0 1 to 4) ylab(0 1 to 4) /// 
title("Figure 7b: Overall model fitness using Cox-snell residuals" /// 
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"After variable transformation (final model)", linegap(2) size(3.5) 
color(black)) /// 
graphregion(color(white)) 
graph save gof1_ph.gph, replace 
 
 
stcox i.riskgroup i.race ib5.eligibility age enrollmnent, mgale(mg) 
 
stcox i.riskgroup i.race ib5.eligibility age log_enrol, mgale(mg) 
predict cs, csnell 
stset cs, failure(scrnd_for_AC ==1) 
sts generate H = na 
line H cs cs, sort xlab(0 1 to 4) ylab(0 1 to 4) /// 
title("Figure 7: Overall model fitness using Cox-snell residuals", size(3.5) 
color(black)) 
drop mg cs H 
*******LOGISTIC REGRESSIONS: EXAMINING GUIDELINE CONCORDANCE OF FOLLOW-UP 
SCREENING**** 
cd /mnt/isilon/data/hpr/yang/HIV/STEVEN/DATA/CLAIM/Working_folder/Stata/ 
 
use for_logistic_regressions, clear 
 
*tsetting the data 
stset time_exit2, scale(30) origin(time_entry2) failure(scrnd_secondtime==1) 
id(msis_id) 
order _t _st 
tab _st 
keep if _st==1 
 
*testing the normality/skewness of time 
mvtest normal _t, univariate 
 
****MAIN ANALYSIS**** 
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**creating some variables 
*any follow-up screening 
tab scrnd_secondtime 
 
gen any_fup_screen=scrnd_secondtime 
label define any_fup_screen 0 "Not screened" 1 "Screened", replace 
label values any_fup_screen any_fup_screen 
tab any_fup_screen scrnd_secondtime 
 
*concordance 
gen concordant=. 
replace concordant=1 if abnanal==0 & _t<=12 &  scrnd_secondtime==1 | 
abnanal==1 & _t<=6 & scrnd_secondtime==1 
replace concordant=0 if concordant==.   
label define concordant 1 "Concordant" 0 "Not concordant", replace 
labe values concordant concordant 
order abnanal _t concordant 
tab concordant abnanal, col chi exp 
tab concordant riskgroup, col chi exp 
tab concordant race, col chi exp 
 
*Categorical age variable 
gen age_cat=. 
replace age_cat=1 if age<=34 
replace age_cat=2 if age>34 & age<=44 
replace age_cat=3 if age>44 & age<=54 
replace age_cat=4 if age>54 
label define age_cat 1 "19-34 years" 2 "35-44 years" 3 "45-54 years" 4 "55-64 
years", replace 
label values age_cat age_cat 
tab age_cat 
oneway age riskfactor, bonferroni tab 
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*enrollment_variable, categorical 
gen continuous_enrollment=continuously_1yr + continuously_2yr + 
continuously_3yr +continuously_4yr 
label define continuous_enrollment 2 "2 years" 3 "3 years" 4 "4 years", 
replace 
label values continuous_enrollment continuous_enrollment 
tab continuous_enrollment 
tab concordant continuous_enrollment, chi exp row col 
 
*summary statistics 
tab abnanal riskfactor, chi 
tab scrnd_secondtime riskfactor, chi 
tab concordant riskfactor   
tab concordant riskfactor  if abnanal==1, chi 
tab concordant riskfactor  if abnanal==0, chi 
tab race riskfactor, chi 
tab eligibility riskfactor, chi 
tab continuous_enrollment riskfactor, chi  
stsum, by(riskfactor) 
stptime,  by(riskfactor) 
 
*working with MCO enrollment variable 
gen mco=. 
replace mco=1 if mco_enrollment <=0.6 
replace mco=2 if mco_enrollment >0.6 & mco_enrollment<=0.8 
replace mco=3 if mco_enrollment >0.8 & mco_enrollment<=1 
label define mco 1 "<=60%" 2 "61%-80%" 3 ">80%", replace 
label values mco mco 
tab mco 
 
*creating numeric state variable 
encode state, gen(state_num) 
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*Any follow up screening 
 
*without state fixed-effects 
logit any_fup_screen  i.riskgroup i.abnanal i.eligibility 
i.continuous_enrollment i.age_cat i.race i.HIVrate_tert i.pcp_tert 
i.spec_tert i.poverty i.less_than_HS i.mco , noconst or  
estimates store anyfup_no_fe 
 
*with state-fixed effects 
logit any_fup_screen  i.riskgroup i.abnanal i.eligibility 
i.continuous_enrollment i.age_cat i.race i.HIVrate_tert i.pcp_tert 
i.spec_tert i.poverty i.less_than_HS i.mco  i.state_num , noconst or  
estimates store anyfup_with_fe 
 
 
**guideline concordance  
*without state fixed-effects 
logit concordant  i.riskgroup i.abnanal i.eligibility i.continuous_enrollment 
i.age_cat i.race i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty 
i.less_than_HS i.mco  , or nocons 
estimates store concordant_no_fe 
 
*with state-fixed effects 
logit concordant  i.riskgroup i.abnanal i.eligibility i.continuous_enrollment 
i.age_cat i.race i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty 
i.less_than_HS i.mco  i.state_num , or nocons 
estimates store concordant_with_fe 
 
margins abnanal 
margins, at(riskgroup=(1 2) abnanal=(0 1)) post 
margins abnanal 
 
esttab concordant_with_fe anyfup_with_fe using logits.rtf, nogaps wide eform 
b(2) ci(2) label replace  nonum star(* 0.10 ** 0.05 *** 0.01) ///  
  collabels("Odds Ratio" "95% Confidence Interval" "Odds Ratio" 
"95% Confidence Interval") /// 
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  mtitle("Guideline-concordant follow-up anal cancer screening" 
"Any follow-up anal cancer screening") /// 
        title( "Table 1: Predictors of guideline-concordant follow-up anal 
cancer screening in high-risk women living with HIV") /// 
  refcat(2.riskgroup "Risk factors (ref: one risk factor)" 
1.abnanal "Result at first test (ref: normal)" /// 
  2.race "Race/ethnicity (ref: non-Hispanic whites)" 2.eligibility 
"Qualification for Medicaid (ref: income)" /// 
  3.continuous_enrollment "Continuous enrollment (ref: 2 years)" 
2.pcp_tert "Physician 10,000 population (ref: 0-3.7)" /// 
  2.spec_tert "Specialists per 10,000 population (ref:0-0.92)" 
2.less_than_HS "Less than high school (ref: 1%-11.4%)" /// 
  2.poverty "Percent poor (ref:0.9%-13.5%)" 2.HIVrate_tert "HIV 
prevalence per 100,000 adults (ref: 0-54)" /// 
  2.mco "Medicaid managed care enrollment (ref: <=60%)" 2.age_cat 
"Age (ref:19-34 years)", nolabel) /// 
  drop (1.riskgroup 0.abnanal 1.race 1.eligibility 
2.continuous_enrollment 1.pcp_tert 1.spec_tert 1.less_than_HS /// 
  1.poverty 1.HIVrate_tert 1.mco 1.age_cat *state_num) 
   
 
*checking for multicollinearity 
collin riskgroup abnanal race eligibility continuous_enrollment age 
number_pcp specialists proportion_college med_hh_inc countycases state_n 
 
**goodness of fit measures  
logit concordant  i.riskgroup i.abnanal i.race i.eligibility 
i.continuous_enrollment age number_pcp specialists proportion_college 
med_hh_inc countycases, or  
 
*Hosmer lemeshow 
estat gof, group(10) 
lfit, group(20) 
 
*predicted probabilities 
predict probability , pr 
gen conc_pred=0 
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replace conc_pred=1 if probability>=0.5 
tab concordant conc_pred, row chi 
 
*plotting residuals 
gen n=_n 
predict residuals, deviance 
sum residual 
gen county_n=countyname if residuals>2 & residuals<10 
gen county_m=countyname if residuals<-2 
label var n "Observation number" 
twoway (scatter residuals n if concordant==1 , mlabel(county_n) mlabsize(2)) 
(scatter residuals n if !concordant, mlabel(county_m) mlabsize(2)), /// 
 yline(-2 2) legend(off) text(1.9 1000 "Concordant") text(0 1000 "Not 
concordant")  /// 
 title("Fig 1: Goodness-of-fit test using deviance residuals", size(4)) 
/// 
 ytitle("Deviance residuals") 
count if county_n!="" | county_m!=""  
  
drop probability conc_pred residuals county_n county_m  
 
 
tab  conc_pred concordant, chi 
roctab  concordant conc_pred, detail table    
 
/////SENSITIVITY ANALYSIS 
//sensitivity analysis 2 
*continuously enrolled for 4 years 
 
sts list if continuously_4yr==1, failure by(abnanal) at (6 12) 
 
sts list if continuously_4yr==1, failure by( riskgroup abnanal) at (6 12) 
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logit concordant  i.riskgroup i.abnanal i.eligibility i.age_cat i.race 
i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty i.less_than_HS i.mco  
i.state_num, or nocons 
estimates store two_years_main 
logit concordant  i.riskgroup i.abnanal i.eligibility i.age_cat i.race 
i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty i.less_than_HS i.mco  
i.state_num if continuously_4yr==1, or nocons 
estimates store four_years 
 
esttab two_years_main four_years, nogaps wide eform b(2) ci(2) label replace  
nonum star(* 0.10 ** 0.05 *** 0.01) ///  
  collabels("Odds Ratio" "95% Confidence Interval" "Odds Ratio" 
"95% Confidence Interval") /// 
  mtitle("Guideline-concordant follow-up anal cancer screening" 
"Any follow-up anal cancer screening") /// 
        title( "Table 1: Predictors of guideline-concordant follow-up anal 
cancer screening in high-risk women living with HIV") /// 
  refcat(2.riskgroup "Risk factors (ref: one risk factor)" 
1.abnanal "Result at first test (ref: normal)" /// 
  2.race "Race/ethnicity (ref: non-Hispanic whites)" 2.eligibility 
"Qualification for Medicaid (ref: income)" /// 
  2.pcp_tert "Physician 10,000 population (ref: 0-3.7)" /// 
  2.spec_tert "Specialists per 10,000 population (ref:0-0.92)" 
2.less_than_HS "Less than high school (ref: 1%-11.4%)" /// 
  2.poverty "Percent poor (ref:0.9%-13.5%)" 2.HIVrate_tert "HIV 
prevalence per 100,000 adults (ref: 0-54)" /// 
  2.mco "Medicaid managed care enrollment (ref: <=60%)" 2.age_cat 
"Age (ref:19-34 years)", nolabel) /// 
  drop (1.riskgroup 0.abnanal 1.race 1.eligibility 1.pcp_tert 
1.spec_tert 1.less_than_HS /// 
  1.poverty 1.HIVrate_tert 1.mco 1.age_cat *state_num) 
 
 
tab  
*concordance 
drop concordant 
gen concordant=. 
  
200 
 
replace concordant=1 if abnanal==0 & _t<=14 &  scrnd_secondtime==1 | 
abnanal==1 & _t<=8 & scrnd_secondtime==1 
replace concordant=0 if concordant==.   
label define concordant 1 "Concordant" 0 "Not concordant", replace 
labe values concordant concordant 
order abnanal _t concordant 
tab concordant abnanal, col chi exp 
tab concordant riskgroup, col chi exp 
 
*without state fixed-effects 
logit concordant  i.riskgroup i.abnanal i.eligibility i.continuous_enrollment 
i.age_cat i.race i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty 
i.less_than_HS i.mco  , or  
estimates store concordant_no_fe 
 
*with state-fixed effects 
logit concordant  i.riskgroup i.abnanal i.eligibility i.continuous_enrollment 
i.age_cat i.race i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty 
i.less_than_HS i.mco  i.state_num , or  
estimates store concordant_with_fe 
margins abnanal 
margins, at(riskgroup=(1 2) abnanal=(0 1)) post 
esttab concordant_with_fe, wide eform ci 
log close 
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Chapter 5: Conclusion 
This dissertation examined the effectiveness of interventions aimed at increasing uptake of 
family planning services and HIV-related preventive care among women in low-income settings. 
The studies show that uptake of these services is low overall but find that interventions at the 
clinic or community levels are effective in increasing the uptake of these services. However, the 
studies also emphasize several areas for future research. For example, paper 1 which reports that 
contraceptive use increased among rural women following the national scale-up of CBDs in rural 
Malawi, the paper suggests that future research should focus on examining the cost-effectiveness 
of the national CBDs given that resources in these settings are very limited. The trial-based cost-
effectiveness of conditional cash transfers in the DRC suggests that future research should focus 
on examining the cost-effectiveness of the cash incentives in larger populations and over a longer 
analytic horizon before further scale-up of the intervention in sub-Saharan Africa. Similarly, 
gathering more evidence about the benefits of anal cancer screening in people living with HIV at 
high risk for anal cancer in the USA can help solidify the guidelines for anal cancer screening 
and improve the rates overall follow-up anal cancer screening. 
  
  
202 
 
References  
[1] National Statistical Office, “Malawi population datasheet,” 2012. 
[2] The World Bank, “Data: Malawi,” 2015. 
[3] M. of E. P. and D. Malawi Government, “Why population matters to Malawi’s 
development,” 2012. 
[4] J. Solo, R. Jacobstein, and D. Malema, “Malawi case study: Choice not chance,” A 
repositioning family planning case study, no. Journal Article, 2005. 
[5] B. Kalanda, “Repositioning family planning through community based distribution agents 
in Malawi,” Malawi Medical Journal, vol. 22, no. 3, 2010. 
[6] The World Bank, “Document of the World Bank. Malawi Population and Family Planning 
Project. Implementation Completion Report (IDA-31330): Report number 27059:,” 2004. 
[7] The World Bank, “Document of the World Bank: Project appraisal document on a 
proposed learning and innovation lending (credit) in the amount of SDR 3.8 million (US$5 
million equivalent) to the Government of Malawi for a population and family planning 
project. Report number: 1792-MAI,” 1998. 
[8] B. Cohen, “Family planning programs, socioeconomic characteristics, and contraceptive 
use in Malawi,” World Dev., vol. 28, no. 5, pp. 843–860, 2000. 
[9] J. Chintsanya, “Trends and Correlates of Contraceptive Use among Married Women in 
Malawi: Evidence from 2000-2010 Malawi Demographic and Health Surveys,” no. 
Journal Article, 2013. 
[10] M. Palamuleni, “Fertility decline in Malawi: an analysis of the proximate determinants,” 
Journal of social development in Africa, vol. 25, no. 1, 2010. 
[11] S. A. Adebowale, S. A. Adedini, L. D. Ibisomi, and M. E. Palamuleni, “Differential effect 
of wealth quintile on modern contraceptive use and fertility: evidence from Malawian 
women,” BMC Womens Health, vol. 14, no. 1, p. 1, 2014. 
[12] A. Brunie, T. H. Hoke, and B. Razafindravony, “Community-based distribution of 
injectable contraceptives in an African setting: community trial in Madagascar,” Sante, 
vol. 21, no. 1, pp. 21–26, 2011. 
[13] T. Hoke et al., “Community-based distribution of injectable contraceptives: introduction 
strategies in four sub-Saharan African countries,” International perspectives on sexual and 
reproductive health, vol. 38, no. 4, pp. 214–219, 2012. 
[14] C. Debpuur, J. F. Phillips, E. F. Jackson, A. Nazzar, P. Ngom, and F. N. Binka, “The 
impact of the Navrongo Project on contraceptive knowledge and use, reproductive 
preferences, and fertility,” Stud.Fam.Plann., vol. 33, no. 2, pp. 141–164, 2002. 
[15] K. R. Katz, C. G. West, F. Doumbia, and F. Kané, “Increasing access to family planning 
services in rural Mali through community-based distribution,” International Family 
Planning Perspectives, no. Journal Article, pp. 104–110, 1998. 
[16] M. Fayemi, G. Momoh, O. Oduola, G. Delano, O. Ladipo, and O. Adebola, “Community 
based distribution agents’ approach to provision of family planning information and 
services in five Nigerian States: A mirage or a reality?,” African journal of primary health 
care & family medicine, vol. 3, no. 1, 2011. 
[17] FHI 360, “Research and Utilization: Expanding the community-based distribution of 
injectable contraceptives in Africa,” 2008. 
[18] A. Jacinto et al., “Safety and Acceptability of Community-Based Distribution of Injectable 
Contraceptives: A Pilot Project in Mozambique,” Glob.Health.Sci.Pract., vol. 4, no. 3, pp. 
410–421, 2016. 
  
203 
 
[19] N. Prata, A. Gessessew, A. Cartwright, and A. Fraser, “Provision of injectable 
contraceptives in Ethiopia through community-based reproductive health agents,” 
Bull.World Health Organ., vol. 89, no. Journal Article, pp. 556–564, 2011. 
[20] Y. Tawye, F. Jotie, T. Shigu, P. Ngom, and N. Maggwa, “The potential impact of 
community-based distribution programmes on contraceptive uptake in resource-poor 
settings: evidence from Ethiopia,” Afr.J.Reprod.Health, no. Journal Article, pp. 15–26, 
2005. 
[21] J. S. White and I. S. Speizer, “Can family planning outreach bridge the urban-rural divide 
in Zambia?,” BMC health services research, vol. 7, no. 1, p. 143, 2007. 
[22] K. Krueger, A. Akol, P. Wamala, and A. Brunie, “Scaling up community provision of 
injectables through the public sector in Uganda,” Stud.Fam.Plann., vol. 42, no. 2, pp. 117–
124, 2011. 
[23] World Health Organization, Community-based distribution of contraceptives: A guide for 
programme managers. World Health Organization, 1995. 
[24] J. F. Phillips, W. L. Greene, and E. F. Jackson, Lessons from community-based 
distribution of family planning in Africa. Population Council New York, NY, USA, 1999. 
[25] J. D. Shelton, L. Bradshaw, B. Hussein, Z. Zubair, T. Drexler, and M. R. McKenna, 
“Putting unmet need to the test: community-based distribution of family planning in 
Pakistan,” International Family Planning Perspectives, no. Journal Article, pp. 191–195, 
1999. 
[26] J. B. Casterline and S. W. Sinding, “Unmet need for family planning in developing 
countries and implications for population policy,” Population and development review, 
vol. 26, no. 4, pp. 691–723, 2000. 
[27] N. Prata, F. Vahidnia, M. Potts, and I. Dries-Daffner, “Revisiting community-based 
distribution programs: are they still needed?,” Contraception, vol. 72, no. 6, pp. 402–407, 
2005. 
[28] R. J. Magnani, D. R. Hotchkiss, C. S. Florence, and L. A. Shafer, “The impact of the 
family planning supply environment on contraceptive intentions and use in Morocco,” 
Stud.Fam.Plann., vol. 30, no. 2, pp. 120–132, 1999. 
[29] J. R. Foreit, M. R. Garate, A. Brazzoduro, F. Guillen, M. del Carmen Herrera, and F. C. 
Suarez, “A comparison of the performance of male and female CBD distributors in Peru,” 
Stud.Fam.Plann., no. Journal Article, pp. 58–62, 1992. 
[30] S. L. Isaacs, “Nonphysician distribution of contraception in Latin America and the 
Caribbean,” Fam.Plann.Perspect., no. Journal Article, pp. 158–164, 1975. 
[31] A. J. Kols, M. J. Wawer, W. Quillin, and J. Kinsey, “Population reports. Community-
based health and family planning.,” Population reports.Series L, Issues in world health, 
no. 3, 1982. 
[32] J. Bongaarts and J. Bruce, “The causes of unmet need for contraception and the social 
content of services,” Stud.Fam.Plann., no. Journal Article, pp. 57–75, 1995. 
[33] N. Rutenberg and S. C. Watkins, “Conversation and contraception in Nyanza province 
Kenya.,” 1996. 
[34] D. C. Kaseje, E. K. Sempebwa, and H. C. Spencer, “Community-based distribution of 
family planning services in Saradidi, Kenya,” Annals of Tropical Medicine & 
Parasitology, vol. 81, no. sup1, pp. 135–143, 1987. 
  
204 
 
[35] Z. Charyeva et al., “Task Shifting Provision of Contraceptive Implants to Community 
Health Extension Workers: Results of Operations Research in Northern Nigeria,” 
Glob.Health.Sci.Pract., vol. 3, no. 3, pp. 382–394, 2015. 
[36] T. H. Hoke et al., “Community-based provision of injectable contraceptives in 
Madagascar: ‘task shifting’ to expand access to injectable contraceptives,” Health Policy 
Plan., vol. 27, no. 1, pp. 52–59, 2012. 
[37] M. Tanabe et al., “Community-Based Distribution of Family Planning Services in 
Humanitarian Settings: Identified Need and Potential from Malakal, South Sudan,” St 
Antony’s International Review, vol. 9, no. 2, pp. 114–132, 2014. 
[38] J. T. Bertrand, M. E. McBride, N. Mangani, N. C. Baughman, and M. Kinuani, 
“Community-based distribution of contraceptives in Zaire,” International Family 
Planning Perspectives, no. Journal Article, pp. 84–91, 1993. 
[39] D. Nyamwaya, R. Morgan, M. Lukhando, A. Fisher, and L. Ndhlovu, “Expanding family 
planning delivery systems using traditional health practitioners: An operations research 
study in rural Kenya, Final Report,” AMREF & Nairobi, Kenya: The Population Council, 
no. Journal Article, 1993. 
[40] M. F. Gallo et al., “Evaluation of a volunteer community-based health worker program for 
providing contraceptive services in Madagascar,” Contraception, vol. 88, no. 5, pp. 657–
665, 2013. 
[41] J. N. Chege and I. Askew, “An assessment of community-based family planning 
programmes in Kenya,” Nairobi: Population Council, no. Journal Article, 1997. 
[42] G. S. Becker, “An economic analysis of fertility,” in Demographic and economic change 
in developed countries, Book, Section vols., Columbia University Press, 1960, pp. 209–
240. 
[43] R. A. Easterlin, “An economic framework for fertility analysis,” Stud.Fam.Plann., vol. 6, 
no. 3, pp. 54–63, 1975. 
[44] D. S. DeGraff, R. E. Bilsborrow, and D. K. Guilkey, “Community-level determinants of 
contraceptive use in the Philippines: a structural analysis,” Demography, vol. 34, no. 3, pp. 
385–398, 1997. 
[45] A. G. Mairiga, A. A. Kullima, B. Bako, and M. A. Kolo, “Sociocultural factors 
influencing decision-making related to fertility among the Kanuri tribe of north-eastern 
Nigeria,” African journal of primary health care & family medicine, vol. 2, no. 1, 2010. 
[46] R. Mussa, “Impact of fertility on objective and subjective poverty in Malawi,” no. Journal 
Article, 2010. 
[47] S. Singh and J. E. Darroch, “Adding it up: Costs and benefits of contraceptive services,” 
Guttmacher Institute and UNFPA, no. Journal Article, 2012. 
[48] J. Bongaarts and S. W. Sinding, “A response to critics of family planning programs,” 
International Perspectives on Sexual and Reproductive Health, vol. 35, no. 1, pp. 39–44, 
2009. 
[49] E. Lule, S. Singh, and S. A. Chowdhury, “Fertility Regulation Behaviors and Their 
Costs,” Contraception and unintended pregnancies in Africa and Eastern Europe and 
Central Asia.Washington: The International Bank for Reconstruction and 
Development.The World Bank, no. Journal Article, 2007. 
[50] Ministry of Health, “Malawi National Heath Accounts with Subaccounts for HIV/AIDS, 
Malaria, Reproductive Health, and Child Health for the Years 2009/10 , 2010/11, and 
2011/12,” 2014. 
  
205 
 
[51] M. Grossman, “On the concept of health capital and the demand for health,” Journal of 
Political economy, vol. 80, no. 2, pp. 223–255, 1972. 
[52] D. S. Kenkel, “Health behavior, health knowledge, and schooling,” Journal of Political 
Economy, no. Journal Article, pp. 287–305, 1991. 
[53] S. Saleem and M. Bobak, “Women’s autonomy, education and contraception use in 
Pakistan: a national study,” Reproductive health, vol. 2, no. 1, p. 1, 2005. 
[54] C. Gordon, R. Sabates, R. Bond, and T. Wubshet, “Women’s education and modern 
contraceptive use in Ethiopia,” International Journal of Education, vol. 3, no. 1, p. 1, 
2011. 
[55] M. Ainsworth, K. Beegle, and A. Nyamete, “The impact of women’s schooling on fertility 
and contraceptive use: A study of fourteen sub-Saharan African countries,” The World 
Bank Economic Review, vol. 10, no. 1, pp. 85–122, 1996. 
[56] C. L. Ejembi, T. Dahiru, and A. A. Aliyu, “DHS WORKING PAPERS,” no. Journal 
Article, 2015. 
[57] National Statistical Office and ICF Macro, “Malawi Demographic and Health Survey 
2010,” 2011. 
[58] S. Pacqué-Margolis, C. Cox, A. Puckett, and L. Schaefer, “Exploring contraceptive use 
differentials in sub-Saharan Africa through a health workforce lens.,” no. Journal Article, 
2013. 
[59] National Statistical Office and ICF Macro, “Malawi Demographic and Health Survey 
2004,” 2005. 
[60] National Statistical Office and ICF Macro, “Malawi Demographic and Health Survey 
2015-16: Key Indicators Report.,” 2017. 
[61] National Statistical Office and ORC Macro, Malawi Demographic and Health Survey 
2000. Zomba, Malawi and Calverton, Maryland, USA: National Statistical Office, 2001. 
[62] National Statistical Office, “2008 Malawi Population and Housing Census: Main census 
report,” 2009. 
[63] S. Rabe‐Hesketh and A. Skrondal, “Multilevel modelling of complex survey data,” 
Journal of the Royal Statistical Society: Series A (Statistics in Society), vol. 169, no. 4, pp. 
805–827, 2006. 
[64] K. Jones, R. J. Johnston, and C. J. Pattie, “People, places and regions: exploring the use of 
multi-level modelling in the analysis of electoral data,” British Journal of Political 
Science, vol. 22, no. 03, pp. 343–380, 1992. 
[65] H. Goldstein, “Multilevel modelling of survey data,” Journal of the Royal Statistical 
Society.Series D (The Statistician), vol. 40, no. 2, pp. 235–244, 1991. 
[66] F. Steele, “Module 7: Multilevel Models for Binary Responses: Concepts,” LEMMA VLE, 
University of Bristol, Centre for Multilevel Modelling.Accessed September, no. Journal 
Article, 2010. 
[67] J. Rasbash, “Module 4: Multilevel structures and classifications,” 2008. 
[68] A. C. Carle, “Fitting multilevel models in complex survey data with design weights: 
Recommendations,” BMC Medical Research Methodology, vol. 9, no. 1, p. 1, 2009. 
[69] ICF International, “Description of the Demographic and Health Surveys individual recode 
data file,” 2008. 
[70] ICF International, “Demographic and Health Surveys Methodology - Questionnaires: 
Household, Man’s, and Woman’s,” 2011. 
  
206 
 
[71] J. S. Long and J. Freese, Regression models for categorical dependent variables using 
Stata. Stata press, 2006. 
[72] E. B. Kaggwa, N. Diop, and J. D. Storey, “The role of individual and community 
normative factors: a multilevel analysis of contraceptive use among women in union in 
Mali,” International family planning perspectives, no. Journal Article, pp. 79–88, 2008. 
[73] Y. Oheneba-Sakyi and B. K. Takyi, “EFFECTS OF COUPLES’CHARACTERISTICS 
ON CONTRACEPTIVE USE IN SUB-SAHARAN AFRICA: THE GHANAIAN 
EXAMPLE,” J.Biosoc.Sci., vol. 29, no. 1, pp. 33–49, 1997. 
[74] R. Stephenson, A. Baschieri, S. Clements, M. Hennink, and N. Madise, “Contextual 
influences on modern contraceptive use in sub-Saharan Africa,” Am.J.Public Health, vol. 
97, no. 7, pp. 1233–1240, 2007. 
[75] K. M. Elfstrom and R. Stephenson, “The role of place in shaping contraceptive use among 
women in Africa,” PloS one, vol. 7, no. 7, p. e40670, 2012. 
[76] T. G. Conley and C. R. Taber, “Inference with ‘difference in differences’ with a small 
number of policy changes,” Rev.Econ.Stat., vol. 93, no. 1, pp. 113–125, 2011. 
[77] W. R. Shadish, T. D. Cook, and D. T. Campbell, Experimental and quasi-experimental 
designs for generalized causal inference. Wadsworth Cengage learning, 2002. 
[78] M. Bertrand, E. Duflo, and S. Mullainathan, “How much should we trust differences-in-
differences estimates?,” The Quarterly journal of economics, vol. 119, no. 1, pp. 249–275, 
2004. 
[79] J. Wooldridge, “What’s new in econometrics? Lecture 10 difference-in-differences 
estimation,” NBER Summer Institute, available at: www.nber.org/WNE/Slides7–31–
07/slides_10_diffindiffs.pdf, accessed April, vol. 9, no. Journal Article, p. 2011, 2007. 
[80] M. A. Manda, “SITUATION OF URBANISATION IN MALAWI REPORT,” no. Journal 
Article, 2013. 
[81] The World Bank, “Malawi public expenditure review,” 2013. 
[82] H. A. Khan, “A hierarchical model of contraceptive use in urban and rural Bangladesh,” 
Contraception, vol. 55, no. 2, pp. 91–96, 1997. 
[83] J. J. Bartko, “The intraclass correlation coefficient as a measure of reliability,” 
Psychol.Rep., vol. 19, no. 1, pp. 3–11, 1966. 
[84] G. G. Koch, “Intraclass correlation coefficient,” Encyclopedia of statistical sciences, no. 
Journal Article, 1982. 
[85] D. Pfeffermann, C. J. Skinner, D. J. Holmes, H. Goldstein, and J. Rasbash, “Weighting for 
unequal selection probabilities in multilevel models,” Journal of the Royal Statistical 
Society: series B (statistical methodology), vol. 60, no. 1, pp. 23–40, 1998. 
[86] E. C. Norton, H. Wang, and C. Ai, “Computing interaction effects and standard errors in 
logit and probit models,” no. Journal Article. 
[87] P. Karaca‐Mandic, E. C. Norton, and B. Dowd, “Interaction terms in nonlinear models,” 
Health Serv.Res., vol. 47, no. 1pt1, pp. 255–274, 2012. 
[88] StataCorp, “Stata Statistical Software: Release 14,” vol. 14, no. Computer Program, 2015. 
[89] StataCorp, “Stata multilevel mixed-effects reference manual release 15,” 2017. 
[90] Stata, “Meqrlogit — Multilevel mixed-effects logistic regression (QR decomposition),” 
2014. 
[91] A. Banerjee, U. Chitnis, S. Jadhav, J. Bhawalkar, and S. Chaudhury, “Hypothesis testing, 
type I and type II errors,” Industrial psychiatry journal, vol. 18, no. 2, p. 127, 2009. 
  
207 
 
[92] M. Aitkin, D. Anderson, and J. Hinde, “Statistical modelling of data on teaching styles,” 
Journal of the Royal Statistical Society.Series A (General), no. Journal Article, pp. 419–
461, 1981. 
[93] M. A. Koenig, J. F. Phillips, R. S. Simmons, and M. A. Khan, “Trends in family size 
preferences and contraceptive use in Matlab, Bangladesh,” Stud.Fam.Plann., vol. 18, no. 
3, pp. 117–127, 1987. 
[94] M. A. Koenig, U. Rob, M. A. Khan, J. Chakraborty, and V. Fauveau, “Contraceptive use 
in Matlab, Bangladesh in 1990: levels, trends, and explanations,” Stud.Fam.Plann., vol. 
23, no. 6, pp. 352–364, 1992. 
[95] J. F. Phillips, W. S. Stinson, S. Bhatia, M. Rahman, and J. Chakraborty, “The 
demographic impact of the family planning--health services project in Matlab, 
Bangladesh,” Stud.Fam.Plann., no. Journal Article, pp. 131–140, 1982. 
[96] USAID, “Three successful Sub-Saharan Africa Family Planning Programs: Lessons for 
meeting the MDGs.,” 2012. 
[97] R. A. Abdul-hadi et al., “The effectiveness of community based distribution of injectable 
contraceptives using community health extension workers in Gombe State, Northern 
Nigeria,” Afr.J.Reprod.Health, vol. 17, no. 2, pp. 80–88, 2013. 
[98] L. Wu, Mixed effects models for complex data. CRC Press, 2009. 
[99] J. M. Zenilman et al., “Condom use to prevent incident STDs: the validity of self-reported 
condom use.,” Sex.Transm.Dis., vol. 22, no. 1, pp. 15–21, 1995. 
[100] M. Pyra et al., “Validity of self-reported hormonal contraceptive use among women with 
and at risk for HIV,” Obstet.Gynecol., vol. 217, no. 6, p. 737, 2017. 
[101] J. D. Fishel, B. Barrère, and S. Kishor, “Validity of data on self-reported HIV status and 
implications for measurement of ARV coverage in Malawi.,” no. Journal Article, 2012. 
[102] S. Becker and E. Costenbader, “Husbands’ and wives’ reports of contraceptive use,” 
Stud.Fam.Plann., no. Journal Article, pp. 111–129, 2001. 
[103] J. F. Phillips, A. A. Bawah, and F. N. Binka, “Accelerating reproductive and child health 
programme impact with community-based services: the Navrongo experiment in Ghana,” 
Bull.World Health Organ., vol. 84, no. 12, pp. 949–955, 2006. 
[104] H. I. Awadalla, “Contraception Use among Egyptian Women: Results from Egypt 
Demographic and Health Survey in 2005,” J.Reprod.Infertil, vol. 13, no. 3, pp. 167–173, 
2012. 
[105] Z. Griliches and W. M. Mason, “Education, income, and ability,” Journal of political 
Economy, vol. 80, no. 3, pp. S74–S103, 1972. 
[106] UNAIDS, “Start Free Stay Free AIDS Free — 2017 progress report,” 2018. 
[107] UNAIDS, “Fact sheet: Latest statistics on the status of the AIDS epidemic,” 2018. 
[108] A. Goga, T.-H. Dinh, and D. Jackson, Evaluation of the effectiveness of the national 
prevention of mother-to-child transmission (PMTCT) programme on infant HIV measured 
at six weeks postpartum in South Africa. South African Medical Research Council, 
National Department of Health South Africa and PEPFAR/US Centers for Disease Control 
& Prevention, 2012. 
[109] C. L. Townsend, M. Cortina-Borja, C. S. Peckham, A. de Ruiter, H. Lyall, and P. A. 
Tookey, “Low rates of mother-to-child transmission of HIV following effective pregnancy 
interventions in the United Kingdom and Ireland, 2000-2006,” AIDS, vol. 22, no. 8, pp. 
973–981, 2008. 
[110] UNAIDS, “How AIDS changed everything,” 2015. 
  
208 
 
[111] UNAIDS, “Fast-Track - Ending the AIDS epidemic by 2030,” 2014. 
[112] S. Diepeveen and C. van Stolk, “How effective are CCTs in low income settings?,” no. 
Journal Article, 2012. 
[113] F. H. Ferreira and D. A. Robalino, “Social protection in Latin America: achievements and 
limitations,” World Bank Policy Research Working Paper Series, Vol, no. Journal Article, 
2010. 
[114] A. Fizbein and N. Schady, “The economic rationale for conditional cash transfers,” 
Conditional Cash Transfers: Reducing Present and Future Poverty, no. Journal Article, 
pp. 45–66, 2009. 
[115] M. Yotebieng et al., “Conditional cash transfers and uptake of and retention in prevention 
of mother-to-child HIV transmission care: a randomised controlled trial,” The Lancet HIV, 
vol. 3, no. 2, pp. e85–e93, 2016. 
[116] F. Behets et al., “Reducing vertical HIV transmission in Kinshasa, Democratic Republic 
of Congo: trends in HIV prevalence and service delivery,” AIDS Care, vol. 21, no. 5, pp. 
583–590, 2009. 
[117] L. Bwirire et al., “Reasons for loss to follow-up among mothers registered in a prevention-
of-mother-to-child transmission program in rural Malawi,” Trans.R.Soc.Trop.Med.Hyg., 
vol. 102, no. 12, pp. 1195–1200, 2008. 
[118] A. Gourlay, I. Birdthistle, G. Mburu, K. Iorpenda, and A. Wringe, “Barriers and 
facilitating factors to the uptake of antiretroviral drugs for prevention of mother-to-child 
transmission of HIV in sub-Saharan Africa: a systematic review,” Journal of the 
International AIDS Society, vol. 16, no. 1, 2013. 
[119] M. Kirere Mathe, D. Sondag‐Thull, and P. Lepage, “Feasibility of prevention of perinatal 
HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 
2002–2004,” J.Med.Virol., vol. 80, no. 5, pp. 772–776, 2008. 
[120] UNICEF, “Options B and B+: Key considerations for countries to implement an equity-
focused approach,” 2012. 
[121] WHO, “Programmatic Update: Use of Antiretroviral Drugs for Treating Pregnant Women 
and Preventing HIV Infection in Infants,” WHO, Geneva, April, no. Journal Article, 2012. 
[122] T.-T. Edejer et al., “WHO guide to cost-effectiveness analysis,” Geneva: World Health 
Organization, no. Journal Article, 2003. 
[123] G. Hutton and R. Baltussen, “Valuation of goods in cost-effectiveness analysis: notions of 
opportunity costs and transferability across time and countries,” Geneva, World Health 
Organization.Global Programme on Evidence for Health Policy Discussion Paper 
[forthcoming], no. Journal Article, 2003. 
[124] G. Hutton and R. Baltussen, “Cost valuation in resource-poor settings,” Health Policy 
Plan., vol. 20, no. 4, pp. 252–259, 2005. 
[125] M. May, A. Boulle, S. Phiri, E. Messou, L. Myer, and R. Wood, “Prognosis of HIV-1 
infected patients starting antiretroviral therapy in sub-Saharan Africa: a collaborative 
analysis of scale-up programmes. Lancet [Internet]. 2010 Aug 7 [cited 2012 Oct 9]; 376 
(9739): 449–57,” 2010. 
[126] J. S. Stringer et al., “Rapid scale-up of antiretroviral therapy at primary care sites in 
Zambia: feasibility and early outcomes,” Jama, vol. 296, no. 7, pp. 782–793, 2006. 
[127] The World Bank, “World Bank Country and Lending Groups: Country classification,” 
2016. 
  
209 
 
[128] Clinton Health Access Initiative, “2015 Antiretroviral (ARV) CHAI reference price list,” 
2016. 
[129] The World Bank, “Price level ratio of PPP conversion factor (GDP) to market exchange 
rate,” 2017. 
[130] The World Bank, “GDP deflator: Linked series (base year varies by country),” 2017. 
[131] H. A. Glick, J. A. Doshi, S. S. Sonnad, and D. Polsky, Economic evaluation in clinical 
trials. OUP Oxford, 2014. 
[132] W. A. Ghali, C. Donaldson, and B. J. Manns, “The impact of using different costing 
methods on the results of an economic evaluation of cardiac care: microcosting vs gross‐
costing approaches,” Health Econ., vol. 18, no. 4, pp. 377–388, 2009. 
[133] M. C. Weinstein, J. E. Siegel, M. R. Gold, M. S. Kamlet, and L. B. Russell, 
“Recommendations of the Panel on Cost-effectiveness in Health and Medicine,” JAMA, 
vol. 276, no. 15, pp. 1253–1258, 1996. 
[134] J. Frappier, G. Tremblay, M. Charny, and L. M. Cloutier, “Costing bias in economic 
evaluations,” Journal of medical economics, vol. 18, no. 8, pp. 596–599, 2015. 
[135] J. E. McFayden, International drug price indicator guide. Management Sciences for 
Health, Drug Management Program, 2014. 
[136] O. Mæstad, G. Torsvik, and A. Aakvik, “Overworked? On the relationship between 
workload and health worker performance,” J.Health Econ., vol. 29, no. 5, pp. 686–698, 
2010. 
[137] A. Adesina and J. Waldron, “Incremental Cost of Providing Key Services to Prevent 
Mother-to-Child Transmission (PMTCT) of HIV in Zambia,” 2013. 
[138] V. Jain et al., “Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals 
with CD4 T-Cell Counts> 350 cells/uL in Rural Uganda,” PloS one, vol. 10, no. 12, p. 
e0143433, 2015. 
[139] H. Maheswaran et al., “Cost and quality of life analysis of HIV self-testing and facility-
based HIV testing and counselling in Blantyre, Malawi,” BMC medicine, vol. 14, no. 1, p. 
1, 2016. 
[140] L. S. Chiwaula et al., “The value of informal care in the context of option B in Malawi: a 
contingent valuation approach,” BMC health services research, vol. 16, no. 1, p. 136, 
2016. 
[141] US Department of State, “Democratic Republic of the Congo: 2016 Human Rights 
Report,” 2017. 
[142] M. Soley-Bori, Dealing with missing data: Key assumptions and methods for applied 
analysis, no. Journal Article, 2013. 
[143] S. Ramsey et al., “Good research practices for cost‐effectiveness analysis alongside 
clinical trials: the ISPOR RCT‐CEA task force report,” Value in health, vol. 8, no. 5, pp. 
521–533, 2005. 
[144] R. J. A. Little, “Missing-Data Adjustments in Large Surveys,” Journal of Business & 
Economic Statistics, vol. 6, no. 3, pp. 287–296, 1988. 
[145] T. P. Morris, I. R. White, and P. Royston, “Tuning multiple imputation by predictive mean 
matching and local residual draws,” BMC medical research methodology, vol. 14, no. 1, p. 
75, 2014. 
[146] J. A. Sterne et al., “Multiple imputation for missing data in epidemiological and clinical 
research: potential and pitfalls,” BMJ, vol. 338, no. Journal Article, p. b2393, 2009. 
  
210 
 
[147] S. K. Gupta, “Intention-to-treat concept: A review,” Perspect.Clin.Res., vol. 2, no. 3, pp. 
109–112, 2011. 
[148] M. Gomes, E. S.-W. Ng, R. Grieve, R. Nixon, J. Carpenter, and S. G. Thompson, 
“Developing appropriate methods for cost-effectiveness analysis of cluster randomized 
trials,” Medical Decision Making, vol. 32, no. 2, pp. 350–361, 2012. 
[149] J. W. (James W. Hardin, Generalized estimating equations, Second edition.. Boca Raton, 
FL : CRC Press, 2013. 
[150] S. L. Zeger, K.-Y. Liang, and P. S. Albert, “Models for longitudinal data: a generalized 
estimating equation approach,” Biometrics, no. Journal Article, pp. 1049–1060, 1988. 
[151] Z. Feng, D. McLerran, and J. Grizzle, “A comparison of statistical methods for clustered 
data analysis with Gaussian error,” Stat.Med., vol. 15, no. 16, pp. 1793–1806, 1996. 
[152] L. StataCorp, “Generalized estimating equations: xtgee.” 
[153] UCLA: Statistical Consulting Group., “How can I estimate relative risk using glm for 
common outcomes in cohort studies?” 
[154] G. Zou, “A Modified Poisson Regression Approach to Prospective Studies with Binary 
Data,” Am.J.Epidemiol., vol. 159, no. 7, pp. 702–706, 2004. 
[155] A. Chen and D. W. Dowdy, “Clinical effectiveness and cost-effectiveness of HIV pre-
exposure prophylaxis in men who have sex with men: risk calculators for real-world 
decision-making,” PLoS One, vol. 9, no. 10, p. e108742, 2014. 
[156] B. J. Adamson, J. J. Carlson, J. G. Kublin, and L. P. Garrison, “The Potential Cost-
Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United 
States,” Vaccines, vol. 5, no. 2, p. 13, 2017. 
[157] A. Laupacis, D. L. Sackett, and R. S. Roberts, “An assessment of clinically useful 
measures of the consequences of treatment,” N.Engl.J.Med., vol. 318, no. 26, pp. 1728–
1733, 1988. 
[158] R. J. Cook and D. L. Sackett, “The number needed to treat: a clinically useful measure of 
treatment effect,” BMJ, vol. 310, no. 6977, pp. 452–454, 1995. 
[159] D. Polsky and H. Glick, “Costing and cost analysis in randomized controlled trials: Caveat 
Emptor,” Pharmacoeconomics, vol. 27, no. 3, pp. 179–188, 2009. 
[160] J. A. Barber and S. G. Thompson, “Analysis of cost data in randomized trials: an 
application of the non‐ parametric bootstrap,” Stat.Med., vol. 19, no. 23, pp. 3219–3236, 
2000. 
[161] J. Cui, “QIC program and model selection in GEE analyses,” Stata journal, vol. 7, no. 2, 
p. 209, 2007. 
[162] M. A. Chaudhary and S. C. Stearns, “Estimating Confidence Intervals For Cost‐
effectiveness Ratios: An Example From A Randomized Trial,” Stat.Med., vol. 15, no. 13, 
pp. 1447–1458, 1996. 
[163] World Health Organization, “Making choices in health: WHO guide to cost-effectiveness 
analysis,” Geneva: World Health Organization, vol. 9, no. Journal Article, 2003. 
[164] E. Marseille, B. Larson, D. S. Kazi, J. G. Kahn, and S. Rosen, “Thresholds for the cost–
effectiveness of interventions: alternative approaches,” Bull.World Health Organ., vol. 93, 
no. Journal Article, pp. 118–124, 2014. 
[165] B. Woods, P. Revill, M. Sculpher, and K. Claxton, “Country-level cost-effectiveness 
thresholds: initial estimates and the need for further research,” Value in Health, vol. 19, 
no. 8, pp. 929–935, 2016. 
  
211 
 
[166] T. Loganathan, C.-W. Ng, W.-S. Lee, R. C. Hutubessy, S. Verguet, and M. Jit, 
“Thresholds for decision-making: informing the cost-effectiveness and affordability of 
rotavirus vaccines in Malaysia,” Health policy and planning, vol. 33, no. 2, pp. 204–214, 
2017. 
[167] R. Jain, M. Grabner, and E. Onukwugha, “Sensitivity analysis in cost-effectiveness 
studies,” Pharmacoeconomics, vol. 29, no. 4, pp. 297–314, 2011. 
[168] A. Briggs, M. Sculpher, and K. Claxton, Decision modelling for health economic 
evaluation. OUP Oxford, 2006. 
[169] L. Andronis, P. Barton, and S. Bryan, “Sensitivity analysis in economic evaluation: an 
audit of NICE current practice and a review of its use and value in decision-making,” 
Health Technol.Assess., vol. 13, no. 29, pp. iii, ix–xi, 1–61, 2009. 
[170] D. Walker and J. Fox-Rushby, “Allowing for uncertainty in economic evaluations: 
qualitative sensitivity analysis,” Health Policy Plan., vol. 16, no. 4, pp. 435–443, 2001. 
[171] L. Trenouth, T. Colbourn, B. Fenn, S. Pietzsch, M. Myatt, and C. Puett, “The cost of 
preventing undernutrition: cost, cost-efficiency and cost-effectiveness of three cash-based 
interventions on nutrition outcomes in Dadu, Pakistan,” Health Policy Plan., vol. 33, no. 
6, pp. 743–754, 2018. 
[172] R. Wilford, K. Golden, and D. G. Walker, “Cost-effectiveness of community-based 
management of acute malnutrition in Malawi,” Health Policy Plan., vol. 27, no. 2, pp. 
127–137, 2011. 
[173] A. Briggs, “Handling Uncertainty in Cost-Effectiveness Models,” Pharmacoeconomics, 
vol. 17, no. 5, pp. 479–500, 2000. 
[174] A. Sinha, O. Levine, M. D. Knoll, F. Muhib, and T. A. Lieu, “Cost-effectiveness of 
pneumococcal conjugate vaccination in the prevention of child mortality: an international 
economic analysis,” The Lancet, vol. 369, no. 9559, pp. 389–396, 2007. 
[175] E. Fenwick and S. Byford, “A guide to cost-effectiveness acceptability curves,” 
Br.J.Psychiatry, vol. 187, no. Journal Article, pp. 106–108, 2005. 
[176] R. M. Baltussen, R. C. Hutubessy, D. B. Evans, and C. J. Murray, “Uncertainty in cost-
effectiveness analysis,” Int.J.Technol.Assess.Health Care, vol. 18, no. 01, pp. 112–119, 
2002. 
[177] A. H. Briggs, D. E. Wonderling, and C. Z. Mooney, “Pulling cost‐effectiveness analysis 
up by its bootstraps: A non‐parametric approach to confidence interval estimation,” Health 
Econ., vol. 6, no. 4, pp. 327–340, 1997. 
[178] R. Davidson and J. G. MacKinnon, “Bootstrap tests: How many bootstraps?,” 
Econometric Reviews, vol. 19, no. 1, pp. 55–68, 2000. 
[179] Penn Medicine, “Stata programs: Sampling Uncertainty for Cost-Effectiveness,” 2015. 
[180] D. J. Cohen and M. R. Reynolds, “Interpreting the results of cost-effectiveness studies,” 
J.Am.Coll.Cardiol., vol. 52, no. 25, pp. 2119–2126, 2008. 
[181] S. Resch, T. Ryckman, and R. Hecht, “Funding AIDS programmes in the era of shared 
responsibility: an analysis of domestic spending in 12 low-income and middle-income 
countries,” The Lancet Global Health, vol. 3, no. 1, pp. e52–e61, 2015. 
[182] M. T. Schneider et al., “Tracking development assistance for HIV/AIDS: the international 
response to a global epidemic,” AIDS, vol. 30, no. 9, pp. 1475–1479, 2016. 
[183] M. Johri and D. Ako-Arrey, “The cost-effectiveness of preventing mother-to-child 
transmission of HIV in low-and middle-income countries: systematic review,” Cost 
Effectiveness and Resource Allocation, vol. 9, no. 1, pp. 1–16, 2011. 
  
212 
 
[184] A. Binagwaho et al., “Prevention of mother-to-child transmission of HIV: cost-
effectiveness of antiretroviral regimens and feeding options in Rwanda,” PLoS One, vol. 
8, no. 2, p. e54180, 2013. 
[185] A. Kuznik et al., “Evaluating the cost-effectiveness of combination antiretroviral therapy 
for the prevention of mother-to-child transmission of HIV in Uganda,” Bull.World Health 
Organ., vol. 90, no. 8, pp. 595–603, 2012. 
[186] N. Ishikawa et al., “Should HIV testing for all pregnant women continue? Cost-
effectiveness of universal antenatal testing compared to focused approaches across high to 
very low HIV prevalence settings,” Journal of the International AIDS Society, vol. 19, no. 
1, 2016. 
[187] S. Soorapanth, S. Sansom, M. Bulterys, M. Besser, G. Theron, and M. G. Fowler, “Cost-
effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV 
transmission in South Africa and other resource-limited settings,” J.Acquir.Immune 
Defic.Syndr., vol. 42, no. 2, pp. 213–221, 2006. 
[188] F. N. John, C. Farquhar, J. N. Kiarie, M. N. Kabura, and G. C. John-Stewart, “Cost 
effectiveness of couple counselling to enhance infant HIV-1 prevention,” Int.J.STD AIDS, 
vol. 19, no. 6, pp. 406–409, 2008. 
[189] L. Bollinger and A. Adesina, “Cost-effectiveness of integrating PMTCT and MNCH 
services: an application of the LiST model for Malawi Mozambique and Uganda.,” no. 
Journal Article, 2013. 
[190] C. Avila, J. Cali, A. Cico, and A. Yemaneberhan, “Evaluating service delivery models for 
prevention of mother-to-child transmission of HIV: Cost and effectiveness of providing 
PMTCT services in public private and civil society organizations.,” no. Journal Article, 
2016. 
[191] M. Besser, “Mothers 2 Mothers,” S.Afr.J.Obstet.Gynaecol., vol. 12, no. 3, pp. 122–128, 
2006. 
[192] C. A. Teasdale and M. J. Besser, “Enhancing PMTCT programmes through psychosocial 
support and empowerment of women: the mothers2mothers model of care,” Southern 
African Journal of HIV Medicine, vol. 9, no. 1, pp. 60–64, 2008. 
[193] C. Zikusooka et al., “External evaluation of the m2m mentor mother model as 
implemented under the STAR-EC Program in Uganda,” Cape Town: Mothers to Mothers, 
2014. 
[194] D. P. Coady and S. W. Parker, “Cost‐effectiveness analysis of demand‐and supply‐side 
education interventions: the case of PROGRESA in Mexico,” Review of Development 
Economics, vol. 8, no. 3, pp. 440–451, 2004. 
[195] S. García and J. E. Saavedra, “Educational Impacts and Cost-Effectiveness of Conditional 
Cash Transfer Programs in Developing Countries: A Meta-Analysis,” Review of 
Educational Research, vol. 87, no. 5, pp. 921–965, 2017. 
[196] D. Gilligan, A. Margolies, E. Quiñones, and S. Roy, “Impact evaluation of cash and food 
transfers at early childhood development centers in Karamoja, Uganda,” Final impact 
report.Washington (District of Columbia): International Food Policy Research Institute, 
no. Journal Article, 2013. 
[197] D. Mozaffarian et al., “Cost-effectiveness of financial incentives and disincentives for 
improving food purchases and health through the US Supplemental Nutrition Assistance 
Program (SNAP): A microsimulation study,” PLoS medicine, vol. 15, no. 10, p. e1002661, 
2018. 
  
213 
 
[198] S. Handa and B. Davis, “The experience of conditional cash transfers in Latin America 
and the Caribbean,” Development policy review, vol. 24, no. 5, pp. 513–536, 2006. 
[199] S. M. Sultan and T. T. Schrofer, “5.4 Building Support to have Targeted Social Protection 
Interventions for the Poorest–The Case of Ghana,” Social Protection for the Poorest in 
Africa, vol. 300, 2008. 
[200] S. Devereux and P. White, “Pilots, principles or patronage: What makes social protection 
succeed in Southern Africa,” presented at the Conference on Social Protection and 
Ideologies of Welfare in Southern Africa, 2007, vol. 6. 
[201] R. L. Thornton, “The demand for, and impact of, learning HIV status,” American 
Economic Review, vol. 98, no. 5, pp. 1829–63, 2008. 
[202] S. J. Baird, R. S. Garfein, C. T. McIntosh, and B. Özler, “Effect of a cash transfer 
programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a 
cluster randomised trial,” The Lancet, vol. 379, no. 9823, pp. 1320–1329, 2012. 
[203] M. Remme, A. Vassall, B. Lutz, and C. Watts, “Paying girls to stay in school: a good 
return on HIV investment?,” The Lancet, vol. 379, no. 9832, p. 2150, 2012. 
[204] U. Gneezy and A. Rustichini, “Pay enough or don’t pay at all,” The Quarterly Journal of 
Economics, vol. 115, no. 3, pp. 791–810, 2000. 
[205] U. Gneezy, S. Meier, and P. Rey-Biel, “When and why incentives (don’t) work to modify 
behavior,” Journal of Economic Perspectives, vol. 25, no. 4, pp. 191–210, 2011. 
[206] V. Paul‐Ebhohimhen and A. Avenell, “Systematic review of the use of financial incentives 
in treatments for obesity and overweight,” Obesity Reviews, vol. 9, no. 4, pp. 355–367, 
2008. 
[207] M. J. Sculpher, K. Claxton, M. Drummond, and C. McCabe, “Whither trial‐based 
economic evaluation for health care decision making?,” Health Econ., vol. 15, no. 7, pp. 
677–687, 2006. 
[208] M. F. Drummond, M. J. Sculpher, K. Claxton, G. L. Stoddart, and G. W. Torrance, 
Methods for the economic evaluation of health care programmes. Oxford university press, 
2015. 
[209] O. Fasawe et al., “Cost-effectiveness analysis of option B for HIV prevention and 
treatment of mothers and children in Malawi,” PLoS One, vol. 8, no. 3, p. e57778, 2013. 
[210] A. VanDeusen, E. Paintsil, T. Agyarko-Poku, and E. F. Long, “Cost effectiveness of 
option B plus for prevention of mother-to-child transmission of HIV in resource-limited 
countries: evidence from Kumasi, Ghana,” BMC infectious diseases, vol. 15, no. 1, p. 130, 
2015. 
[211] H. Tweya et al., “Comparative cost-effectiveness of Option B+ for prevention of mother 
to child transmission of HIV in Malawi: Mathematical modelling study,” AIDS (London, 
England), vol. 30, no. 6, p. 953, 2016. 
[212] C. Wettstein et al., “Missed opportunities to prevent mother-to-child-transmission: 
systematic review and meta-analysis,” AIDS, vol. 26, no. 18, pp. 2361–2373, 2012. 
[213] A. Gamell et al., “Prevention of mother-to-child transmission of HIV Option B cascade in 
rural Tanzania: The One Stop Clinic model,” PloS one, vol. 12, no. 7, p. e0181096, 2017. 
[214] M. J. Rotheram-Borus et al., “A cluster randomized controlled trial evaluating the efficacy 
of peer mentors to support South African women living with HIV and their infants,” PLoS 
One, vol. 9, no. 1, p. e84867, 2014. 
  
214 
 
[215] L. Myer et al., “Differentiated models of care for postpartum women on antiretroviral 
therapy in Cape Town, South Africa: a cohort study,” Journal of the International AIDS 
Society, vol. 20, no. S4, 2017. 
[216] N. A. Sam-Agudu et al., “The impact of structured mentor mother programs on 6-month 
postpartum retention and viral suppression among HIV-positive women in rural Nigeria: a 
prospective paired cohort study,” JAIDS J.Acquired Immune Defic.Syndromes, vol. 75, no. 
Journal Article, pp. S173–S181, 2017. 
[217] S. Phiri et al., “Impact of facility-and community-based peer support models on maternal 
uptake and retention in Malawi’s option B HIV prevention of mother-to-child 
transmission program: a 3-arm cluster randomized controlled trial (PURE Malawi),” 
JAIDS J.Acquired Immune Defic.Syndromes, vol. 75, no. Journal Article, pp. S140–S148, 
2017. 
[218] G. Foster et al., “Impact of Facility-Based Mother Support Groups on Retention in Care 
and PMTCT Outcomes in Rural Zimbabwe: The EPAZ Cluster-Randomized Controlled 
Trial,” J.Acquir.Immune Defic.Syndr., vol. 75 Suppl 2, no. Journal Article, pp. S207–
S215, 2017. 
[219] F. Cataldo, J. Seeley, M. J. Nkhata, Z. Mupambireyi, E. Tumwesige, and D. M. Gibb, 
“She knows that she will not come back: tracing patients and new thresholds of collective 
surveillance in PMTCT Option B,” BMC health services research, vol. 18, no. 1, p. 76, 
2018. 
[220] G. D. Sanders et al., “Recommendations for conduct, methodological practices, and 
reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and 
medicine,” JAMA, vol. 316, no. 10, pp. 1093–1103, 2016. 
[221] C. A. Scott et al., “Retention in care, resource utilization, and costs for adults receiving 
antiretroviral therapy in Zambia: a retrospective cohort study,” BMC Public Health, vol. 
14, no. 1, p. 1, 2014. 
[222] World Health Organization, “Taking stock: HIV in children,” 2006. 
[223] S. Khamadi et al., “Rapid identification of infants for antiretroviral therapy in a resource 
poor setting: the Kenya experience,” J.Trop.Pediatr., vol. 54, no. 6, pp. 370–374, 2008. 
[224] Kongo Innocent Emmanuel, “The Access to health care in the Democratic Republic of 
Congo: Major challenge for the poor,” vol. Volume 1, no. 1, pp. 6–8, 2016. 
[225] S. I. Becker-Dreps et al., “Cost-effectiveness of adding bed net distribution for malaria 
prevention to antenatal services in Kinshasa, Democratic Republic of the Congo,” 
Am.J.Trop.Med.Hyg., vol. 81, no. 3, pp. 496–502, 2009. 
[226] J. H. Bratt, K. Torpey, M. Kabaso, and Y. Gondwe, “Costs of HIV/AIDS outpatient 
services delivered through Zambian public health facilities,” Tropical Medicine & 
International Health, vol. 16, no. 1, pp. 110–118, 2011. 
[227] N. A. Menzies et al., “The cost of providing comprehensive HIV treatment in PEPFAR-
supported programs,” AIDS, vol. 25, no. 14, pp. 1753–1760, 2011. 
[228] IntraHealth International, “Strengthening health workforce information in the Democratic 
Republic of the Congo: Implementing IHRIS in Kasai and Kasai central provinces,” 2016. 
[229] D. McCoy et al., “Salaries and incomes of health workers in sub-Saharan Africa,” The 
Lancet, vol. 371, no. 9613, pp. 675–681, 2008. 
[230] Arise Project, “Assessing costs and effectiveness of expanding high quality PMTCT 
services by community and facility strengthening in Mashonaland Central Province, 
Zimbabwe,” 2013. 
  
215 
 
[231] E. Tagar et al., “Multi-country analysis of treatment costs for HIV/AIDS (MATCH): 
facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and 
Zambia,” PLoS One, vol. 9, no. 11, p. e108304, 2014. 
[232] H. Touré et al., “Public sector services for the prevention of mother-to-child transmission 
of HIV infection: a micro-costing survey in Namibia and Rwanda,” Bull.World Health 
Organ., vol. 91, no. 6, pp. 407–415, 2013. 
[233] A. D. Bikilla, D. Jerene, B. Robberstad, and B. Lindtjorn, “Cost estimates of HIV care and 
treatment with and without anti- retroviral therapy at Arba Minch Hospital in southern 
Ethiopia,” Cost Effectiveness and Resource Allocation : C/E, vol. 7, no. Journal Article, 
pp. 6–6, 2009. 
[234] A. Dutta, C. Barker, and A. Kallarakal, “The HIV Treatment Gap: Estimates of the 
Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 
97 Countries from 2015 to 2020,” PLoS Med, vol. 12, no. 11, p. e1001907, 2015. 
[235] N. Ishikawa et al., “Health outcomes and cost impact of the new WHO 2013 guidelines on 
prevention of mother-to-child transmission of HIV in Zambia,” PloS one, vol. 9, no. 3, p. 
e90991, 2014. 
[236] J. H. Perriëns, V. Habiyambere, B. Dongmo-Nguimfack, and G. Hirnschall, “Prices paid 
for adult and paediatric antiretroviral treatment by low-and middle-income countries in 
2012: high, low or just right,” Antivir.Ther.(Lond.), vol. 19, no. suppl 3, pp. 39–47, 2014. 
[237] C. C. Maclean and J. S. Stringer, “Potential cost-effectiveness of maternal and infant 
antiretroviral interventions to prevent mother-to-child transmission during breast-feeding,” 
JAIDS J.Acquired Immune Defic.Syndromes, vol. 38, no. 5, pp. 570–577, 2005. 
[238] A. L. Ciaranello et al., “Cost-effectiveness of World Health Organization 2010 guidelines 
for prevention of mother-to-child HIV transmission in Zimbabwe,” Clin.Infect.Dis., vol. 
56, no. 3, pp. 430–446, 2013. 
[239] B. M. Chitah, “Costing of Paediatric Treatment alongside Clinical Trials under Low 
Resource Constraint Environments: Cotrimoxazole and Antiretroviral Medications in 
Children Living with HIV/AIDS,” AIDS Research and Treatment, vol. 2016, no. Journal 
Article, 2016. 
[240] The World Bank, “Democratic Republic of Congo Health, Nutrition and Population 
Country: Status Report,” 2005. 
[241] L. Gibbons, J. M. Belizán, J. A. Lauer, A. P. Betrán, M. Merialdi, and F. Althabe, “The 
global numbers and costs of additionally needed and unnecessary caesarean sections 
performed per year: overuse as a barrier to universal coverage,” World health report, vol. 
30, no. Journal Article, pp. 1–31, 2010. 
[242] O. Galárraga et al., “Unit Costs for Delivery of Antiretroviral Treatment and Prevention of 
Mother-to-Child Transmission of HIV,” Pharmacoeconomics, vol. 29, no. 7, pp. 579–99, 
2011. 
[243] Cordaid, “Annual Report,” 2016. 
[244] P. Musgrove and J. Fox-Rushby, “Cost-effectiveness analysis for priority setting,” Disease 
control priorities in developing countries, vol. 2, no. Journal Article, 2006. 
[245] The World Bank, “Efficiency or cost-effectiveness.” 
[246] B. R. Luce, “Estimating costs in cost-effectiveness analysis,” Cost-effectiveness in health 
and medicine, no. Journal Article, 1996. 
[247] R. H. Lee, “Future costs in cost effectiveness analysis,” J.Health Econ., vol. 27, no. 4, pp. 
809–818, 2008. 
  
216 
 
[248] M. Kruse, J. Sørensen, and D. Gyrd-Hansen, “Future costs in cost-effectiveness analysis: 
an empirical assessment,” The European Journal of Health Economics, vol. 13, no. 1, pp. 
63–70, 2012. 
[249] M. R. Gold, Cost-effectiveness in health and medicine. Oxford university press, 1996. 
[250] S. E. Casey et al., “Use of facility assessment data to improve reproductive health service 
delivery in the Democratic Republic of the Congo,” Conflict and health, vol. 3, no. 1, p. 1, 
2009. 
[251] Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), “Review of the Democratic 
Republic of the Congo (DRC) by the Committee on the Elimination of Discrimination 
Against Women (CEDAW),” 2013. 
[252] World Health Organization, “Cost effectiveness and strategic planning (WHO-CHOICE),” 
2016. 
[253] C. Ma, “Account for sector heterogeneity in China’s energy consumption: Sector price 
indices vs. GDP deflator,” Energy Econ, vol. 32, no. 1, pp. 24–29, 2010. 
[254] J. Fox-Rushby and J. Cairns, Economic evaluation. McGraw-Hill Education (UK), 2005. 
[255] Centers for Disease Control and Prevention, “Morbidity and mortality weekly report 
(MMWR), Appendix A: AIDS-defining conditions,” 2008. 
[256] M. S. Shiels et al., “Cancer burden in the HIV-infected population in the United States,” 
J.Natl.Cancer Inst., vol. 103, no. 9, pp. 753–762, 2011. 
[257] E. Y. Chiao, S. E. Krown, E. A. Stier, and D. Schrag, “A population-based analysis of 
temporal trends in the incidence of squamous anal canal cancer in relation to the HIV 
epidemic,” JAIDS J.Acquired Immune Defic.Syndromes, vol. 40, no. 4, pp. 451–455, 2005. 
[258] S. Mitra and L. Crane, “Diagnosis, treatment, and prevention of anal cancer,” 
Curr.Infect.Dis.Rep., vol. 14, no. 1, pp. 61–66, 2012. 
[259] L. G. Johnson, M. M. Madeleine, L. M. Newcomer, S. M. Schwartz, and J. R. Daling, 
“Anal cancer incidence and survival: the surveillance, epidemiology, and end results 
experience, 1973–2000,” Cancer, vol. 101, no. 2, pp. 281–288, 2004. 
[260] “Anal Cancer - Cancer Stat Facts.” [Online]. Available: 
https://seer.cancer.gov/statfacts/html/anus.html#incidence-mortality. [Accessed: 09-Sep-
2018]. 
[261] F. Nakagawa, M. May, and A. Phillips, “Life expectancy living with HIV: recent 
estimates and future implications,” Curr.Opin.Infect.Dis., vol. 26, no. 1, pp. 17–25, 2013. 
[262] A. Trickey et al., “Survival of HIV-positive patients starting antiretroviral therapy 
between 1996 and 2013: a collaborative analysis of cohort studies,” The Lancet HIV, vol. 
4, no. 8, pp. e349–e356, 2017. 
[263] H. Samji et al., “Closing the gap: increases in life expectancy among treated HIV-positive 
individuals in the United States and Canada,” PloS one, vol. 8, no. 12, p. e81355, 2013. 
[264] M. J. Silverberg et al., “Risk of anal cancer in HIV-infected and HIV-uninfected 
individuals in North America,” Clin.Infect.Dis., vol. 54, no. 7, pp. 1026–1034, 2012. 
[265] D. Solomon et al., “The 2001 Bethesda System: terminology for reporting results of 
cervical cytology,” JAMA, vol. 287, no. 16, pp. 2114–2119, 2002. 
[266] B. S. Apgar, L. Zoschnick, and T. C. Wright Jr, “The 2001 Bethesda System 
terminology,” Am.Fam.Physician, vol. 68, no. 10, pp. 1992–1998, 2003. 
[267] J. M. Palefsky et al., “Virologic, immunologic, and clinical parameters in the incidence 
and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-
  
217 
 
negative homosexual men,” JAIDS J.Acquired Immune Defic.Syndromes, vol. 17, no. 4, 
pp. 314–319, 1998. 
[268] A. Kreuter et al., “Anal carcinoma in human immunodeficiency virus‐positive men: 
results of a prospective study from Germany,” Br.J.Dermatol., vol. 162, no. 6, pp. 1269–
1277, 2010. 
[269] E. A. Holly, M. L. Ralston, T. M. Darragh, R. M. Greenblatt, N. Jay, and J. M. Palefsky, 
“Prevalence and risk factors for anal squamous intraepithelial lesions in women,” 
J.Natl.Cancer Inst., vol. 93, no. 11, pp. 843–849, 2001. 
[270] A. J. Durante, A. B. Williams, M. Da Costa, T. M. Darragh, K. Khoshnood, and J. M. 
Palefsky, “Incidence of anal cytological abnormalities in a cohort of human 
immunodeficiency virus-infected women,” Cancer Epidemiol.Biomarkers Prev., vol. 12, 
no. 7, pp. 638–642, 2003. 
[271] A.-B. Moscicki et al., “Human papillomavirus infection and abnormal cytology of the 
anus in HIV-infected and uninfected adolescents,” AIDS, vol. 17, no. 3, pp. 311–320, 
2003. 
[272] N. A. Hessol et al., “Anal intraepithelial neoplasia in a multisite study of HIV-infected and 
high-risk HIV-uninfected women,” AIDS, vol. 23, no. 1, pp. 59–70, 2009. 
[273] A. S. Baranoski, R. Tandon, J. Weinberg, F. F. Huang, and E. A. Stier, “Risk factors for 
abnormal anal cytology over time in HIV-infected women,” Obstet.Gynecol., vol. 207, no. 
2, pp. 107. e1-107. e8, 2012. 
[274] M. Gaisa, K. Sigel, J. Hand, and S. Goldstone, “High rates of anal dysplasia in HIV-
infected men who have sex with men, women, and heterosexual men,” AIDS, vol. 28, no. 
2, pp. 215–222, 2014. 
[275] M. Gaisa et al., “High Rates of Anal High-Grade Squamous Intraepithelial Lesions in 
HIV-Infected Women Who Do Not Meet Screening Guidelines,” Clin.Infect.Dis., vol. 64, 
no. 3, pp. 289–294, 2017. 
[276] A. Wexler et al., “Invasive anal squamous-cell carcinoma in the HIV-positive patient: 
outcome in the era of highly active antiretroviral therapy,” Diseases of the colon & 
rectum, vol. 51, no. 1, pp. 73–81, 2008. 
[277] J. A. Aberg et al., “Primary care guidelines for the management of persons infected with 
human immunodeficiency virus: 2009 update by the HIV medicine Association of the 
Infectious Diseases Society of America,” Clinical infectious diseases, vol. 49, no. 5, pp. 
651–681, 2009. 
[278] New York State Department of Health AIDS Institute. HIV Clinical Resource, “Anal 
dysplasia and cancer guideline,” 2007. 
[279] USPSTF/Veterans Administration, “Anal dysplasia,” 2016. 
[280] R. D. Cranston, S. Hart, J. Gornbein, S. Hirschowitz, G. Cortina, and A. Moe, “The 
prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in 
a population of HIV-positive men who have sex with men,” Int.J.STD AIDS, vol. 18, no. 
2, pp. 77–80, 2007. 
[281] J. M. Berry, J. M. Palefsky, N. Jay, S. C. Cheng, T. M. Darragh, and P. V. Chin-Hong, 
“Performance characteristics of anal cytology and human papillomavirus testing in 
patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial 
neoplasia,” Dis.Colon Rectum, vol. 52, no. 2, pp. 239–247, 2009. 
  
218 
 
[282] J. J. Kwong, P. Cook, and L. Bradley-Springer, “Improving anal cancer screening in an 
ambulatory HIV clinic: experience from a quality improvement initiative,” AIDS Patient 
Care STDS, vol. 25, no. 2, pp. 73–78, 2011. 
[283] H. Scott, J. Khoury, B. A. Moore, and S. Weissman, “Routine anal cytology screening for 
anal squamous intraepithelial lesions in an urban HIV clinic,” Sex.Transm.Dis., vol. 35, 
no. 2, pp. 197–202, 2008. 
[284] J. M. Palefsky, E. A. Holly, C. J. Hogeboom, J. M. Berry, N. Jay, and T. M. Darragh, 
“Anal cytology as a screening tool for anal squamous intraepithelial lesions,” JAIDS 
J.Acquired Immune Defic.Syndromes, vol. 14, no. 5, pp. 415–422, 1997. 
[285] A. P. Chung and D. B. Rosenfeld, “Intraoperative high-resolution anoscopy: a minimally 
invasive approach in the treatment of patients with Bowen’s disease and results in a 
private practice setting,” Am.Surg., vol. 73, no. 12, pp. 1279–1283, 2007. 
[286] W. G. Willeford, L. Barroso, J. Keller, N. Fino, and L. H. Bachmann, “Anal Dysplasia 
Screening and Treatment in a Southern Human Immunodeficiency Virus Clinic,” 
Sex.Transm.Dis., vol. 43, no. 8, pp. 479–482, 2016. 
[287] W. C. Mathews, A. Sitapati, J. C. Caperna, R. E. Barber, A. Tugend, and U. Go, 
“Measurement characteristics of anal cytology, histopathology, and high-resolution 
anoscopic visual impression in an anal dysplasia screening program,” JAIDS J.Acquired 
Immune Defic.Syndromes, vol. 37, no. 5, pp. 1610–1615, 2004. 
[288] S. E. Weis et al., “Prevalence of anal intraepithelial neoplasia defined by anal cytology 
screening and high-resolution anoscopy in a primary care population of HIV-infected men 
and women,” Diseases of the Colon & Rectum, vol. 54, no. 4, pp. 433–441, 2011. 
[289] R. M. Andersen, “Revisiting the behavioral model and access to medical care: does it 
matter?,” J.Health Soc.Behav., no. Journal Article, pp. 1–10, 1995. 
[290] R. Andersen and J. F. Newman, “Societal and individual determinants of medical care 
utilization in the United States,” Milbank Q., vol. 83, no. 4, p. Online‐only-Online‐only, 
2005. 
[291] R. M. Andersen, P. L. Davidson, and S. E. Baumeister, “Improving access to care,” 
Changing the US health care system: Key issues in health services policy and 
management, no. Journal Article, pp. 33–69, 2013. 
[292] G. M. Clifford et al., “Cancer risk in the Swiss HIV Cohort Study: associations with 
immunodeficiency, smoking, and highly active antiretroviral therapy,” J.Natl.Cancer Inst., 
vol. 97, no. 6, pp. 425–432, 2005. 
[293] E. A. Engels et al., “Cancer risk in people infected with human immunodeficiency virus in 
the United States,” International journal of cancer, vol. 123, no. 1, pp. 187–194, 2008. 
[294] P. Patel et al., “Incidence of types of cancer among HIV-infected persons compared with 
the general population in the United States, 1992–2003,” Ann.Intern.Med., vol. 148, no. 
10, pp. 728–736, 2008. 
[295] M. J. Silverberg et al., “HIV infection, immunodeficiency, viral replication, and the risk of 
cancer,” Cancer Epidemiol.Biomarkers Prev., vol. 20, no. 12, pp. 2551–2559, 2011. 
[296] E. L. Yanik, K. Tamburro, J. J. Eron, B. Damania, S. Napravnik, and D. P. Dittmer, 
“Recent cancer incidence trends in an observational clinical cohort of HIV-infected 
patients in the US, 2000 to 2011,” Infectious agents and cancer, vol. 8, no. 1, p. 18, 2013. 
[297] Centers for Medicare and Medicaid Services, “Medicaid Analytic eXtract (MAX) general 
Information,” 2017. 
  
219 
 
[298] S. Crystal, A. Akincigil, S. Bilder, and J. T. Walkup, “Studying prescription drug use and 
outcomes with medicaid claims data: strengths, limitations, and strategies,” Med.Care, 
vol. 45, no. 10 Supl 2, pp. S58-65, 2007. 
[299] M. A. Ford and C. M. Spicer, “Sources of Data on HIV Care to Assess Indicators of HIV 
Care and Access to Supportive Services,” no. Journal Article, 2012. 
[300] Centers for Medicare & Medicaid Services, “Medicaid Analytic eXtract (MAX) 
validation,” 2013. 
[301] US Department of Health and Human Services, “Area Health Resources File,” 2013. 
[302] W. E. Cunningham et al., “The effect of socioeconomic status on the survival of people 
receiving care for HIV infection in the United States,” J.Health Care Poor Underserved, 
vol. 16, no. 4, pp. 655–676, 2005. 
[303] H. A. Robbins et al., “Patterns of repeated anal cytology results among HIV-positive and 
HIV-negative men who have sex with men,” Papillomavirus Research, vol. 5, no. Journal 
Article, pp. 143–149, 2018. 
[304] AIDSVu, “About AIDSVu,” 2017. 
[305] K. Baicker, A. Chandra, and J. Skinner, “Geographic variation in health care and the 
problem of measuring racial disparities,” Perspectives in biology and medicine, vol. 48, 
no. 1, pp. 42-S53, 2005. 
[306] P. Larie, “Official authorized addenda: Human immunodeficiency virus infection codes 
and official guidelines for coding and reporting ICD-9-CM,” Morbidity and Mortality 
Weekly Report: Recommendations and Reports, pp. 11–19, 1994. 
[307] Family Planning National Training Center, “Commonly used ICD-9 codes in reproductive 
healthcare,” 2013. 
[308] “Free HCPCS Code List.” [Online]. Available: http://www.icd9data.com/HCPCS/. 
[Accessed: 13-Sep-2018]. 
[309] L. L. Siekas and D. M. Aboulafia, “Establishing an anal dysplasia clinic for HIV-infected 
men: initial experience,” AIDS Read, vol. 19, no. 5, pp. 178–86, 2009. 
[310] T. Darragh and B. Winkler, “The ABCs of anal-rectal cytology,” CAP Today. May, pp. 
42–50, 2004. 
[311] K. Lindsey, C. DeCristofaro, and J. James, “Anal Pap smears: should we be doing them?,” 
Journal of the American Academy of Nurse Practitioners, vol. 21, no. 8, pp. 437–443, 
2009. 
[312] M. L. Welton, B. Winkler, and T. M. Darragh, “Anal-rectal cytology and anal cancer 
screening,” presented at the Seminars in Colon and Rectal Surgery, 2004, vol. 15, pp. 
196–200. 
[313] J. M. Bland and D. G. Altman, “Survival probabilities (the Kaplan-Meier method),” BMJ, 
vol. 317, no. 7172, p. 1572, 1998. 
[314] M. Goel, P. Khanna, and J. Kishore, “Understanding survival analysis: Kaplan-Meier 
estimate,” International journal of Ayurveda research, vol. 1, no. 4, p. 274, 2010. 
[315] M. Cleves, An introduction to survival analysis using Stata, Revised third. Stata Press, 
2016. 
[316] “Lesson 3 Logistic Regression Diagnostics.” [Online]. Available: 
https://stats.idre.ucla.edu/stata/webbooks/logistic/chapter3/lesson-3-logistic-regression-
diagnostics/. [Accessed: 14-Sep-2018]. 
[317] R. M. O’brien, “A caution regarding rules of thumb for variance inflation factors,” Quality 
& quantity, vol. 41, no. 5, pp. 673–690, 2007. 
  
220 
 
[318] I. L. Leeds and S. H. Fang, “Anal cancer and intraepithelial neoplasia screening: A 
review,” World journal of gastrointestinal surgery, vol. 8, no. 1, p. 41, 2016. 
[319] P. V. Chin-Hong and J. M. Palefsky, “Natural history and clinical management of anal 
human papillomavirus disease in men and women infected with human immunodeficiency 
virus,” Clin.Infect.Dis., vol. 35, no. 9, pp. 1127–1134, 2002. 
[320] University of California, San Frascisco, “DARE and HRA | Anal Cancer Information,” 
Anal Cancer Information, 2014. [Online]. Available: https://analcancerinfo.ucsf.edu/dare-
and-hra. [Accessed: 28-Oct-2018]. 
[321] R. A. Ortoski and C. S. Kell, “Anal cancer and screening guidelines for human 
papillomavirus in men,” J.Am.Osteopath.Assoc., vol. 111, no. 3_suppl_2, pp. S35–S43, 
2011. 
[322] J. R. Roberts, L. L. Siekas, and A. M. Kaz, “Anal intraepithelial neoplasia: A review of 
diagnosis and management,” World journal of gastrointestinal oncology, vol. 9, no. 2, p. 
50, 2017. 
[323] J. M. Palefsky, “Practising high-resolution anoscopy,” Sexual health, vol. 9, no. 6, pp. 
580–586, 2012. 
[324] O. Richel, J. M. Prins, and H. J. de Vries, “Screening for anal cancer precursors: what is 
the learning curve for high-resolution anoscopy?,” AIDS, vol. 28, no. 9, pp. 1376–1377, 
2014. 
[325] G. Kaplan, M. H. Lopez, and J. M. McGinnis, “Transforming health care scheduling and 
access: Getting to now,” Washington DC: Institute of Medicine, 2015. 
[326] I. B. T. LEE, “Reducing Waits and Delays in the Referral Process.” 
[327] T. Parker-Pope, “Fear and Procrastination Delay Cancer Diagnoses,” Well, 14-May-2008. 
. 
[328] J. A. Cook et al., “Do HIV-positive women receive depression treatment that meets best 
practice guidelines?,” AIDS and Behavior, vol. 18, no. 6, pp. 1094–1102, 2014. 
[329] A. Barnes et al., “Cervical cancer screening among HIV-infected women in an urban, 
United States safety-net healthcare system,” AIDS, vol. 32, no. 13, pp. 1861–1870, 2018. 
[330] J. R. Gaither et al., “Guideline-concordant management of opioid therapy among human 
immunodeficiency virus (HIV)-infected and uninfected veterans,” The Journal of Pain, 
vol. 15, no. 11, pp. 1130–1140, 2014. 
[331] A. M. Kilbourne et al., “Development and application of a method to assess timeliness of 
medical care for HIV symptoms,” Health Serv.Outcomes Res., vol. 2, no. 2, pp. 101–115, 
2001. 
[332] L. V. Torian and E. W. Wiewel, “Continuity of HIV-related medical care, New York City, 
2005–2009: Do patients who initiate care stay in care?,” AIDS patient care and STDs, vol. 
25, no. 2, pp. 79–88, 2011. 
[333] P. M. Gorbach, L. E. Manhart, K. L. Hess, B. P. Stoner, D. H. Martin, and K. K. Holmes, 
“Anal intercourse among young heterosexuals in three sexually transmitted disease clinics 
in the United States,” Sex.Transm.Dis., vol. 36, no. 4, pp. 193–198, 2009. 
[334] B. D. Sommers, R. Gourevitch, B. Maylone, R. J. Blendon, and A. M. Epstein, “Insurance 
churning rates for low-income adults under health reform: lower than expected but still 
harmful for many,” Health Aff., vol. 35, no. 10, pp. 1816–1824, 2016. 
[335] L. Ku and E. Steinmetz, “Bridging the Gap: Continuity and Quality of Coverage in 
Medicaid,” George Washington University.Published September, no. Journal Article, 
2013. 
  
221 
 
[336] T. M. Darragh and B. Winkler, “Anal cancer and cervical cancer screening: key 
differences,” Cancer cytopathology, vol. 119, no. 1, pp. 5–19, 2011. 
[337] J. S. Wells, M. M. Holstad, T. Thomas, and D. W. Bruner, “An integrative review of 
guidelines for anal cancer screening in HIV-infected persons,” AIDS patient care and 
STDs, vol. 28, no. 7, pp. 350–357, 2014. 
[338] The ANCHOR study, “About the Anal Cancer HSIL Outcomes Research (ANCHOR) 
study,” 2017. 
[339] Centers for Medicare and Medicaid Services, “Physician fee schedule search,” 2017. 
[340] Aetna, “High-resolution anoscopy,” 2017. 
[341] A. C. Reed, P. L. Reiter, J. S. Smith, J. M. Palefsky, and N. T. Brewer, “Gay and bisexual 
men’s willingness to receive anal Papanicolaou testing,” Am.J.Public Health, vol. 100, no. 
6, pp. 1123–1129, 2010. 
[342] I. Rosa-Cunha et al., “Description of a pilot anal pap smear screening program among 
individuals attending a Veteran’s Affairs HIV clinic,” AIDS Patient Care STDS, vol. 25, 
no. 4, pp. 213–219, 2011. 
[343] G. D’souza et al., “Uptake and predictors of anal cancer screening in men who have sex 
with men,” Am.J.Public Health, vol. 103, no. 9, pp. e88–e95, 2013. 
[344] K. Z. Apaydin, H. B. Fontenot, D. L. Shtasel, K. H. Mayer, and A. S. Keuroghlian, 
“Primary care provider practices and perceptions regarding HPV vaccination and anal 
cancer screening at a Boston community health center,” J.Community Health, no. Journal 
Article, pp. 1–10, 2018. 
[345] Mathematica Policy Research, “Medicaid Managed Care Enrollment and Program 
Characteristics, 2016,” 2018. 
[346] M. J. Mugavero et al., “Racial disparities in HIV virologic failure: do missed visits 
matter?,” J.Acquir.Immune Defic.Syndr., vol. 50, no. 1, pp. 100–108, 2009. 
[347] V. E. Stone, “Optimizing the care of minority patients with HIV/AIDS,” Clinical 
infectious diseases, vol. 38, no. 3, pp. 400–404, 2004. 
[348] L. E. Wilson et al., “HIV-related medical service use by rural/urban residents: a multistate 
perspective,” AIDS Care, vol. 23, no. 8, pp. 971–979, 2011. 
[349] G. Suneja et al., “Cancer treatment disparities in HIV-infected individuals in the United 
States,” J.Clin.Oncol., vol. 32, no. 22, pp. 2344–2350, 2014. 
[350] J. F. Deeken et al., “The rising challenge of non-AIDS-defining cancers in HIV-infected 
patients,” Clin.Infect.Dis., vol. 55, no. 9, pp. 1228–1235, 2012. 
[351] M. Bower et al., “British HIV Association guidelines for HIV‐associated malignancies 
2008,” HIV medicine, vol. 9, no. 6, pp. 336–388, 2008. 
[352] D. Mark Freedman MPH, M. John Weiser MPH, P. Linda R. Beer, and M. R. Luke 
Shouse MPH, “Anal Cancer Screening in Men who have sex with Men in Care for HIV 
infection, United States, 2009-2012,” 2016. 
[353] R. H. Miller and H. S. Luft, “Does managed care lead to better or worse quality of care?,” 
Health.Aff.(Millwood), vol. 16, no. 5, pp. 7–25, 1997. 
[354] R. P. Insinga, E. J. Dasbach, and E. H. Elbasha, “Assessing the annual economic burden of 
preventing and treating anogenital human papillomavirus-related disease in the US,” 
Pharmacoeconomics, vol. 23, no. 11, pp. 1107–1122, 2005. 
[355] B. Sirovich, D. Gottlieb, and E. Fisher, “The burden of prevention: downstream 
consequences of Pap smear testing in the elderly,” Journal of Medical Screening, vol. 10, 
no. 4, pp. 189–195, 2003. 
  
222 
 
[356] H. J. Henk, R. P. Insinga, P. K. Singhal, and T. Darkow, “Incidence and costs of cervical 
intraepithelial neoplasia in a US commercially insured population,” Journal of lower 
genital tract disease, vol. 14, no. 1, pp. 29–36, 2010. 
[357] A. II, “MedStar Health, Inc.” 
[358] R. P. Insinga, E. J. Dasbach, and E. R. Myers, “The health and economic burden of genital 
warts in a set of private health plans in the United States,” Clinical Infectious Diseases, 
vol. 36, no. 11, pp. 1397–1403, 2003. 
 
 
 
